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Abstract 
The overall aim of this thesis was to determine the effects of administration of 
(recombinant human erythropoietin) r-HuEpo on endurance performance and to explore 
the psychosocial effects of taking this drug.  In addition, the effects of injecting a Placebo, 
believed to be an erythropoietin-like substance was assessed, quantitatively and 
qualitatively, to determine what role the placebo effect may play in mediating the effects of 
r-HuEpo on endurance performance.  All tests were also carried out in the field to ensure 
that studies had high ecological validity.  
The first study, presented in this thesis (Chapter 3), aimed to assess the validity of the 
Cosmed K4b2 portable metabolic analyser (K4b2) in measuring V
．
O2 during submaximal 
and maximal running velocities in an outdoor environment.  Nineteen trained male 
volunteers (age: 22.9 ± 1.0 years; weight: 74.1 ± 1.8 kg; height: 179.2 ± 1.4 cm; mean ± 
SD; V
．
O2max 59.37 ± 0.30; mean ± SEM) completed maximal continuous incremental 
running tests which involved 3 minute exercise stages at running speeds between 8 to 16 
km·h-1 in 2 km·h-1 increments.  Measured gas exchange variables included fractional 
content of expired oxygen (FEO2) and fractional content of expired carbon dioxide 
(FECO2), oxygen uptake (V
．
O2), carbon dioxide output (V
．
CO2), ventilation (V
．
E) and 
respiratory exchange ratio (RER).  The Douglas bag method was used for comparison 
purposes.  The typical error in V
．
O2 measurement for the K4b2 outdoors compared to the 
Douglas bag method was 6.5 ml.kg-1.min-1.  This degree of error for the measurement of 
was considered unacceptable and it was therefore decided that the K4b2 was not accurate 
enough to justify its use in subsequent studies.   
The aim of Chapter 4 was to assess the effect of r-HuEpo administration on 
haematological, psychological and performance measures.  Seven well-trained males (age: 
25.7 ± 2.2 y; BMI 22.5 ± 0.7 kg.m-2; V
．
O2max: 57.7 ± 2.9 ml
.kg-1.min-1) participated in a 10 
week protocol divided into three phases; baseline (2 weeks), r-HuEpo administration (4 
weeks) and post administration (4 weeks).  Fifty IU.kg-1 subcutaneous injections were 
administered every two days during the r-HuEpo administration phase.  Blood measures 
included the determination of hemoglobin concentration ([Hb]), haematocrit (Hct), 
reticulocytes (ret) and total haemoglobin mass (tHb).  Cognitive State Anxiety Inventory 
(CSAI-2) and Profile of Mood States (POMS) were utilised for psychological measures.  
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Maximal oxygen uptake was measured and 3 km time trial performance was assessed at 
baseline, immediately post (i.e. at 4 weeks) and 4 weeks post r-HuEpo administration.  
Cognitive State Anxiety questionnaires were obtained immediately prior V
．
O2max and 3 km 
time trials.  Profile of Moods States questionnaires were obtained at baseline, immediately 
and 4 weeks post.  At immediately the post r-HuEpo administration time-point, [Hb], Hct, 
ret and tHb significantly increased compared to baseline (P < 0.05) by 21.2%, 21.3%, 
75.0% and 11.7%, respectively.  At 4 weeks post r-HuEpo administration, [Hb], Hct and 
tHb decreased compared to the immediately post time-point, but remained significantly 
elevated compared to baseline by 7.9%, 9.3% and 6.9%, respectively (P < 0.05).  Ret 
decreased to below baseline levels (by 41.7%) 4 weeks post r-HuEpo administration (P < 
0.05).  V
．
O2max did not significantly change (P = 0.07) over the course of the protocol, but 
was numerically 5.2% higher immediately post r-HuEpo administration when compared to 
baseline.  Running speed at which the LT occurred was significantly higher by 6.4% (P < 
0.05) immediately post r-HuEpo administration when compared to baseline.  Running 
speed at OBLA was significantly higher immediately post r-HuEpo administration when 
compared to baseline by 5.9% (P < 0.05) and this remained elevated 4 weeks post, by 
5.3%, when compared to baseline (P < 0.05).  The %V
．
O2max at LT was significantly higher 
immediately post r-HuEpo administration when compared to baseline by 6.6% (P < 0.05).  
Lactate turn-point values were also significantly higher (P < 0.05) immediately post r-
HuEpo administration when compared to baseline and 4 weeks post by 9.6 and 7.6%, 
respectively.  The CSAI-2 cognitive subscale decreased significantly (18.3%; P<0.05) 
immediately post.  The POMS tension subscale decreased significantly immediately and 4 
weeks post baseline (61% and 50% respectively; P<0.05).  Three km time trial 
performance significantly improved immediately post r-HuEpo administration by 4.9% (P 
< 0.05) when compared to baseline.  Faster times were sustained 4 weeks post r-HuEpo 
administration, when compared to baseline, by 3.9% (P < 0.05). Changes in [Hb] 
significantly correlated with changes in V
．
O2max (r = 0.985; P = 0.016) with a tendency for 
changes in Hct to correlate with changes in V
．
O2max (r = 0.807; P = 0.053).  A significant 
negative relationship was found between changes in %V
．
O2max at LT with changes in [Hb] 
(r = -0.882; P = 0.048) and Hct (r = -0.926; P = 0.024) immediately post r-HuEpo 
administration.  This study confirmed r-HuEpo increases [Hb] and Hct, and these were 
associated with improvements in V
．
O2max.  Three km time trial performance improved 
immediately post r-HuEpo administration by 4.9%.  However, no clear association was 
found between [Hb], Hct or V
．
O2max and 3 km performance, suggesting that factors other 
than changes in [Hb], Hct and V
．
O2max are likely to have influenced running performance.  
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Positive changes were also observed in psychological components which warrant further 
investigation.  Performance benefits persisted 4 weeks post r-HuEpo administration. 
 
Chapter 5 aimed to assess the effect of r-HuEpo use on psychosocial factors associated 
with the practice.  The use of substance abuse in sport, with the aim of improving 
performance, has been prevalent in sport for decades.  Recent studies, have attempted to 
measure athlete viewpoints on doping in sport.  However, few studies have been able 
report viewpoints related to illegal substance use, whilst participants are actually being 
administered with a banned substance.  Six well-trained males (age: 26 ± 2 y; BMI: 22 ± 1 
kg.m-2; V
．
O2max: 58 ± 3 ml
.kg-1.min-1) individually participated in semi-structured 
interviews after completing the trial involving the administration of r-HuEpo by 
subcutaneous injection for 4 weeks.  Participants individually participated in semi-
structured interviews which were carried out within 2 weeks of completing the study.  
Varied responses were given in relation to psychosocial impacts and experiences.  Five 
participants reported feeling a substantial performance enhancing effect.  One individual 
expected a greater performance effect.  Four individuals stood by their initial stance of 
‘drugs should be banned in sport’.  One individual entertained the idea that drugs should be 
allowed, but in a ‘controlled’ manner.  One participant suggested that his views had 
changed, since being involved in the trial, sighting being geographically disadvantaged in 
the UK in comparison competitors with access to higher altitude.  However, the emotions 
of guilt, shame and/or embarrassment were prominent themes which may be considered as 
a significant deterrent to doping. 
 
Chapter 6 aimed to determine whether an injectable placebo, claiming to be a legal 
substance with similar effects to r-HuEpo, would improve endurance running performance 
in simulated race conditions.  Fifteen endurance-trained male volunteers (age: 27.5 ± 6.8 
years, height: 1.79 ± 0.05 m, body mass: 73.4 ± 7.6 kg: BMI 22.9 ± 2.0 kg.m-2) 
successfully completed the randomised cross-over study design consisting of 3 km 
competition races before and after a 7-day ‘control’ phase and ‘placebo’ phase.  During the 
placebo phase, participants self-administered daily subcutaneous saline injections in the 
belief that they were receiving a performance enhancing drug called OxyRBX.  At the start 
and end of each 7 day phase haematological variables, CSAI-2, POMS and competitive 3 
km race performance were assessed.  Participants were interviewed throughout the study 
and upon study completion.  Participants completed the 3 km race distance significantly 
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faster by 1.2% post the placebo condition (652.4 ± 13.1 s) when compared to the control 
condition (664.0 ± 13.6 s; p<0.05).  An explanation as to these findings remains unknown 
but may be related the notion of a ‘dissociative task’ which, in turn, may have limited the 
participant’s ability to pick up distressing cues during running.  This may have diminished 
or attenuated the perception of fatigue during the races immediately post placebo 
administration.  
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with the addition of the Central Governor Model (CGM) (orange lines), the 
known (red arrows) and potential (red arrows with question mark) pathways 
that r-HuEpo and an r-HuEpo placebo injection (blow arrows with question 
mark) may influence. Variables measured in Chapter 5 (green border).  
HRmax = maximal heart rate; SVmax = maximal stroke volume; [Hb] = 
haemoglobin concentration; %SaO2 = percent oxygen saturation; COmax = 
maximal cardiac output; (Ca-CvO2)max = maximal arterial-venous 
difference; V
．
O2max = maximal oxygen uptake; % V
．
O2max at LT = percentage 
of maximal oxygen uptake at lactate threshold. Adapted from (Bassett and 
Howley, 2000) 
 
Figure 6.2:     Study design.  F: Familiarisation; I: Interview; FI: Final interview, in two 
phases, prior to and post revealing deception.  Vertical arrows indicate data 
collection days (i.e. demographics, blood, questionnaires and 3 km time 
trials).  Placebo injections were self-administered on each day of the 
placebo phase. 
Figure 6.3:    a) Average 3 km Completion Time Difference and b) Individual 3 km 
Completion Time Differences (post-pre) (Secs). *P < 0.05. Values shown as 
mean ± SEM. 
 
Figure 6.4:  This diagram shows the major variables which determine VO2max and the 
maximum sustained running velocity. The known interactions are shown as 
black lines. The known interactions with the Central Governor Model 
(CGM) are shown as orange lines.   The known influences of r-HuEpo 
injections are shown by red arrows. Potential influences of placebo 
injections are shown by blue arrows with question mark.  
Red ticks mark variables found to be of significance immediately post 
placebo administration and red crosses mark variables which were not 
found to be of significance immediately post placebo administration.  
HRmax = maximal heart rate; SVmax = maximal stroke volume; [Hb] = 
haemoglobin concentration; %SaO2 = percent oxygen saturation; COmax = 
maximal cardiac output; (Ca-CvO2)max = maximal arterial-venous 
difference; V O2max = maximal oxygen uptake; % VO2max at LT = 
percentage of maximal oxygen uptake at lactate threshold.   This figure is 
adapted from (Bassett and Howley, 2000). 
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Figure 7.1: Summary of determined and potential effects of r-HuEpo and injected r-
HuEpo placebo immediately post administration on endurance performance 
capability. Red coloured ticks, crosses and question marks refer to r-HuEpo 
administration. Blue coloured ticks, crosses and question marks refer to 
injected r-HuEpo placebo administration. 
Figure 7.2: Simplified summary of selected outcomes associated with r-HuEpo 
administration and believing r-HuEpo was being administered 
 
Figure 7.3: Finishing line photo shot at a) Beijing Olympics 2008 and b) London 
Olympics 2012 
 
Other 
 
Box 1.1: Substances and Methods Prohibited In- and Out-Of-Competition 
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Definitions/Abbreviations 
% SaO2 Percent Arterial Oxygen Saturation 
%ret Percent reticulocytes 
[Ca2+] Calcium Concentration 
[Hb] Haemoglobin Concentration 
∆HbCO Delta Carboxy-haemoglobin 
[La] Blood Lactate Concentration 
%V
．
O2max Percentage of Maximal Oxygen Uptake 
A-aO2 Alveolar to Arterial Oxygen Exchange 
ATP Adenosine Tri-Phosphate 
ADP Adenosine diphosphate 
A-vO2 Arterio-venous Oxygen Difference 
BMI Body Mass Index 
CaO2 Arterial Oxygen Content 
CaO2 – CvO2 Arterio-venous Oxygen Difference 
CGM Central Governor Model 
CNS Central Nervous System 
CO Carbon Monoxide 
Cr Creatine 
CSAI-2 Competitive State Anxiety Inventory 
DB Douglas Bag 
EMG Electromyogram 
EPO Erythropoietin 
FECO2 Fractional Carbon Dioxide 
FEO2 Fractional Expired Oxygen 
FiO2 Fraction Inspired Oxygen  
Hb Haemoglobin 
HbCO Carboxy-haemoglobin 
Hct Haematocrit 
HR Heart Rate 
LT Lactate Threshold 
LTP Lactate Turnpoint 
MCV Mean Cell Volume 
MCH Mean Corpuscular Volume 
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MLSS Maximal Lactate Steady State 
O2 Oxygen 
OBLA Onset of Blood Lactate 
PCr Phospho-creatine 
Pi Inorganic Phosphate 
POMS Profile of Mood Scales 
PO2 Oxygen Partial Pressure 
RBC Red-blood cell count 
RE Running economy 
RER Respiratory exchange ratio 
Ret Reticulocytes 
r-HuEpo Recombinant human erythropoietin 
RPE Rate of Perceived Exertion 
SV Stroke Volume 
tHb Total Haemoglobin Mass 
V
．
CO2 Carbon Dioxide Production 
VD Dead space 
V
．
E Minute Ventilation 
V
．
O2 Oxygen Uptake 
V
．
O2max  Maximal Oxygen Uptake 
V
．
O2peak Peak Oxygen Uptake 
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1. General Introduction 
1.1 Overview 
Research into factors which limit human endurance performance dates back centuries.  For 
example, questions were raised about human physiological limitations, as far back as 
490BC, when it was reported that Pheidippides ran 40 km from Marathon to Athens.  
However, it was the Nobel Laureate in Physiology, Professor Archibald Vivian Hill (A.V. 
Hill), inspired and persuaded by the works of British physiologists Sir F.G. Hopkins and 
W.M. Fletcher, who in 1923, truly sparked the debate on ‘what limits human performance’.  
Hill proposed exercise performance was limited by anaerobiosis in exercising muscle due 
to inadequate delivery of oxygen (O2) by the cardiovascular system (Hartree and Hill, 
1923).  This model has been has been challenged and refined over time, but it remains 
clear that O2 supply and utilisation by skeletal muscle plays a key role in determining 
endurance performance.  
 
This thesis is about the potential effects of the drug erythropoietin – which stimulates bone 
marrow to increase red blood cell production and therefore increases O2 delivery to muscle 
–on endurance performance.  The purpose of this introduction is to provide the background 
and rationale for the research studies that will be described in subsequent Chapters.  The 
Chapter has been divided into several sections.  After a brief overview of the energy 
systems used to sustain muscular contractions, the limitations to endurance performance 
will be considered, with an initial emphasis on the importance of maximal oxygen uptake 
(V
．
O2max), and the key factors influencing this parameter. Then, factors other than V
．
O2max 
that influence endurance performance capability will be discussed.  The effects of human 
recombinant erythropoietin (r-HuEpo) administration on the endurance performance and 
the potential physiological and psychological mechanisms responsible will then be 
addressed whilst also discussing psychosocial considerations.  The placebo effect will then 
be discussed.  The final section will address the role of field-based approaches, for 
improved ecological validity, when assessing exercise performance. 
 
1.2 Energy for Muscular Contractions 
Energy, in the form of adenosine triphosphate (ATP), is essential for muscular contractions 
to enable external work to be done.  Adenosine triphosphate is composed of an adenine 
nucleotide, a ribose sugar (i.e. forming adenosine) and 3 phosphate groups (i.e. forming the 
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triphosphate segment).  Adenosine triphosphate is hydrolysed, with the breakage of the 
high energy yielding phosphate bonds, in order to release the required stored energy and 
this also results in the formation of adenosine diphosphate (ADP).  As ATP is required to 
provide energy, ATP is resynthesised from ADP by the addition of a third phosphate 
group, thus, allowing continuation of the ATP cycle.  There is only sufficient ATP in the 
cell to sustain 1-2 seconds of contraction.   Thus, the resynthesis of ATP is vital in order to 
enable a sustained energy supply to exercising muscle to enable them to continually 
contract which then allows for endurance activities to be performed.   
 
Humans are reliant on three interactive metabolic systems to resynthesise ATP and their 
relative contributions to energy provision, during exercise over time, is illustrated in Figure 
1.1.  The first metabolic system involves the hydrolysis of phosphocreatine which provides 
an immediate energy source of energy.  The phosphocreatine (PCr) metabolic system 
resynthesises ATP by hydrolysing creatine phosphate, located in the cytoplasm of the 
myocyte, which provides energy to add the third phosphate group to ADP in order to form 
ATP.  This is carried out in the absence of O2 and allows ATP to be synthesised at a fast 
rate with no metabolic by-products formed.  However, the phosphocreatine system is only 
capable of providing energy for ~10-15 seconds (due to the depletion of muscle 
phosphocreatine) and so its importance in endurance performance, where prolonged energy 
supply is essential, is limited.   
 
The second metabolic system for regenerating ATP, anaerobic glycolysis, is slower acting, 
with its contribution to energy provision peaking after muscle phosphocreatine is depleted.   
Anaerobic glycolysis/glycogenolysis involves the hydrolysis of glucose/glycogen, to 
pyruvic acid which provides energy to resynthesise two ATP molecules per glucose 
molecule and three per glycogen molecule.  Again, this metabolic pathway occurs in the 
absence of O2, in order to provide energy to muscles relatively quickly (although at a 
slower rate in comparison to phosphocreatine).  This is the main energy system when ATP 
requirements are high; however, debilitating metabolic by-products are produced, during 
the hydrolysis of glucose to pyruvic acid, which interfere with the muscle contraction cycle 
and ultimately causes muscle fatigue within 1-3 minutes.  Thus, this pathway is also 
limited in its ability to regenerate ATP for prolonged endurance activities.   
 
Aerobic metabolism, involving the oxidation of carbohydrates and fats, and providing 
38/39 and 129 ATP molecules per glucose/glycogen and fat molecule, respectively, is 
slower than the two anaerobic energy systems, but has a capacity for ATP regeneration that 
Chapter 1. General Introduction  28 
______________________________________________________________________________ 
28 
 
is many hundred-fold greater.  Further, there is no production of the debilitating 
metabolites that interfere with the muscle contraction cycle. Thus, the aerobic metabolic 
system is predominantly relied upon to provide energy during prolonged endurance 
activities.  As the reaction of metabolic fuels with O2 is fundamental to this pathway, 
factors associated with O2 delivery and utilisation are key in determining endurance 
exercise performance capability.  For example, oxygen uptake (V
．
O2) increases linearly 
with work rate or running speed (Brooks, 1985, Maloney et al., 2007), thus, the ability to 
utilise O2 at high rates is associated, in part, with high performance in endurance events.   
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Figure 1.1: Metabolic energy systems and their respective percent contribution to total energy 
expenditure over time during exercise. Modified from Davis et al. (2000). 
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1.3 Maximal Oxygen Uptake 
Maximal oxygen uptake is defined as the highest rate at which O2 can be taken up and used 
by the body during severe exercise (Bassett and Howley, 2000).  To accurately measure 
V
．
O2max, a graded exercise protocol is carried out where exercise intensity is progressively 
increased with time, to progressively tax the aerobic system to a point where the exercise 
intensity can no longer be voluntarily maintained.  Substantial evidence exists indicating a 
strong relationship between V
．
O2max and endurance performance.  Researchers in the first 
half of the 20th century first observed that a high V
．
O2max was a key physiological 
characteristic of elite endurance athletes (Hill and Lupton, 1923, Robinson et al., 1937).  
Over the next half century a number of studies confirmed this with high correlations 
observed between V
．
O2max and endurance performance over a range of running distances 
(Table 1.1).  Thus, given the strong relationship between V
．
O2max and endurance 
performance, understanding limitations to endurance performance requires an 
understanding of the factors which determine and limit V
．
O2max.   
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Table 1.1.  Summary of study correlations between V
．
O2max and performance at different running distances  
Study Subject Type Age 
range 
(years) 
N & Sex V
．
O2max Range 
(ml
.
kg
-1.
min
-1
) 
Performanc
e Distance 
(km)  
Performance 
Time range 
(min) 
Race Pace 
range 
(m
.
min
-1
) 
Correlation between 
V
．
O2max and  
Performance Time (r) 
Costill et al., 
1973 
Highly trained 
runners 
25-48 16 males 54.8-81.2 16.1 48.9-67.8 237-329 -0.91* 
Farrell et al., 
1979 
Well-trained 
endurance 
athletes 
18-54 18 males 46.3-73.7 42.2 138-229 184-306 -0.91* 
     19.3 60-98 196-322 -0.91* 
     15 46-74 203-326 -0.89* 
     9.7 29-44 218-340 -0.86* 
     3.2 9-14 230-374 -0.83* 
Ramsbottom et 
al., 1987 
PE students N/A 69 males 
   55 females 
35.0-78.0 5 15.0-34.0 147-333 -0.89* 
Mello et al,, 
1987 
Various fitness 
levels 
22-51 44 males 
17 females 
36.0-58.1 3.2 12.4-20.3 158-258 -0.91* 
Ramsbottom et 
al., 1988 
Well-motivated 
volunteers 
19-36 36 males 
38 females 
45.9-77.8 5 14.8-21.9 228-338 -0.94* 
*Significant at p <0.05; PE: Physical Education; mean ± SD  
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1.4 What Limits V
．
O2max? 
The transport of O2 from the atmosphere to the mitochondrion in muscles involves several 
stages: these are illustrated in Figure 1.2.  Air enters the body via the nose and/or mouth, 
passes through the larynx, trachea, bronchi and bronchioles before arriving at the alveoli in 
the lungs.  The alveoli are the site of diffusion of O2 into the pulmonary circulatory system 
where the heart is then responsible for pumping oxygenated blood around the systemic 
circulatory system.  Diffusion of O2 then takes place between systemic blood vessels and 
muscle tissue.  
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Figure 1.2: Simplified model of the O2 transport pathway.  Modified from Wagner (2008). 
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The ability of the cardiorespiratory system (i.e. lungs, heart and consequent oxygenated 
blood supply) to transport O2 is described as the ‘central component’ of O2 transport 
(Robergs and Roberts, 1997, Bassett and Howley, 2000). Thus the potential ‘central’ 
factors that could limit V
．
O2max include: 1) pulmonary diffusion capacity, 2) cardiac output 
and 3) O2 carrying capacity of the blood (Bassett and Howley, 2000).  The ability of 
exercising muscles (i.e. skeletal muscle) to then extract and utilise O2 supplied by the 
cardiorespiratory system is described as the ‘peripheral’ component (Robergs and Roberts, 
1997, Bassett and Howley, 2000) of V
．
O2max.  Figure 1.3 illustrates this classic 
cardiovascular model, often described as a ‘central dogma’, which is widely taught and 
accepted in exercise physiology.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: ‘Central Dogma’ approach to explaining fatigue.   
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According to the Fick Principle  V
．
O2max is the product of the volume of blood pumped by 
the heart in one minute and the difference in arterial and venous blood O2 content (Rose, 
1956): 
  
V
．
O2max = Cardiac Output x Arterio-venous Oxygen Difference (CaO2 – CvO2) 
 
Cardiac output refers the amount of blood pumped by the heart per minute and CaO2 – 
CvO2 refers to the difference in O2 content between arteries and veins.  Thus, factors which 
influence the right side of the Fick equation (i.e. cardiac output x (CaO2 – CvO2) are the 
key factors which limit V
．
O2max. 
 
1.4.1  Pulmonary System Limitations  
The pulmonary system is responsible for delivering atmospheric O2 into the blood.  
Oxygen diffuses from the alveoli in the lungs into red blood cells where it binds with 
haemoglobin to form the oxy-haemoglobin complex.  The proportion of haemoglobin 
molecules in the oxygenated form is termed O2 saturation (%SaO2). The %SaO2 is one of 
the two key determinants of the ‘CaO2’ (the total number of O2 molecules in arterial blood 
– both bound and unbound to haemoglobin) component of the Fick equation (the other 
being O2 carrying capacity of the blood).  Thus, any potential pulmonary system limitation 
to V
．
O2max would manifest as a reduction in %SaO2 (Dempsey et al., 1990). 
In average, healthy individuals at sea level the weight of evidence supports the lungs’ 
ability to effectively saturate arterial blood with O2 during submaximal and maximal 
exercise, as %SaO2 is maintained at ~95% (Powers et al., 1989, Rowell et al., 1964, 
Koskolou and McKenzie, 1994, Prefaut et al., 2000, Dempsey et al., 1984, Dempsey et al., 
1980, Wasserman et al., 1981).  In highly trained individuals at sea level, however, there is 
evidence of arterial hypoxemia at high exercise intensities (Amann et al., 2006, Romer and 
Dempsey, 2006).  This is a consequence of the higher maximal cardiac output in highly 
trained individuals leading to a lower transit time of red blood cells in the pulmonary 
circulation.  This resulting in insufficient time to effectively saturate haemoglobin (Hb) in 
red blood cells in the pulmonary circulation (Hammond et al., 1986).   
This specific pulmonary limitation in highly trained athletes with high maximal cardiac 
output was further illustrated by Powers and colleagues (Powers et al., 1989) who 
demonstrated that breathing a hyperoxic gas mixture (26% O2) – which increases the 
alveolar-arterial diffusion gradient  – increased  %SaO2 from 90.6% to 95.9% and V
．
O2max 
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from 70.1 to 74.7 ml.kg-1.min-1 in highly trained athletes, but did not alter these factors in 
subjects with more modest  V
．
O2max values (~56.5 ml
.kg-1.min-1).  
Pulmonary limitations are also evident in conditions of moderately high altitude, where 
atmospheric O2 partial pressure (PO2) is reduced, thereby reducing the alveolar-arterial 
diffusion gradient (West et al., 1962, Daniels and Oldridge, 1970).  For example,  West 
and colleagues (West et al., 1962) measured six participants, from the Himalayan 
Scientific and Mountaineering Expedition (1960-1961), at an elevation of 5800 m 
(equivalent to a barometric pressure of 380 mmHg) at rest and during a range of exercise 
intensities up to maximal efforts.  These authors reported average %SaO2 values of 67% at 
rest and ≤50% during maximal exercise, indicating a limitation of pulmonary diffusing 
capacity at altitude.  This is further illustrated by data, from various studies, showing a 
linear decrease in V
．
O2max in endurance athletes with increasing altitudes  (Wehrlin and 
Hallen, 2006) (Figure 1.4).   
 
 
 
 
Figure 1.4: Percent decrease in V
．
O2max from sea level (Wehrlin and Hallen, 2006). 
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As part of the assessment of pulmonary limitations, the trainability of lung parenchyma has 
also been investigated.  Overall, the trainability of the lung parenchyma by respiratory 
muscle training remains controversial.  The general consensus suggests that respiratory 
muscle training influences physical performance measures to only a limited extent, if at all 
(Sheel, 2002, McKenzie, 2012).  For example, no differences in structural properties were 
found in healthy individuals after an exercise training programme according to Dempsey & 
Wagner (Dempsey and Wagner, 1999).  Research by Sonetti and colleagues (Sonetti et al., 
2001) concluded a very limited effect of respiratory muscle training on exercise 
performance in highly fit and competitive subjects. 
 
Thus, the weight of evidence suggests that pulmonary diffusion capacity does not limit 
V
．
O2max in individuals with ‘normal’ V
．
O2max levels when exercising at sea level.  However, 
in highly trained endurance athletes, where cardiac output is high and pulmonary transit 
time for red blood cells is low at maximal intensities, arterial hypoxemia may occur, 
limiting V
．
O2max to some degree (<10%).  In addition, at altitude, where there is a reduced 
alveolar-arterial O2 gradient, a clear pulmonary limitation to V
．
O2max is evident. 
 
1.4.2 Cardiovascular System Limitations 
1.4.2.1 Cardiac Output 
The ability of the cardiovascular system to deliver O2 to the exercising muscles, after 
pulmonary diffusion has occurred, is highly dependent on cardiac output.  As the Fick 
equation illustrates, V
．
O2 is directly proportional to cardiac output (for a given arterio-
venous O2 difference).  Indeed, a linear relationship between V
．
O2 and cardiac output over 
a wide range of submaximal work rates has been reported (Astrand et al., 1964).  
Furthermore, the performance enhancing effects of endurance training on V
．
O2max has been 
highly correlated to increasing cardiac output (Saltin and Strange, 1992).    
 
Cardiac output is described as the product of heart rate (HR) multiplied by stroke volume 
(SV) (i.e. cardiac output = HR x SV) and it has been suggested to account up to 85% of the 
limitation of V
．
O2max (di Prampero and Ferretti, 1990, Bassett and Howley, 2000).  This has 
been demonstrated during maximal exercise where the majority of O2 present in arterial 
blood, ~200 ml O2
.l-1, is extracted and perfused into exercising muscles with only  ~25 ml 
O2
.L-1 remaining in venous blood (Shephard, 1970).  The main training adaptation that 
facilitates this is the expanded capacity of both ventricles in the heart which, in turn, elicits 
a greater elastic recoil for oxygenated blood delivery to the periphery – an improved 
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Starling effect (Starling and Visscher, 1927, La Gerche and Gewillig, 2010).  Greater 
elastic recoil allows for a greater amount of oxygenated blood to be delivered, per 
heartbeat, to exercising muscles as well as increasing venous return. An increase in venous 
return also contributes to increasing ventricular filling and therefore preload, which in turn 
increases SV and, consequently, cardiac output (Starling and Visscher, 1927, La Gerche 
and Gewillig, 2010).  
 
A number of studies, utilising various testing protocols, have indicated cardiac output to be 
the key limiter of V
．
O2max.  Saltin and colleagues demonstrated that the difference in 
V
．
O2max between deconditioned and conditioned individuals was explained predominantly 
by a difference in cardiac output (Saltin et al., 1968).  Interestingly, in the 40-year follow-
up of this study it was reported that the age-related decline in V
．
O2max was primarily due to 
declines in maximal cardiac output (McGavock et al., 2009), primarily as a consequence of 
reduced maximal HR (Fleg et al., 2005).  Ekblom and colleagues (Ekblom et al., 1968) 
also assessed changes in V
．
O2max in healthy individuals after 16 weeks of physical training 
and reported that ~50% of the increase in V
．
O2max with training could be explained by an 
increase in cardiac output.  The increase in cardiac output was, in turn, explained by an 
increase in SV.   
 
It has been proposed that SV alone can explain most of the range observed in V
．
O2max 
(Ekblom and Hermansen, 1968, Coyle, 1999).  During incremental exercise, SV has been 
reported to plateau, particularly in untrained individuals, at approximately 40% of V
．
O2max 
whereas in the trained individual, SV has been reported to continually increase up to 
V
．
O2max (Vella and Robergs, 2005).  Gledhill and colleagues (Gledhill et al., 1994) were the 
first to report this phenomenon after comparing competitive endurance cyclists and 
normally active males (matched for heart rates ranging from 90 to 190 b.min-1) during 
incremental cycle ergometry exercise.  The authors reported a progressive increase in SV 
in the endurance trained group, whilst the normally active group demonstrated a plateau at 
an average heart rate of 120 b.min-1, equivalent to 40% V
．
O2max .  In addition, the SV of the 
endurance trained group were significantly larger than their untrained counterparts at all 
heart rates. 
 
Using an alternative approach, studies have also assessed the cardiac output limitation on 
V
．
O2max by decreasing cardiac output, artificially, with the use of beta-blockers  to reduce 
HR, and to a lesser extent, SV (Tesch, 1985).  Using this approach,  maximal cardiac 
output was reduced by ~18%, which in turn reduced V
．
O2max by 5 to 15% (Tesch, 1985).  
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These authors reported that the smaller reduction in V
．
O2max, when compared to the 
reduction cardiac output, was primarily due to a compensatory increase in arterio-venous 
oxygen difference (a-vO2) with some individuals showing a greater compensatory effect 
than others.  Overall, studies demonstrate that that the decline in V
．
O2max, as a result of 
cardio-selective beta-blockers, is primarily caused by a reduction in blood flow and O2 
delivery to exercising muscles.  
 
Other intervention studies have also assessed the effect of mechanical limitations, 
associated with the heart, on cardiac function.  Evidence from animal pericardiecotomy 
studies has demonstrated the importance of the heart pericardium on cardiac function and 
V
．
O2max (Stray-Gundersen et al., 1986, Hammond et al., 1992, Shabetai et al., 1992).  For 
example, Stray-Gundersen and colleagues (Stray-Gundersen et al., 1986) demonstrated that 
the removal or opening of the restrictive pericardium resulted in higher V
．
O2max 
measurements in dogs. Oxygen uptake, cardiac output, HR and SV measurements were 
taken during submaximal and maximal exercise, before and after the removal of the 
pericardium.  At maximal exercise intensity, the removal of the pericardium increased 
cardiac output by 19.8%, SV by 16.9% and V
．
O2max by 7.6%.  Although these results were 
obtained using untrained dogs, this does provide proof-of-principle that experimental 
manipulation to increase SV and cardiac output also increases V
．
O2max, highlighting the 
central limiting role of SV and cardiac output in V
．
O2max determination.   
 
Further evidence is provided by studies that have also assessed the effect of training 
separate parts of the body on V
．
O2.  For example, Clausen and colleagues (Clausen et al., 
1973) assessed changes in central and peripheral blood circulation after training of the 
arms or legs.  After leg training, the authors reported an increase in V
．
O2max during exercise 
in non-trained arms, clearly indicating a training effect related to the heart, blood flow and 
O2 delivery.  Similarly, in 13 healthy male subjects, Saltin and colleagues (Saltin et al., 
1976) assessed and compared the effects of a control (i.e. no training), one and two-legged 
cycling performance, after training, at a work intensity of 70% of V
．
O2max.  The authors 
reported a ~6%, ~22% and ~10% change in V
．
O2max, respectively.  Thus, an improvement 
of ~22% was reported in one-legged V
．
O2max after endurance training of two-legs, 
however, this was reduced to ~10% when participants were assessed during two-legged 
exercise at 70% V
．
O2max.  Although cardiac output was not measured, the smaller increase 
in V
．
O2max during two-legged exercise is indicative of central limitations as oxygenated 
blood was having to be shared between the legs, thus reducing oxygenated blood flow and 
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respective O2 delivery to exercising muscles.  Therefore, cardiac output distribution 
remained as the main limiting factor.  
 
More recently, Trinity and colleagues (Trinity et al., 2012) have reported a reduction in the 
rate of increase in cardiac output for a given increase in V
．
O2 from submaximal (40 to 70% 
V
．
O2max) to maximal exercise intensities (70 to 100% V
．
O2max).  This was reported in ten 
well-trained male cyclists where reductions in cardiac output were underpinned by 
reductions in SV. The authors concluded a plateau in cardiac output prior the attainment of 
V
．
O2max, as a result of compromised cardiovascular function, primarily caused by a decline 
in SV as HR increased in a linear manner during incremental exercise to maximal exertion. 
 
In summary, the standpoint of the cardiovascular approach is one where the heart is 
identified as the key limitation to V
．
O2max.  Thus, the key characteristic that enables elite 
endurance athletes to run fast over a prolonged period of time is an enlarged, compliant 
heart where the pericardium elasticity can accommodate a large volume of blood, very 
quickly, thus enhancing the Starling mechanism of the which, in turn, generates a large SV. 
 
1.4.2.2 Oxygen Carrying Capacity 
Along with cardiac output, the O2 carrying capacity of blood is the other key determinant 
of the amount of O2 made available to exercising muscle.  Thus, this is also a 
cardiovascular determinant of V
．
O2max.  The O2 carrying capacity of blood influences the 
arterio-venous O2 difference of the Fick equation and is primarily determined by 
haemoglobin concentration [Hb].    
 
It is well documented that altering the O2 carrying capacity of blood by increasing [Hb], 
via autologous infusion of blood, increases V
．
O2max (Ekblom et al., 1976, Berglund and 
Ekblom, 1991, Gledhill, 1982, Gledhill, 1985).  For example, the re-infusion of 900 to 
1350 ml of blood has been reported to increase V
．
O2max by 4-9% (Gledhill, 1982, Gledhill, 
1985) and this due to the artificial increase in total red blood cells which, in turn, increases 
the total O2 carrying capacity of blood.  This increases central O2 delivery to peripheral 
muscles due to more oxy-haemoglobin complexes being formed, as well as by increasing 
cardiac output due to the increase in blood volume.  Strong correlations (r = 0.97) have 
been demonstrated between total haemoglobin mass measures (tHb) (i.e. total O2 carrying 
capacity of blood) and V
．
O2max (Figure 1.5) (Schmidt and Prommer, 2010).  Thus, 
manipulating the total O2 carrying capacity of blood, by increasing [Hb], increases V
．
O2max.  
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1.5 An Integrated O2 Delivery System 
It is clear that the transportation of O2 from the atmosphere to the mitochondrion 
incorporates several sequential steps (as indicated in Figure 1.2).  As a result, an integrated 
model has also been proposed where, it has been suggested, impediments on O2 delivery 
occur at different points or steps.  This complex transport pathway (Weibel, 1994) can also 
be described as an integrated system (Wagner, 1996a) where limitations exist, in series (a 
‘bucket brigade’), at each component associated with O2 delivery. The integrated 
components, each, contribute to limiting overall O2 availability to exercising muscles 
which, in turn, collectively limit V
．
O2max.  As indicated in Figure 1.2, the principal 
components of the integrated O2 transport pathway, its structures and major functions can 
be summarised in 4 steps: 
 
1) Ventilation – a convective process where inspired air is transported to the 
pulmonary alveoli. 
2) Diffusion in the lungs – the movement of oxygen from alveolar gas into pulmonary 
capillary blood. 
Figure 1.5: Relationship between tHb mass and V
．
O2max (Schmidt and 
Prommer, 2010).  
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3) Perfusion – movement of oxygenated blood from capillaries to pulmonary veins to 
the left ventricle of the heart to body tissues. 
4) Diffusion in the tissues – release of oxygen from carrier Hb, in red blood cells, to 
body tissue followed by diffusion of oxygen to mitochondria for ATP production. 
 
It is argued that as the above steps are linked in series to each other, each step has, 
therefore, the ability to affect the whole O2 delivery system.  As a result, Wagner argues 
that O2 delivery is the key limitation, but there is no single ‘limiting factor’ for V
．
O2max 
(Wagner, 2008, Wagner, 1996a).  Wagner goes further by proposing that the enhanced 
function of just one step has a relatively minor effect on overall O2 delivery capability.  
Conversely, however, any reduced function in any one step of O2 delivery (i.e. ventilation, 
pulmonary diffusion, blood circulation and tissue O2 diffusion) can have a considerable 
negative effect on V
．
O2 as illustrated in Figure 1.6 (Wagner, 1996b).  This is effectively 
depicted when considering the relationship between V
．
O2 and mitochondrial PO2 in vitro 
(Figure 1.7) (Wilson et al., 1977).  Wilson and colleagues demonstrated, in vitro, the 
importance of O2 delivery to muscle where any limitations, associated with the steps prior 
O2 delivery to mitochondria that cause a decline in mitochondrial PO2 below 1 mmHg, will 
seriously decelerate V
．
O2.   
 
 
 
 
 
 
 
Figure 1.6: Calculations of the sensitivity of V
．
O2max to each of the transport system 
components when maximal mitochondrial capacity to consume O2 is taken to be 4 l
.min-
1. Each component shows relatively similar sensitivity. When one component has 
diminished function, V
．
O2max can fall significantly (Wagner, 2008). 
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Wagner uses the Fick equation to describe the determining mechanism of V
．
O2 as one 
limited primarily by O2 delivery; however, he also acknowledges the potential influence of 
peripheral musculature mechanisms associated with determining CaO2 – CvO2.  For 
example, it has been demonstrated that, at rest, when blood flow is reduced by 73%, there 
is a compensatory 94% increase in O2 extraction in order to maintain V
．
O2 (Wagner, 2008).  
The same compensatory mechanisms can also been seen during exercise, albeit to a lesser 
degree.  For example, as previously highlighted by Tesch and colleagues (Tesch, 1985), 
the use of cardio-selective beta-blockers to limit muscle blood flow, by reducing cardiac 
output, can be somewhat compensated for by a relatively small increase in CaO2 – CvO2.   
 
Thus, the evidence clearly supports the assertion that the key limitation is in O2 delivery.  
However, it is evident that this is regulated by a complex integrated system which 
collectively determines the effectiveness of O2 delivery and, in turn, collectively limits 
V
．
O2max.   
 
1.6 Peripheral System Limitations 
The ability of exercising muscles to extract O2 from blood, delivered by the cardiovascular 
system, is associated with the CaO2 – CvO2 part of the Fick equation.  The ability of 
exercising muscles to extract O2 is determined by an interaction of several key factors: 1) 
Figure 1.7: In vitro mitochondrial respiration curve showing dependence of O2 
consumption on mitochondrial PO2. Maximal O2 consumption occurs at a PO2 of only 2 
mmHg (Wilson et al., 1977). 
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peripheral diffusion gradients, 2) capillary density and 3) muscle metabolism.  As part of 
these key factors, key processes include 1) the dissociation of O2 from haemoglobin, 2) the 
diffusion of O2 from red blood cells to muscle cells and 3) the diffusion and transport of 
O2 to the mitochondria within muscle.  
 
1.6.1 Peripheral Diffusion Gradients 
The transportation of O2 from capillaries to muscle is largely dependent on a diffusion 
gradient between red blood cells in capillaries and muscle tissue.   The transport of O2 is 
thus facilitated by a low PO2 in mitochondria, in comparison to the higher PO2 within 
capillaries, encouraging the diffusion of O2 into muscles.  In addition, myoglobin – the 
oxygen binding protein in muscle – has a stronger affinity for O2 than haemoglobin does, 
which also acts to facilitate O2 transfer into muscle.  Furthermore, muscles during exercise 
contribute to creating a diffusion gradient by using O2 which consequently decreases  
muscle PO2 (Honig et al., 1992).  Exercise at V
．
O2max elicits a maximal potential gradient 
difference and thus maximises the potential for O2 diffusion into exercising muscles.  
Honig and colleagues demonstrated this by assessing blood flow to exercising muscle in 
isolation and during whole body exercise.  Increased cardiovascular blood flow was 
effective in increasing V
．
O2 only if mitochondria concomitantly consumed O2 in order to 
draw down mitochondrial PO2 to maintain a diffusion gradient (Honig et al., 1992).  
The extraction of O2 by exercising muscle, however, is never absolute (Shephard, 1970) 
and this may be, in part, as a result of distally decreasing PO2 levels which reduces the 
pressure gradient between distally located capillaries and muscle tissue.  Another 
explanation involves a ‘carrier-free region’, a short distance between the interior of the red 
blood cell surface and muscle tissue sarcolemma, where a decrease in PO2 has been 
reported.  The resulting decrease in PO2 hinders O2 diffusion capacity by reducing the 
diffusion gradient between red blood cells and muscle tissue (Honig et al., 1992).   
Thus, the evidence indicates that while V
．
O2max is dependent on O2 blood delivery, 
maintaining a peripheral diffusion gradient is also necessary to draw O2 into exercising 
musculature. There is general agreement with regards to the importance of a peripheral O2 
diffusion gradient.  However, as this model is an integrated one (i.e. an interaction between 
cardiovascular and peripheral PO2), peripheral diffusion gradients alone cannot be the sole 
factor that limits V
．
O2max. 
Chapter 1. General Introduction  43 
______________________________________________________________________________ 
43 
 
1.6.2 Capillary Density 
The importance of O2 blood delivery and the maintenance of a peripheral diffusion gradient 
on V
．
O2max have been discussed.  Not surprisingly as a result, studies have investigated 
whether V
．
O2max can be improved via training adaptations that could influence the O2 blood 
supply and/or the peripheral diffusion gradient and thus improve overall O2 delivery to 
exercising muscles. 
One such adaptation of the periphery, as a result of training, is an increase in capillary 
density (Andersen and Henriksson, 1977) and this has been explored as to its potential to 
improve V
．
O2max.  Overall, an increase in capillary density has been reported to improve 
redistribution of cardiac output which in turn assists to increase O2 delivery to exercising 
muscles (Evans, 1985).  In addition, just as the red blood cell transit time limitation 
located centrally, an increase in capillary density has been reported to extend mean blood 
flow transit time within muscle itself.  This, in turn, has been reported to enhance muscle 
O2 delivery by helping maintain a sufficient CaO2 – CvO2, particularly at high blood flow 
rates.  Indeed, the beneficial effects of an increase in capillary density have been reported 
in several studies where, for example a 16% increase in V
．
O2max has been reported with a 
concomitant 20% increase in capillary density (Andersen and Henriksson, 1977). 
However, any resulting increase in V
．
O2max, as a result of an increased capillary density, is 
one that is secondary to cardiovascular adaptations as, for example, the redistribution of 
cardiac output can only occur once cardiac output improvements have initially occurred at 
the heart.  Thus, the role of capillary density must be viewed as a means to help improve 
endurance performance, but not as a key limiting factor on V
．
O2max. 
 
1.6.3 Muscle Metabolism  
Oxygen reaches its final destination in mitochondria, located in muscle, where it is utilised 
in the final steps of the electron transport chain in order to resynthesise ATP.  Muscle 
metabolism of O2 contributes to the arterio-venous O2 difference (i.e. CaO2 – CvO2), as 
indicated in the Fick equation, where muscle O2 consumption determines CvO2. 
 
Several muscle metabolic mechanisms can undermine muscular performance (Westerblad 
and Allen, 2002, Westerblad et al., 2002) which, in turn, can be considered as a potential 
limitation on V
．
O2max.  As previously discussed, during prolonged and high intensity 
exercise, the energy consumption of skeletal muscle cells can increase, one hundred-fold, 
when compared to rest (Westerblad and Allen, 2002, Westerblad et al., 2002) and so there 
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is an inevitable eventual reliance on energy regeneration via anaerobic energy systems in 
attempt to supply ATP from muscle mitochondria to exercising muscle fibres.    
 
Several consequences arise as a result of this change and includes the production of 
inorganic acids such as hydrogen ions as a result of the disassociation of lactic acid 
(Posterino et al., 2001), which also increases muscle acidosis levels, and this then 
interferes with the muscle contractility.  In addition, the hydrolysis of muscle PCr to Cr 
and Pi results in an increase Pi (Allen et al., 2008) which has also been reported to interfere 
with muscle filament cross-bridge formation by reducing myofibrillar Ca2+ sensitivity 
(Dahlstedt and Westerblad, 2001) and sarcoplasmic reticulum Ca2+ reuptake  and release 
(Patel et al., 2000). 
 
Given the key role of mitochondria, as the site for ATP regeneration, an individual with 
superior O2 delivery adaptations may still be limited in his/her ability to regenerate and 
supply ATP to exercising muscle fibres. Theoretically, it has been suggested that low 
mitochondrial concentrations may limit the rate of ATP supply to exercising muscles and 
so studies have assessed the effects of increasing muscle mitochondrion concentrations on 
V
．
O2max via mechanisms associated with improved capacity to increase ATP supply.  Some 
studies, in humans, have indeed shown increases of between 20 to 30% in V
．
O2max after ~2 
fold increases in mitochondrial enzymes (Saltin et al., 1977).  In addition, Costill and 
colleagues (Costill et al., 1976) reported succinate dehydrogenase activity (a respiratory 
enzyme located in mitochondrion) in elite distance and middle distance endurance male 
runners was 3.4- and 2.8-fold higher, respectively, compared to levels found in untrained 
males.  However, the overall evidence indicates mitochondrial concentrations to play a 
minor role in limiting V
．
O2max and this is indicated in studies that have revealed that 
individuals, with nearly identical V
．
O2max values, can have up to a two-fold difference in 
mitochondrial enzyme levels and vice versa (Hartgens et al., 2004, Alen et al., 1984, 
Kuipers et al., 1993).   
 
Thus, the coupling of a high O2 transport capacity with an equally effective cellular O2 
utilisation capability is important for overall endurance performance and, in agreement 
with several authors (Jacobs et al., 2011) (Hepple, 2002, Hepple et al., 2002), peripheral 
components cannot be regarded as being key on limiting V
．
O2max, but are important in 
improving endurance performance.  Thus, the effects described do indeed contribute to 
causing fatigue at V
．
O2max; however, these effects are a consequence of cardiovascular 
limitations associated with O2 delivery (primarily a cardiac output limitation) and not the 
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initial cause.  Thus, improving muscle metabolism (e.g. by increasing mitochondrial 
enzymes) is beneficial for improving general endurance performance, but cannot be 
regarded as the key factor limiting V
．
O2max.   
 
1.7 Factors other than V
．
O2max Influencing Endurance Performance 
Despite the clear evidence that V
．
O2max is a good predictor if endurance performance in a 
heterogeneous group (see Section 1.3), this is not the case when homogenous groups of 
endurance athletes with relatively high V
．
O2max values are studied.  For example, Conley 
and Krahenbuhl reported that V
．
O2max explained only 1.4% of the variance in 10 km 
performance in elite distance runners (Conley and Krahenbuhl, 1980). Similarly, Weston 
and colleagues (Weston et al., 2000) compared physiological characteristics of sub-elite 
African and Caucasian runners, and reported that African runners had V
．
O2max values ~14% 
lower than the Caucasians, but 10 km race times for the two groups were very similar (2% 
slower in Africans).  This is further illustrated in a case-study of an Olympic athlete, whose 
3000 m  race performance time improved by 8% over a five-year period, despite V
．
O2max 
decreasing by 9.6% over the same period (Jones, 1998). Thus, while a high V
．
O2max is a 
necessary condition for elite endurance performance, it is not sufficient, and other factors 
also play a key role. 
 
Beyond durations of a few minutes, all endurance exercise is sub-maximal (i.e. conducted 
at intensities below V
．
O2max).  Thus a key determinant of performance in endurance events 
is the highest V
．
O2 that can be sustained for a prolonged period. While improvements in  
V
．
O2max plateau within a few months of endurance training, the maximal sustainable V
．
O2 
continues to improve beyond this (Astrand and Rodahl, 1970).  A key determinant of 
maximal sustainable V
．
O2 is the lactate threshold. 
 
1.7.1 Lactate Threshold 
The lactate threshold (LT) can be defined as the point where lactic acid starts to 
accumulate in blood faster than it can be removed and is indicative of an inability of the 
aerobic energy system to regenerate ATP at the required rate (Jones and Doust, 1998).  
Thus, the LT influences the maximal sustainable V
．
O2 and, therefore, the maximal 
sustainable pace that can be maintained throughout an endurance event.   
 
A common technique for LT determination involves the visual inspection of the 
relationship between work rate or V
．
O2 and [La] to identify the initial ‘deflection’ point 
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where [La] increases consistently above baseline concentrations (Wasserman et al., 1973) 
(Figure 1.8).  Studies have also indicated a second ‘deflection’ point, termed the lactate 
turnpoint (LTP), where blood [La] increases at a faster and consistent rate (Smith and 
Jones, 2001).  Alternatively, researchers have also utilised a fixed point that is a 
standardised pre-determined [La].    For example, a [La] of 4 mmol/l, in blood (Figure 1.8), 
has been proposed (Coyle et al., 1983) and this has been termed the onset of blood lactate 
accumulation (OBLA) (Kindermann et al., 1979, Sjodin and Jacobs, 1981).  More recently, 
the determination of the ‘maximal lactate steady state’ (MLSS) has also been proposed for 
profiling lactate response during submaximal exercise.  The maximal lactate steady state 
represents the highest work intensity that can be sustained whilst a constant [La] (i.e. no 
increase in [La] greater than 1 mmol/l) is maintained over the final 20 minutes of a 30 
minute constant work rate exercise test (Pringle and Jones, 2002, LaFontaine et al., 1981) 
(Figure 1.9).   
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Figure 1.8: Illustration of a typical blood [La] response to incremental exercise.  LT is 
defined as the initial ‘deflection’ point where [La] increases consistently above baseline 
concentrations. LTP is defined as the second ‘deflection’ point where blood [La] increases at a 
faster and consistent rate OBLA is defined as the point where [La] reaches 4 mmol/l. 
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Lactate threshold, OBLA, MLSS and LTP are highly correlated with each other although 
the work rates/speeds and V
．
O2 values at which they occur within an individual differ 
(Aunola and Rusko, 1992).  The importance of LT and related concepts (i.e. LT, LTP 
OBLA, MLSS) on endurance performance has been clearly demonstrated.   For example, 
in a homogenous group of endurance athletes (V
．
O2max range of 4.6 to 5.0 l
.min-1), the 
percentage V
．
O2max achieved at OBLA was a strong determinant of time-to-fatigue at 88% 
of V
．
O2max (Coyle et al., 1988).  In another example, LT was found to be the best predictor 
for distance covered in 12 minutes in untrained female participants (Yoshida, 1987). 
 
Whilst the LT is an important predictor of endurance performance capability, a number of 
studies have shown that the corresponding velocity or power output, at which the LT 
occurs, is a better predictor (Farrell et al., 1979, Hagberg and Coyle, 1983, Sjodin and 
Jacobs, 1981, Karlsson and Jacobs, 1982).  This is a function of both the V
．
O2 achieved at 
LT, and the velocity that can be achieved in that individual for that given V
．
O2.  Thus 
velocity at LT brings a third major determinant of performance into play – running 
economy (RE). 
 
 
Figure 1.9: An example for determining MLSS in an endurance athlete.  The individual 
completed several treadmill runs, up to 30 minutes in duration, at 14, 15 and 16 km.h-1 
running speeds.  15 km.h-1 running speed is identified as MLSS as a higher yet still constant 
blood [La] was reached.   
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1.7.2 Running Economy  
It has been well documented that a linear relationship exists between submaximal running 
velocities and V
．
O2.  However, the amount of O2 required to run at a particular running 
velocity varies quite considerably between individuals (Bransford and Howley, 1977, 
Morgan et al., 1995).  Thus, RE can be defined as the steady-state V
．
O2 for a given running 
velocity (Morgan et al., 1989).   
   
Studies have assessed the variance in oxygen cost for a given speed between differently 
trained groups of individuals, from untrained to elite. Overall, elite runners are the most 
economical and even within each training group category (i.e. untrained to elite), up to a 
20% difference in V
．
O2, at a given speed, between the least and the most economical can be 
observed (Morgan et al., 1995).  The physiological importance of RE has also been 
illustrated by Conley and Krahenbuhl (Conley and Krahenbuhl, 1980) who assessed the 
top 19 finishers of a prominent 10 km race and reported a strong relationship (r = 0.79-
0.83; P < 0.01) between RE and 10 km race times.  Furthermore, Daniels and Daniels 
(Daniels and Daniels, 1992) demonstrated how the interaction between V
．
O2max and running 
economy can affect running velocity at V
．
O2max between genders.  The authors 
demonstrated that, on average, woman displayed a lower V
．
O2max by 14% and that this also 
translated into a 14% lower velocity at V
．
O2max (when compared to male counterparts with a 
similar running economy profile).  Such findings where RE is lower in women than men, 
of similar training status (Daniels and Daniels, 1992), has partly been explained by woman 
naturally possessing higher percentage body fat (which is additional economy impairing 
carried weight).  Such explanations do, in part, explain the lower performance in endurance 
events of women in comparison to male counterparts. 
 
While it is clear that RE influences endurance performance capability, explanations for 
differences in economy between individuals have not been fully elucidated.  It appears that 
both genetic and environmental factors contribute.  For example, contrasts have been made 
between African and Caucasian runners where Africans have been reported to exhibit 
better RE in comparison to the Caucasian comparisons (47.3 ± 3.2 vs. 49.9 ± 2.4 ml.kg-
1.min-1  at 16 km.h-1, respectively; P < 0.05) (Weston et al., 2000).  Several explanation 
have been suggested in an attempt to explain such a phenomena and these have included: 
smaller body mass in African individuals (thus reducing the oxygen cost at a given running 
speed), a better ability to sustain a higher percentage of V
．
O2max (over a given distance, e.g. 
10 km) in African individuals and  the ability to accumulate less plasma lactate  in 
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comparison to Caucasian counterparts (Weston et al., 2000).  The authors suggest that such 
explanations, in part, help explain the dominance of African runners on the world-stage.  
 
Conversely, Jones (Jones, 2006) physiologically assessed the current female world record 
holder for the marathon distance, Paula Radcliffe, over a 7-year period and reported a 15% 
improvement in RE over this period (but no change in V
．
O2max).  Jones (Jones, 1998) also 
assessed the effect of long-term endurance training and its impact on 3000 m running 
performance and reported improvements in velocity at LT (from 15 to 18 km.h-1) as well as 
an improved RE (from 53 to 48 ml.kg-1.min-1 at 16 km.h-1).  Strength and power training 
have also been shown to improve RE and, consequentially, endurance performance 
(Hickson et al., 1988, Millet et al., 2002, Spurrs et al., 2003, Paavolainen et al., 1999). 
 
Further, in addition to training and the application of the above interventions, Saunders et 
al. (Saunders et al., 2004a) have also described several physiological and biomechanical 
factors, related to improved RE in runners. Such factors include increased mitochondrion 
and oxidative enzyme levels within exercising muscles as well as the ability to generate 
low ground reaction forces (Saunders et al., 2004a).  Detailed discussion of the 
determinants of RE is beyond the scope of this Chapter and interested readers are directed 
to a review by Saunders and colleagues (Saunders et al., 2004a) for further information.  
 
1.7.3 Integrated Effects of V
．
O2max, LT and Running Economy on Endurance 
Performance 
To summarise, V
．
O2max determines the ‘upper limit’ for oxidative ATP regeneration and 
V
．
O2max and LT together determine the maximal sustainable V
．
O2 in endurance events 
(Bassett and Howley, 2000).  The velocity achieved for this V
．
O2 is determined by RE.  
Thus, V
．
O2max, LT and RE integrate to determine endurance performance. Key 
cardiovascular limitations on V
．
O2max and key factors that influence endurance performance 
capability have been discussed and these are summarised in Figure 1.10.  However, while 
the factors described here are strong predictors of endurance performance, they do not 
explain 100% of its variance.  Thus, other factors must also play a role in determining 
endurance performance.  A number of researchers have investigated how factors other than 
those illustrated in Figure 1.10 may influence endurance performance.  The most 
prominent alternative/complementary paradigm to the cardiovascular model is the Central 
Governor Model.  This will be discussed in the following section. 
 
  
 
© Ramzy Ross (2013) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Ca-CvO2)max 
Figure 1.10:  Summary of the major cardiovascular variables related to V
．
O2max and the maximal velocity that can be maintained 
in a distance race. Adapted from (Bassett and Howley, 2000).  HRmax = maximal heart rate; SVmax = maximal stroke volume; [Hb] = haemoglobin 
concentration; %SaO2 = percent oxygen saturation; COmax = maximal cardiac output; (Ca-CvO2)max = maximal arterial-venous difference; V
．
O2max = maximal 
oxygen uptake; %V
．
O2max at LT = percentage of maximal oxygen uptake at lactate threshold.  
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1.8 The Central Governor Model 
An alternative to the cardiovascular model exists which emphasises the inclusion of the 
central nervous system (CNS) as the ‘central’ contributor to the regulation of endurance 
performance capability and V
．
O2max.  The importance of assessing the potential role of the 
CNS on endurance performance, which is not considered in the cardiovascular model, 
seems logical as without the brain all other factors become redundant.  In the context of the 
Central Governor Model (CGM), the CNS determines the muscles ability to generate force 
(Noakes et al., 2004, Noakes et al., 2005).   
 
Thus, the Central Governor Model (CGM) proposes an ‘integrative central neural 
regulation of effort and fatigue during exercise in humans’ (Noakes et al., 2004, Noakes et 
al., 2005). The Model’s key proponent, Professor Tim Noakes, describes exercise 
regulation as ‘using feed forward control in response to afferent feedback from different 
physiological systems, and the extent of skeletal muscle recruitment is controlled as part of 
a continuously altering pacing strategy with the sensation of fatigue being the conscious 
interpretation of these homoeostatic, central governor control mechanism’ (Noakes, 2011). 
It is important to highlight, at this stage, that one must be careful when considering what 
limits V
．
O2max and what limits endurance performance. These are two different questions, 
but have often been conflated in academic debates on limitations to human performance 
(Spurway et al., 2012). 
 
There are areas of disagreement between the cardiovascular model and the CGM, notably 
on the factors limiting V
．
O2max, with the CGM questioning the cardiovascular model 
assertion that cardiac output is the key limiter of V
．
O2max.  The CGM proposes that V
．
O2max, 
during maximal exercise, is indeed a result preceded by a plateau in cardiac output but that 
this is secondary to a plateau in coronary blood flow (Figure 1.11) (Noakes, 1998).  At this 
point, the CGM proponents argue, if exercise were to continue, the heart would be exposed 
to myocardial ischaemia, thus the plateau in cardiac output is a protective mechanism 
(Noakes, 1998) (Figure 1.12).  Accordingly, the coronary flow plateau leads to a feed-
forward neuronal mechanism, from the brain to the peripheral exercising muscles, reducing 
the recruitment of muscle fibres in order elicit a reduction in workload which, in turn, 
preserves the heart from experiencing myocardial ischaemia –a life threatening condition 
(Digenio et al., 1999).  Furthermore, endurance training increases maximal coronary blood 
flow.  Proponents of the CGM argue that it is this change which enables the training-
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induced increases in cardiac output and muscle O2 perfusion capability to occur (Noakes, 
2000).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: According to the CGM, the first variable to plateau during incremental 
exercise to exhaustion is coronary flow.  Peak coronary flow (indicated with black 
arrow) then induces a plateau in cardiac output (CO) as a result of progressive 
myocardial ischaemia (Noakes, 1998).  
Plateau in coronary flow 
Plateau in cardiac output 
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Figure 1.12:  The weakness of the cardiovascular approach, according to the CGM model, is the 
failure to recognise that the attainment of maximal cardiac output has more serious consequences for 
the heart than skeletal muscles.  Continuing to exercise at maximal cardiac output would cause 
myocardial ischaemia.  The heart, unable to increase coronary flow (as dependent on an increase in 
cardiac output), thus limits the hearts ability to meet myocardial oxygen demand caused by increased 
work rates.  Taken from (Noakes, 1998).  
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Beltrami and colleagues (Beltrami et al., 2012) have recently provided new evidence 
challenging the cardiovascular system’s maximal capacity to transport O2 in a study where 
subjects were randomised to conventional or reverse V
．
O2max test protocols.  The 
conventional group carried out several standard incremental V
．
O2max tests, whilst the 
reverse group carried out: l) an incremental uphill running test plus verification test, 2) a 
decremental running test where the same starting speed was used as during the verification, 
but was reduced progressively and 3) a final incremental test.  The results revealed that 
V
．
O2max values were 4.4% higher in the decremental tests when compared to the 
incremental test (63.9 ± 3.8 vs. 61.2 ± 4.8 ml.kg-1.min-1, respectively, P = 0.004).  Reasons 
as to why V
．
O2max was higher in the reverse group remains to be elucidated, but the authors 
concluded subjects must have terminated the conventional incremental test with a 
cardiorespiratory reserve (as indicated by a higher V
．
O2max during the decremental 
protocol).  Thus, termination of exercise was caused by factors other than those associated 
with the cardiovascular system. 
 
When discussing CGM tenets with regards to how endurance performance is regulated 
(rather and not what limits V
．
O2max) recent studies have reported an interaction between the 
CNS and peripheral systems.  The CGM proposes that peripheral fatigue influences the 
rate of central fatigue via neural feedback pathways from the working muscle to motor 
control areas of the CNS (Amann et al. 2006, 2007; Amann and Dempsey 2008; Dempsey 
et al. 2008).  Furthermore, it has also been suggested that peripheral muscular fatigue is 
tightly regulated during exercise, and may act as a protective mechanism, where central 
motor control is adjusted by the performer in order to prevent peripheral muscular fatigue 
from rising above a ‘critical threshold’ (Amann and Dempsey 2008).  It is argued that 
beyond this ‘critical threshold’, the level of sensory input (i.e. demand for work or training 
duration or training intensity) would not be tolerated (Gandevia, 2001).  For example, 
Amman and Dempsey (Amann and Dempsey 2008) demonstrated that despite eliciting 
significant differences in quadriceps muscle fatigue immediately prior the start of self-
paced 5 km cycling time trials,  the level of peripheral muscle fatigue at the end of the trial 
was identical (as determined by quadriceps twitch force using electromyography).   
 
The evidence supporting the interaction of central and peripheral components has been 
highlighted; however, studies have also focused solely on the brain and exercise regulation 
alone.  One approach, to assess this, has been via the manipulation of brain temperature on 
exercise performance (Nybo, 2012).  Experiments involving manipulations of brain 
temperature, independent of core body temperature, in exercising goats have shown 
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debilitating effects on motor performance under excessive brain hyperthermia.  For 
example, Caputa and colleagues (Caputa et al., 1986) demonstrated this using goats where 
head and trunk temperatures were independently manipulated in order to assess the effect 
on a treadmill based exercise performance test.  The authors reported that blood lactate 
increased concomitantly with rising brain and trunk temperatures; however, hyperthermic 
brain temperatures, alone, of 42 to 42.9oC reduced performance in 25% of cases 
independent of body core temperature (Caputa et al., 1986).   
 
Studies have also carried out manipulations of CNS neurotransmitter levels (e.g. dopamine 
and serotonin) on exercise performance (Roelands and Meeusen, 2010).  Concentrations of 
serotonin and dopamine, neurotransmitters involved in signal transduction between 
neurons in the brain, have been associated with several factors in humans including sleep-
wakefulness, emotion and appetite (Meeusen et al., 2006).  The identified associations with 
sleep-wakefulness (e.g. increased serotonin levels associated with fatigue) (Meeusen et al., 
2001) have been investigated to see if manipulations can influence characteristics such as 
motivation during exercise, for example.  Under normal ambient conditions, an interaction 
between serotonin/dopamine have been suggested to influence CNS fatigue, with low and 
high ratios reported to improve (by improving motivation) and decrease performance (by 
decreasing motivation and augmenting lethargy), respectively (Davis and Bailey, 1997).  
Exercise has also been reported to induce CNS increases in the concentrations of 
tryptophan (a precursor of serotonin) and the resulting increase in brain concentrations, via 
movement across the blood-brain barrier, have been reported to increase serotonin 
concentrations (Meeusen et al., 2006).  This has been associated with debilitating effects 
on exercise performance (Meeusen et al., 2001).  Overall however, studies manipulating 
neurotransmitter brain concentrations have been inconclusive with either no change 
(Strachan et al., 2004, Roelands et al., 2009, Strachan et al., 2005) or an improvement in 
performance (Bridge et al., 2003, Roelands et al., 2008, Watson et al., 2005) being 
reported.   
 
In support of the CGM model, Tim Noakes has also recently cited 21 studies (Noakes, 
2011a) to support the notion that exercise performance can be modified by varying 
‘centrally acting performance modifiers’ including music (Lim et al., 2009, Barwood, 
2009), placebos (Trojian and Beedie, 2008), self-belief (Micklewright et al., 2010), time 
deception (Morton, 2009), prior experience (Mauger et al., 2009) and mental fatigue 
(Marcora et al., 2009).  Noakes argues, more directly against the ‘cardiovascularists’, 
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where he describes their ‘brainless’ (Noakes, 2011b) approach as being incapable of 
explaining how such interventions can influence the performance of the heart.   
 
On closer inspection, not all of the cited studies are fully supportive of the CGM.  For 
example, Lim and colleagues (Lim et al., 2009) assessed the effects of music introduced 
and removed during 10 km cycling time trial performance.  Male participants completed a 
10 km time trial under 3 conditions: 1) no music, 2) music played initially then removed 
and 3) music introduced for 5 to 10 km distance.  Although differences in pacing 
approaches were identified (e.g. participants in group 3 where music was introduced 
produced faster starting speeds in the first 5 km), there was no significant difference in 
overall completion times (P = 0.10).  In a similar example, Micklewright and colleagues 
(Micklewright et al., 2010) assessed the influence of self-belief on exercise performance.  
The authors reported higher than usual power outputs and speeds (i.e. a change in pacing 
strategy) during the first 5 km when cyclists were led to believe, via false feedback, that 
they were capable of producing a better performance.  However, 20 km completion times 
did not statistically differ between groups given true or false feedback. Thus, whilst 
manipulations of central factors altered pacing, it did not influence overall performance.   
 
There are a few examples, however, cited by Noakes (Noakes, 2011b) that do warrant 
further consideration.  Morton and colleagues (Morton, 2009) assessed the influence of 
time deception on exercise performance.  In this study, a subject feedback clock was 
manipulated to test the effect on maximal effort during endurance cycle ergometry exercise 
where male and female subjects cycled at 90 rpm at a work intensity of 300 W and 250 W, 
respectively, for as long as possible.  In a double-blinded fashion, participants took part in 
3 conditions: 1) clock normally calibrated, 2) clock calibrated 10% faster and 3) clock 
calibrated 10% slower.  Results indicated a significant clock calibration effect on real 
endurance times where times were longer during the slower clock condition when 
compared to normal (by 18.3%) and faster (by 20.5%) conditions.  Furthermore, in a 
separate example, Marcora and colleagues (Marcora et al., 2009) reported that time to 
exhaustion at 80% of peak power output was significantly reduced by ~15% after 90 
minutes of a demanding cognitive task.  Thus, there is some evidence to suggest that 
mental fatigue can limit tolerance to exercise via mechanism other than those associated 
with cardiovascular system.  
 
Further, it must be noted that the mind or ‘psyche’ must also play a key role on 
performance outcome as the desired exercising output may only be attempted if the ‘mind’ 
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is motivated to do so.  Psychological approaches are often criticised due to methodologies 
lacking enough true validity (i.e. not very well controlled); nevertheless, the 
psychological/motivational model essentially describes that a conscious effort is required 
in order to sustain prolonged exercise (Davis and Bailey, 1997).     
 
Finally, Marino (Marino, 2008), a firm believer of the CGM concedes that, “the evidence 
for the governor is scarce in comparison to that supporting the classic view” [in reference 
to the cardiovascular model], however, “evidence for the governor will come in due 
course".  Figure 1.13 illustrates how the CGM may interact with variables, as proposed by 
the traditional ‘central dogma’ approach, which determine endurance performance.  
 
In summary, the standpoint of the CGM is one where the brain and CNS carefully 
regulates exercise in a manner not to compromise body homeostasis and, in particular, the 
potentially life-threatening event of myocardial ischaemia from occurring during strenuous 
exercise.  The central governor achieves this via neural control where the reduction of 
muscle fibre recruitment leads to the sensation of fatigue, in turn, causing a reduction in 
work rate.  
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Figure 1.13:  Summary of the major cardiovascular variables (black lines), with the addition of the Central Governor Model (CGM) (orange 
lines), related to V
．
O2max and the maximal velocity that can be maintained in a distance race. Adapted from (Bassett and Howley, 2000).   HRmax 
= maximal heart rate; SVmax = maximal stroke volume; [Hb] = haemoglobin concentration; %SaO2 = percent oxygen saturation; COmax = maximal cardiac output; (Ca-CvO2)max = 
maximal arterial-venous difference; V
．
O2max = maximal oxygen uptake; %V
．
O2max at LT = percentage of maximal oxygen uptake at lactate threshold.  
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1.9 Using Performance Enhancing Drugs to Understand Endurance 
Performance Limitations 
It is vital that research continues in order to better understand what and how endurance 
performance is limited.  One way of approaching this is by using performance enhancing 
drugs and investigating their potential to improve endurance performance.  The World 
Anti-doping Agency (WADA) is responsible for preparing and publishing the ‘Prohibited 
List’, on an annual basis, and a simplified illustration is provided in Box 1.1.  This list 
identifies substances and methods prohibited in sport and these are categorised based on 
their ergogenic effect or purpose.  Different banned substances are prohibited in-
competition or out-of-competition, or both, and can be banned for particular sports.   
 
 
 
 
Box 1.1:  Substances and Methods Prohibited In- and Out-Of-Competition 
 
- Substances and Methods Prohibited In-and Out of Competition Only: 
 
S0: Non-Approved Substances 
S1: Anabolic Agents 
S2: Peptide Hormones, Growth Factors and Related Substances 
S3. Beta-2 Agonists 
S4. Hormone and Metabolic Modulators 
S5. Diuretics and Other Masking Agents 
M1. Enhancement of Oxygen Transfer 
M2. Chemical and Physical Manipulation 
M3. Gene Doping 
 
- Substances and Methods Prohibited In-Competition Only: 
 
S6. Stimulants 
S7. Narcotics 
S8. Cannabinoids 
S9. Glucocorticosteroids 
 
- Substances and Methods Prohibited In Particular Sports: 
 
P1. Alcohol 
P2. Beta-Blockers 
 
Simplified version of the WADA Prohibited List (Full list available at: 
http://list.wada-ama.org/) 
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There are reports of increasing use of performance enhancing drugs in both elite 
(Waddington et al., 2005, Pitsch, 2011, Weiss, 2012) and recreational level sport 
(Waddington et al., 2005, Weiss, 2012, Bojsen-Moller and Christiansen, 2010).  This has 
been recently illustrated in the case of Lance Armstrong (United States Anti-doping 
Agency (USADA), 2012).  As a result, recent years has seen a growing body of research 
assessing the performance and health implications of taking such substances (Bahrke et al., 
1998, Dawson, 2001).  Different classes of drugs are influencing exercise performance in 
different ways; from improving power by stimulating muscle hypertrophy for sprint events 
to increasing the carrying O2 capacity of blood to enhance endurance performance for 
prolonged events.   
 
For example, use of androgenic-anabolic steroids – synthetically produced derivatives of 
the male hormone testosterone – have been shown to induce strength gains up to 20% 
(Hartgens and Kuipers, 2004), mainly attributable to muscle hypertrophy (Hartgens and 
Kuipers, 2004); and stimulants, such as amphetamines and caffeine, which work on the 
CNS (Avois et al., 2006), have been shown to improve strength and endurance 
performance (Chandler and Blair, 1980, Doherty and Smith, 2004).  However, it is drugs 
which increase O2 delivery which have the largest potential to influence endurance 
performance. 
 
One such drug that improves O2 delivery and uptake is r-HuEpo (also more commonly 
known as ‘EPO’) where the performance benefits of increased [Hb] and haematocrit (Hct), 
often associated with living at altitude, can be replicated at sea-level with a series of r-
HuEpo injections.  The use of r-HuEpo falls under category M1 (Substances and Methods 
Prohibited In- and Out-Of-Competition) on the WADA Prohibited List.  However, if used 
appropriately and only for research purposes, it can further our understanding on 
endurance performance capability.  
 
1.9.1 Erythropoietin 
Erythropoietin is an glycoprotein based hormone which, endogenously, is primarily 
secreted by the kidneys with a small amount also synthesised in the liver (Fisher, 2003).   
Endogenously present erythropoietin is the main regulator of erythropoiesis via the 
stimulation of pluripotent stem cell proliferation in bone marrow into reticulocytes (Ret) 
which enter the circulatory system and mature into red blood cells (RBC) (Fisher, 2003).  
The pharmaceutically engineered recombinant form of erythropoietin, r-HuEpo, was first 
developed in the 1980s and is now used in clinical applications; including the  
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administration to critically ill patients suffering from illnesses such as anaemia due to 
chronic renal failure (Macdougall et al., 1996) and cancer patients undergoing 
chemotherapy (Corwin, 2007).  For example, in those anaemic patients who suffer from a 
significant reduction in the number of blood cells in circulation, r-HuEpo administration 
has been shown to increase red blood cell count.  This effectively counter-acts the anaemic 
effect by mainly increasing total oxygen carrying capacity of blood and does not alter the 
oxygen saturation properties of haemoglobin (in relation to the oxy-haemoglobin 
dissociation curve as saturation is maintained, if at sea level, at ~96%).  Research studies 
have also demonstrated that r-HuEpo administration, in healthy individuals, also increases 
Hct and therefore O2 carrying capacity often improving the endurance performance of 
athletes as explained predominantly by the cardiovascular model (Audran et al., 1999, 
Ashenden et al., 2001, Ashenden et al., 2006, Lundby et al., 2007).  As previously 
discussed (please see section 1.4.2.2), an enhancing blood O2 carrying capacity simply 
increases the amount of O2 that is made available to exercising muscle.  Recombinant 
erythropoietin administration increases the O2 carrying capacity of blood (in-turn 
increasing arterio-venous O2 difference, as part of the Fick equation) and this is primarily 
caused by an increase in [Hb].  In addition to more oxy-haemoglobin complexes being 
formed, this enhancement of central O2 delivery to peripheral musculature is also coupled 
with an increase in cardiac output (due to potential increases in blood volume) (please see 
section 1.4.2.1).  As previously discussed, such enhancements (e.g. total O2 carrying 
capacity of blood determined by total haemoglobin mass measures) are strongly correlated 
with enhancement in performance measures such as V
．
O2max, for example (Figure 1.5). 
  
The regulation of erythropoietin, in humans, has been reported to involve a feed-back 
mechanism based on the level of blood oxygenation involving erythropoietin transcription 
factors known as hypoxia-inducible factors (Jelkmann, 2007) which bind to erythropoietin 
receptors located on surfaces including red blood cells, bone marrow cells and 
central/peripheral nerve cells (Reid and Mohandas, 2004).   Interestingly, r-HuEpo 
administration has also been reported as having beneficial effects on patients suffering 
from specific neurological diseases such as schizophrenia (Ehrenreich et al., 2004) and 
cerebral malaria (Core et al., 2011).  Currently, the evidence indicates that r-HuEpo use 
can improve limitations associated with the cardiovascular system; however, some 
evidence has also suggested r-HuEpo administration to have potential effects on the CNS.   
 
Table 1.2 shows studies, to date, which have assessed r-HuEpo administration on exercise 
performance.  The administration of  r-HuEpo for 4 to 15 weeks has been widely reported 
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to increase [Hb] and Hct by up to approximately 10-20% with an associated increases in 
V
．
O2max by approximately 7 to 13% (Russell et al., 2002b, Berglund and Ekblom, 1991, 
Parisotto et al., 2000b, Lundby et al., 2007), (Birkeland et al., 2000, Audran et al., 1999, 
Thomsen et al., 2007, Lundby et al., 2007, Robach et al., 2008).  Recombinant 
erythropoietin administration has been reported not to change cardiac output, blood 
pressure, heart rate, ventilation and blood lactate concentrations during maximal running 
exercise (Berglund and Ekblom, 1991).  The magnitude of change in [Hb], Hct and V
．
O2max 
have been reported to be similar to red blood cell reinfusion (Ekblom and Berglund, 1991).  
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Table 1.2  Previous literature assessing r-HuEpo administration for haematological measures and V
．
O2max 
Study Participants 
r-HuEpo Dose 
(IU/Kg/Week) 
Treatment 
Period (Weeks) 
Hct 
(%∆) 
[Hb] 
(%∆) 
tHb 
(%∆) 
V
．
O2max 
(%∆) 
Ekblom and Berglund (1991) 15 Healthy 20-40 6 11.7 11.2 - 8.0 
Audran et al. (1999) 9 Trained 350 4 11.5 9.3 - 9.3 
Birkeland et al. (2000) 10 Well-trained 207 4 19.0 14.5 - 7.1 
Parisotto et al. (2000) 8 Trained 150 4 10.1 10.7 12 6.9 
Russel et al. (2002) 9  Recreational 94 8 14.3 - - 7.0 
Ashenden et al. (2006) 2 Well-trained 348 5 - 18.1 - - 
Thomsen et al. (2007) 16 Healthy 61 13 10.8 11.1 - 12.6 
Lundby et al. (2008) 8 Healthy 120 4 12.0 11.6 - 7.6 
Robach et al. (2008) 8 Healthy 60-181 15 7.0 11.1 - 7.2 
r-HuEpo: Recombinant Human Erythropoietin; Hct: Haematocrit; Hb: Haemoglobin; tHb: Total Haemoglobin Mass; V
．
O2max: 
Maximal Oxygen Uptake.   
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In addition to increasing red cell mass, administration of r-HuEpo also reduces plasma 
volume, magnifying the effects on [Hb] (Lundby et al., 2007) (Lundby et al., 2008a) 
(Olsen et al., 2010). This is reported to occur due to a down-regulation of proximal renal 
tubular reabsorption in the kidneys which consequently causes a decrease in glomerular 
filtration rate (Olsen et al., 2010).   
 
Stopping r-HuEpo administration leads to the decrease in [Hb].  This may be mediated by 
the apoptosis of r-HuEpo induced newly formed red cells (Chang et al., 2009).  However, 
clear evidence indicates that the initial reduction in [Hb], post r-HuEpo administration is as 
a result of a normalisation of plasma volume which, in turn, reduces [Hb] (Lundby et al., 
2007).  This has been supported by direct measures which show that red cell mass is 
maintained for ~2 weeks following the cessation of r-HuEpo despite the drop in [Hb] 
(Olsen et al., 2010).   
 
The effects of r-HuEpo administration on skeletal muscle have also been assessed. Micro 
RNA levels of several muscular components remained largely unchanged but with minor 
changes in myoglobin, transferring receptor mRNA level and MRF4 reported (Lundby et 
al., 2008b).  As a result, r-HuEpo may indeed directly influence peripheral musculature; 
however, the physiological importance of this effect is presently thought to be very limited 
with no changes in muscle composition including capillary density, fibre type distribution 
and muscle fibre cross-sectional area (Lundby et al., 2008b).   
 
More recent studies have also attempted to assess the effect of r-HuEpo on central 
mechanisms (i.e. brain and CNS).  Recently,  Rasmussen and colleagues (Rasmussen et al., 
2010) assessed 15 healthy young men who received 3 days of high doses of r-HuEpo in a 
double-blinded placebo controlled study design.  Exercise capacity, transcranial 
ultrasonography-derived middle cerebral artery blood velocity and arterial-internal jugular 
venous concentration differences of glucose and lactate were assessed.  The authors 
reported an increase in cerebrospinal fluid concentrations of EPO as well as increased 
glucose and lactate concentrations (P < 0.05).  However, this had no impact on cognition or 
voluntary muscle fibre recruitment.  However, total work capacity increased by ~15% (P < 
0.01).  The authors concluded that the improvement in exercise capacity was solely 
explained by mechanisms associated with the cardiovascular system; primarily an 
improved O2 carrying capacity of blood and, therefore, improved O2 delivery to exercising 
muscles.   
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Interestingly, non-exercise studies have shown the potential for r-HuEpo mediated central 
effects.  For example, Miskowiak and colleagues (Miskowiak et al., 2008a) assessed 
potential r-HuEpo mediated central effects on cognitive function after high doses (40000 
IU) of r-HuEpo administration.  The authors reported improved neural processing and 
cognitive function, in healthy subjects, during a verbal fluency test as a result of r-HuEpo 
administration.  Similar improvements in neural processing have been reported in patients 
suffering from neuropsychiatric diseases (Miskowiak et al., 2008b) and patients with 
schizophrenia have also shown improvements in cognitive function after similar doses of r-
HuEpo (Ehrenreich et al., 2004). 
 
As a result of an r-HuEpo administration period, improvements in exercise capacity are 
well documented (Audran et al., 1999, Ashenden et al., 2001, Ashenden et al., 2006, 
Lundby et al., 2007).  The majority of studies have assessed the effects by determining the 
impacts on V
．
O2max and these are indicated in Table 1.2; however, some studies have also 
demonstrated the potential of r-HuEpo to improve exercise capacity at submaximal 
intensities.  For example, Thomsen and colleagues (Thomsen et al., 2007) assessed 16 
male volunteers who carried out time to exhaustion cycle tests where increase time to 
exhaustion at 80% of V
．
O2max.  In this study, 5000 IU r-HuEpo was administered every two 
days for 14 days followed by a weekly dose of 5000 IU for 10 weeks.  The authors 
reported that r-HuEpo administration improved time to exhaustion at 80% of V
．
O2max by 54 
and 54.3% after 4 and 11 weeks of r-HuEpo administration, respectively.  This change was 
greater than the improvement in V
．
O2max (12.6 and 11.6%, at week 4 and 11; P < 0.05, 
respectively).  
 
To summarise, the administration of r-HuEpo on endurance exercise performance strongly 
indicates the primary effect as being one on the cardiovascular system by improving O2 
carrying capacity of blood and, therefore, O2 delivery to exercising muscles.  However, as 
evidence out with the exercise field suggests a potential central effect of r-HuEpo 
(Miskowiak et al., 2008a).  Therefore, it is possible that the drug may also influence 
exercise performance by central mechanism.  Figure 1.14 illustrates proven and potential r-
HuEpo influences on human endurance performance.  Further, as part of central 
mechanisms, the administration of r-HuEpo may also work via a placebo effect.  This will 
be discussed in the following section. 
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Figure 1.14:  Summary of the major cardiovascular variables (black lines), with the addition of the Central Governor Model (CGM) (orange lines), 
related to V
．
O2max and the maximal velocity that can be maintained in distance races. The documented (red arrows) and potential effects (red arrows 
with question mark) of r-HuEpo are also included.  HRmax = maximal heart rate; SVmax = maximal stroke volume; [Hb] = haemoglobin concentration; %SaO2 = percent oxygen 
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O2max at LT = percentage of maximal oxygen uptake at 
lactate threshold.  
r-HuEpo? 
Chapter 1. General Introduction  67 
_____________________________________________________________________________ 
67 
 
1.10 Using the Placebo Effect to Understand Endurance Performance 
Limitations 
1.10.1 The Placebo Effect in Medicine and Sports Performance 
 
The ‘placebo’ (Latin for ‘I shall please’) effect is one where a desired outcome effect is 
achieved via the subscription of an inert or ineffective treatment (Gensini et al., 2005).  
The placebo effect dates back centuries and is widely acknowledged as a key factor in 
medical research (Hrobjartsson and Gotzsche, 2003, Hrobjartsson and Norup, 2003).  
Placebos can be administered in varying forms from inactive drugs, sham surgery and 
other procedures involving sham protocols or the provision of false information (Lanotte et 
al., 2005).  As a consequence, its effect has been controlled for in clinical trials for over 50 
years (Beedie and Foad, 2009).   
 
The evidence also suggests that the performance enhancing effect of any drug could partly 
be due to a placebo effect.  This effect has been recognised in the context of sports 
medicine where researchers have reported placebo mediated changes of similar magnitude 
to those found in ‘real’ interventions (Price et al., 2008, Beedie and Foad, 2009).  
Furthermore, in an electronic survey,  97% of respondents believed that the placebo effect 
can positively influence sporting performance (Beedie, 2007b).   
 
Clearly, the benefits of placebo cannot be explained in the context of the cardiovascular 
model and must be centrally mediated.  The manipulations of belief systems, underpinned 
by expectations and conditioning, is often what placebo effects are reliant on.  In other 
words the belief of change can result in real or tangible change (Kirsch, 2004).  For 
example, a study examining the effect of bedside manner of doctors in interactions with 
patients found that the effectiveness of a placebo treatment increased from 44% to 62% 
when an extra effort was made by the doctor to be warm, attentive and confident, as 
opposed to being neutral (Kaptchuk et al., 2008).  Furthermore, the brain and spinal cord, 
either subconsciously or consciously, have been proposed to regulate a response to 
override an undesired effect (e.g. pain) or to stimulate an enhancement effect of a process 
(Benedetti et al., 2005, Wager and Nitschke, 2005, Eippert et al., 2009).  There is evidence 
of a direct cerebral effect of placebo in clinical studies.  For example, Petrovic and 
colleagues (Petrovic et al., 2002) examined the effect of no intervention, placebo injection 
or analgesic injection on brain responses to a brief un-harmful experience.  Positron 
emission tomography scans indicated activation of the rostral anterior cingulated cortex for 
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both the placebo and analgesic treatment, although the injected analgesic did provide more 
pain relief (Petrovic et al., 2002). 
 
While there is a substantial body of research of the placebo in clinical settings, the study of 
the effects of placebo on sporting performance is still in its infancy.  Furthermore, even 
less is understood about the placebo effect in real competition scenarios, as opposed to 
tests confined to the laboratory.  Laboratory studies have reported positive effects 
associated with a placebo intervention on the enhancement of endurance, sprint and 
strength performance (Ariel and Saville, 1972, Maganaris et al., 2000, Foster et al., 2004b, 
Beedie and Foad, 2009).  Studies evaluating the effect of placebo on endurance 
performance are shown in Table 1.3.    
 
Studies have shown that an orally administered placebo can improve endurance 
performance by 1.1% to 8% (Clark et al., 2000, Foster et al., 2004b, Beedie et al., 2006, 
McClung and Collins, 2007, Foad et al., 2008, Wright et al., 2009) and Table 1.3 provides 
a summary of studies that have been carried out to assess the effects of a placebo 
intervention of endurance exercise performance.   
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Table 1.3.  Summary of studies assessing the placebo effect on endurance exercise performance 
Study Participants Study Design 
Performance 
Measure 
Intervention 
Informed 
Intervention Received % Change 
Clark et al. 
(2000) 
43 Sub-elite 
cyclists 
Balanced repeated measures, 6 
cell Latin square design. After 
baseline time trial (water), 
subjects split into 6 treatment 
groups in total: two subgroups 
(given carbohydrate, given 
placebo) for each of three main 
groups (told carbohydrate, told 
placebo, not told) 
Mean power over 
40 km cycling 
power distance 
CHO Placebo   
 
CHO  
7.8% 
 
1.5% 
  
 
 
Placebo Placebo  
 
CHO   
 
-0.3 
 
0.2 
  
 
 
Not told (i.e. 50/50 
chance of receiving 
CHO or placebo) 
Placebo  
 
CHO  
-1.0 
 
0.1 
Chapter 1. General Introduction  70 
_____________________________________________________________________________ 
70 
 
Foster et al. 
(2004) 
16 Sub-elite 
runners 
Within subjects design. 
Subjects performed random-
ordered 5 km time trials after 
consuming either water (and 
told water) or water falsely 
purporting to contain the 
ergogenic aid (and told this). 
 
5 km running 
time 
New ergogenic aid Placebo 1.1 
Porcari et al. 
(2006) 
32 Sub-elite 
runners 
Between-subjects design. 
1 x habituation and 2 x 
counterbalanced experimental 
where participants informed 
either water (and given water) 
or super-oxygenated water (and 
given water) 
5 km running 
time 
Super-oxygenated 
water 
Placebo 8.0 
Beedie et al. 
(2006) 
6 Sub-elite 
cyclists 
 
Within-subjects design. 
1 x habituation, 1 x baseline 
and 3 experimental trials 
10 km cycling 
power 
0mg/kg caffeine Placebo -1.4 
    4.5 mg/kg caffeine Placebo 1.3 
    9.0 mg/kg caffeine Placebo 3.1 
Chapter 1. General Introduction  71 
_____________________________________________________________________________ 
71 
 
McClung and 
Collins 
(2007) 
16 Sub-elite 
endurance 
athletes 
Within-subjects, Latin 
square/balanced placebo design 
(4-cell).  5 x 1000-m time trials 
(1 x habituation and 1 x trial per 
counterbalanced condition) 
1000 m running 
time 
Sodium bicarbonate 
Sodium bicarbonate 
Placebo 
Placebo 
Sodium bicarbonate 
Placebo 
Sodium bicarbonate 
Placebo 
1.7 
1.5 
-0.3 
0.0 
Foad et al. 
(2008) 
14 Sub-elite 
cyclists 
 
Within-subjects, Latin 
square/balanced placebo design 
(4-cell). Subjects performed 2 x 
40 km time trials, before and 
after, in each of four 
experimental conditions  
40 km cycling 
power 
Caffeine Caffeine 2.3 
    Caffeine Placebo 0.1  
    Placebo Caffeine 2.9  
    Placebo No treatment -1.9  
        
 
Wright et al. 
(2009) # 
 
32 runners 
 
Within-subjects design. 1 x 
control and 1 x placebo  where 
participants informed either 
 
5 km running 
time 
 
Super-oxygenated 
water 
 
Placebo 
 
6.5 
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Subject descriptions have been taken from original papers. ^ Magnitude-based inference.  CHO = carbohydrates.  # Part 1 of a 3 part study.
water (and given water) or 
super-oxygenated water (and 
given water) 
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In one example, Foster and colleagues (Foster et al., 2004b) assessed the effects of a ‘new’ 
ergogenic aid on 5 km running performance in sixteen well-trained runners (V
．
O2peak 58 ± 8 
ml.kg-1.min-1).  The authors reported a competitively meaningful improvement in 5 km 
time trial performance, although this was not statistically significant, after participants had 
ingested the ergogenic aid when compared to control (21.54 vs 21.40 minutes, 
respectively; P = 0.11).  Interestingly, no differences were reported between conditions in 
RPE (8.2 ± 1.0 vs 8.4 ± 1.2), peak heart rate (177 ± 5 vs 177 ± 6 b.min-1) or blood lactate 
(12.2 ± 3.2 vs 11.4 ± 2.2 mmol.l-1).  In another example, Porcari and colleagues (Porcari et 
al., 2006) assessed the effect of a placebo intervention on 5 km running performance, but 
in this instance the placebo was ‘super-oxygenated’ water and the control group was 
‘control water’.  Thirty-two experienced runners (V
．
O2max 60.8 ± 8.2 ml
.kg-1.min-1) 
completed three 5 km time trials on an indoor 200 m track (1 x habituation and 2 x 
counterbalanced experimental).  Significant differences were reported between the two 
conditions for 5 km total completion time (control water: 21.04 ± 3.34 minutes; placebo 
water: 19.41 ± 2.32 minutes; P < 0.05).  Similarly, as with the previous study however, no 
significant differences were found in HR, RPE and blood lactate (P > 0.05).  Interestingly, 
in this study the largest improvements reported after placebo ingestion were the in less 
accomplished runners in comparison to the more experienced runners (142 second vs. 28 
second improvement, for less accomplished and more accomplished runners, respectively).  
 
Caffeine supplementation has been a popular means in attempt to improve performance, as 
previously discussed.  Thus, several studies have assessed the potential of a placebo effect 
in caffeine’s capability to influence endurance performance. A study by Foad and 
colleagues (Foad et al., 2008) assessed the effects of  caffeine and placebo interventions on 
40 km cycling performance in fourteen well-trained competitive cyclists.  The authors 
found the effects of caffeine not significantly different from placebo on endurance 
performance.  The study by Foad assessed the interaction between performance enhancing 
beliefs and expectations in relation to the administration of caffeine or a placebo.  
Performance did not improve when subjects were not given caffeine.  However, 
performance was enhanced similarly when subjects were given caffeine irrespective of 
whether or not they believed caffeine had been administered.  Interestingly, the authors 
reported a nocebo effect when participants were informed that no caffeine would be 
administered and caffeine was not administered (Table 1.3).  The authors highlighted the 
presence of key interactions between pharmacology and psychology which they propose 
warrants further investigation.   
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Thus a number of studies have shown that improvements in endurance performance can 
elicited by the use of various placebo interventions purporting to be established or novel 
ergogenic aids.  However, all the above mentioned studies administered the placebo orally.  
Studies from clinical medicine have shown that the route of placebo administration can 
influence the magnitude of the placebo effect.  Thus, a limitation in the present literature is 
that no study has assessed the effects of administrating a placebo, by other routes, on 
endurance sports performance.   
 
1.10.2 The Placebo Effect and Route of Delivery 
 
A key feature of r-HuEpo administration is that it is given by injection.  Evidence from 
clinical medicine indicates that the route of delivery is a key mediator of the placebo effect 
size, with placebos administered by injection inducing a larger effect than placebos 
administered orally (Zhang et al., 2008).  For example,  Zhang and colleagues (Zhang et al., 
2008) carried out a meta-analysis on the studies examining determinants of the magnitude 
of the placebo effect in the treatment of osteoarthritis.  One hundred and nighty eight trials 
with 193 placebo groups (16364 patients) and 14 untreated control groups (1167 patients) 
were included in the analysis.  The trials involved varying treatment strategies from non-
pharmacological to pharmacological to surgical interventions.  Overall, the authors reported 
a significant placebo effect for pain relief when compared to untreated controls (placebo 
effect size: 0.51, 95% CI 0.46 to 0.55 vs. untreated control effect size: 0.03, 95% CI -0.13 to 
0.18; P = 0.020).  Furthermore, the effect size for placebos administered by 
injection/needles (acupuncture: 0.71, 95% 0.53 to 0.90, intra-arterial hyaluronan (0.73, 95% 
CI 0.56 to 0.91) was significantly greater than those orally administered.  Other studies have 
reported similar findings, for example, Kaptchuk and colleagues (Kaptchuk et al., 2006) 
reported that sham acupuncture (i.e. a needle placebo) was superior to a tablet, administered 
orally, in patients with arm pain. 
 
Furthermore, Benedetti and colleagues (Benedetti, 2009) have highlighted the importance 
of the “open-hidden” paradigm.  In the “open” approach a patient receives a treatment in the 
normal clinical “open” manner where the patient is fully aware of the treatment.  
Conversely, in a “hidden” manner, the patient is unaware that the treatment is being 
administered.  The “open” administration approach has been reported as being at least 50% 
more effective than “hidden” for pain relief (Benedetti et al., 2004) and this is speculated to 
be due to higher therapeutic expectations when administration is observed.  This may play a 
role in the performance benefits observed with the administration of r-HuEpo. 
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The application of placebo injections, in the context of sports performance, has only been 
assessed in one study which assessed the effects of a placebo administered injection on pain 
tolerance (Benedetti et al., 2007).  Benedetti and colleagues assessed the effects of placebo 
mediated analgesia via use of morphine on a pain endurance test designed to stimulate sport 
competition (forearm spring exercise to maximum capacity whilst restricted with a 
tourniquet wrapped around the forearm).  Forty recreationally active male participants took 
part in the study where morphine or placebo (saline or naloxone) was administered in a 
randomised and double-blinded fashion.  Participants were split in two 4 groups: a) no 
pharmacological substance during training and received no treatment during competition, b) 
no pharmacological substance given in training and placebo given 1 hour prior competition, 
c) trained with morphine and given placebo morphine 1 hour prior competition and d) 
trained with morphine and received placebo yet told morphine was administered, but 
naloxone (i.e. an opiode antagonist what abolishes the morphine preconditioning effect) was 
actually administered prior competition.  The authors reported the greatest change in 
tolerance times, on the day of competition, in group C (baseline: 13.8 ± 2.7 vs. competition: 
20.8 ± 3.3 minutes; P < 0.001) in comparison to group B (baseline: 14.2 ± 3.2 vs. 
competition: 16.7 ± 2.5 minutes; P < 0.01), group A (baseline: 14.6 ± 2.9 vs. competition: 
15.7 ± 1.7 minutes; P > 0.05) and group D (baseline: 14.5 ± 3.2 vs. competition: 15.4 ± 2.9 
minutes; P > 0.05). 
 
Thus, as only one study has incorporated an injection/needle element to understand the 
impacts of the placebo in ‘sporting’ context, there is a clear need to assess the route of 
which r-HuEpo is administration and its impact on endurance performance.  Figure 1.15 
illustrates how an injected r-HuEpo placebo may influence variables associated with 
endurance performance. 
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Figure 1.15:  Summary of the major cardiovascular variables (black lines) related to V
．
O2max and the maximal velocity that can be maintained in 
distance races with the addition of the Central Governor Model (CGM) (orange lines), the known (red arrows) and potential (red arrows with 
question mark) pathways that r-HuEpo and an r-HuEpo placebo injection (blow arrows with question mark) may influence.  HRmax = maximal heart 
rate; SVmax = maximal stroke volume; [Hb] = haemoglobin concentration; %SaO2 = percent oxygen saturation; COmax = maximal cardiac output; (Ca-CvO2)max = maximal arterial-
venous difference; V
．
O2max = maximal oxygen uptake; % V
．
O2max at LT = percentage of maximal oxygen uptake at lactate threshold. Adapted from (Bassett and Howley, 2000). 
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Given the clinical significance of injected/needle mediated placebo effects, the fact that r-
HuEpo is administered by this route and that no study has assessed the implication of this 
in the context of endurance sporting performance there is a clear need for such a study to 
be undertaken. 
Furthermore, it is vital that such studies assess any such intervention in an environment 
truly representative of a real-life sporting scenario.  This would ensure that any potential 
findings are ecologically valid.  For example, time to exhaustion protocols are commonly 
employed to investigate endurance performance; however it is generally acknowledged 
that such tests can often haven a large coefficient of variation as compared to alternative 
testing methodologies like time trials (Jeukendrup et al., 1996).  Thus, this can often be a 
problem when attempting to deduce performance enhancing effects of an ergogenic aid.  In 
addition, laboratory tests are not realistic reflections of the experience of a real life 
performance situation (e.g. a race).  No study (to the best of the author’s knowledge), has 
assessed the effect of an r-HuEpo placebo administration phase on time trial performance 
in the field and in a competitive environment. Thus, field-based performance assessments 
are vital in order to truly understand, and further validate, the reported performance 
enhancing capabilities of r-HuEpo administration.  Thus, the importance of ecologically 
valid assessments for meaningful measures will be discussed in the following section. 
 
 
1.11 Measuring True Performance 
Many tests evaluating the effects of interventions on performance measures are performed 
under laboratory conditions.  However, studies have shown that care must be taken when 
extrapolating results obtained in a laboratory setting to the field, as the former may not 
provide an accurate representation of ‘real life’ events.  Thus, in order to elicit a truly valid 
human sporting performance response exercise protocols must replicate, as closely as 
possible, real life conditions so that a true performance response is measured. 
 
Studies have assessed various factors between laboratory and field-based conditions and 
their relative impacts on various performance outcome measures.  Studies have often 
questioned the transferability of laboratory results to the field.  For example, 
Kunduracioglu and colleagues (Kunduracioglu et al., 2007) reported a significantly higher 
running velocity during the employed field-based test in comparison to a laboratory test 
when running at a fixed blood lactate of 4 mmol/l (i.e. OBLA) (P < 0.01).  Similarly, Di 
Michele and colleagues (Di Michele et al., 2009) compared blood lactate concentrations 
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during running tests carried out on a treadmill, natural grass and synthetic turf.  The 
authors reported elevated blood lactate concentrations, by a minimum of 0.6 mmol.l-1for a 
given speed (in this case at  8, 10, 12 and 14 km.h-1), on the synthetic surface versus both 
natural grass and treadmill conditions (P < 0.05) and running speed at 4 mmol.l-1 (i.e. 
OBLA) was significantly lower (P < 0.05) during running on the synthetic surface (13.1 ± 
1.1 km.h-1) than when compared to natural grass (13.9 ± 1.2 km.h-1) and treadmill (14.4 ± 
1.3 km.h-1).  The authors concluded that the results are most likely explained by altered 
biomechanics during running upon the various surfaces and as a result stressed the 
importance of testing soccer players on specific services used during training.   
 
Interestingly, differences in physiological characteristics between laboratory and field-
based assessments may offer some explanation as to the reasons behind these findings.  For 
example, Palatini (Palatini, 1997) assessed the effects of exercise on haemodynamics 
during athletic based field activities and laboratory tests and reported that blood pressure 
variations, recorded in the field, were not accurately reproduced in the laboratory tests 
where the latter often yielded lower values.  This, therefore, raises further questions as to 
cardiovascular function during laboratory and field-based assessment protocols where the 
latter may indeed be able to induce a truer fatigue response.  
 
Another indication that highlights limitations in laboratory assessment approaches is the 
inability of such assessments to differentiate between calibres of athlete.  For example, in a 
recent study, Wells and colleagues (Wells et al., 2012) reported that sports-specific fitness 
testing was effective for differentiating between professional and amateur soccer players 
whereas V
．
O2max and V
．
O2 kinetics were not.  Thirty-six men (18 professional and 18 
amateur) participated in the study in which both groups were similar for V
．
O2max 
(professional 56.5 ± 2.9 ml.kg-1.min-1; amateur 55.7±3.5 ml.kg-1.min-1: P = 0.484).  
However,  amateurs were out-performed by the professionals in both the employed field-
based yo-yo intermittent recovery (professional 966±153 m; amateur 840±156 m; P = 
0.034) and repeated sprint tests (best time, professional 6.46 ± 0.27 s; amateur 6.84 ± 0.24 
s; P = 0.012).   
 
As a result of the potential limitations associated with the ability of laboratory based 
assessment protocols to elicit a true fatigue and/or exercise performance response, it is 
essential that exercise assessment protocols include a field-based running assessment 
protocol.  In addition, the effect of competition (i.e. in a form of a race with runners 
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competing against one another) is also an important consideration for the same reasons and 
will now be discussed. 
 
Several studies have assessed the effect of competition on exercise performance-related 
variables (Pierce et al., 1976, Matlina et al., 1979, Booth et al., 1989, Filaire et al., 2001) 
where numerous approaches have been employed to compare and contrast potential 
differences in physiological and psychological variables between the laboratory, training 
and competition environments.  Such studies also provide vital insights into the 
transferability of data, collected under non-competitive scenarios, to competitive situations.   
 
The assessment of catecholamine levels (e.g. adrenaline, noradrenaline and dopamine), 
which are released by the adrenal glands as part of the fight-or-flight response (Jansen et 
al., 1995), has been one approach to assess potential physiological differences in exercising 
individuals in differing environments (Passelergue and Lac, 1999, Gonzalez-Bono et al., 
1999, Suay et al., 1999, Elloumi et al., 2003, Filaire et al., 2009).  For example, studies 
have reported significantly higher levels of adrenaline during competition when compared 
to training in various sports (P < 0.01) (i.e. in intercollegiate basketball and track and field 
teams) (Pierce et al., 1976).  In this particular study, the track and field athletes who were 
attempting qualification for an international team also exhibited significantly higher (P < 
0.01) adrenaline levels when compared to other members in the team.  The assessment of 
testosterone has also revealed higher levels immediately prior competitive matches and 
higher levels demonstrated the most improvement in positive mood (Booth et al., 1989) – a 
potential influencing factor on performance. 
 
Interestingly, more recent studies have suggested the importance of combining such 
physiological measures with psychological measures.  For example, Filaire and colleagues 
(Filaire et al., 2001) suggested that the concomitant use of salivary cortisol (a measure of 
‘stress’) and measures of anxiety may provide more meaningful results.  Filaire and 
colleagues (Filaire et al., 2001) reported, in twelve male judo competitors prior judo 
competitions at regional and interregional levels, higher cortisol levels (by ~2.5 fold) when 
compared to resting non-competition values (P < 0.05) in both groups.  In addition, 
cognitive and somatic anxiety levels were higher in interregional championships compared 
to regional championships whereas self-confidence was significantly lower in the latter.  
Thus, there is evidence to suggest that performance outcome, as a result of underlying 
physiological and psychological factors, may indeed vary depending on the testing 
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environment and, although limited research has been carried out in this area, studies have 
shown the effects on performance outcome. 
 
Wilmore and colleagues (Wilmore, 1968), for example, assessed 22 males during total 
work capacity cycle ergometry exercise under three conditions in the order: 1) control 
conditions with no competition (i.e. cycling alone), 2) with competition introduced and 3) a 
repeat control condition with no competition (i.e. cycling alone).  Competition was 
introduced by pairing participants based on their control values for work output.  The 
authors reported greater work output measures and total cycling time when competition 
was introduced then when compared to both control conditions (work output control 1: 
8760 ± 318 kJ; competition: 11136 ± 4199 kJ; control 2: 9798 ± 3484 kJ; P < 0.05 and 
total cycling time control 1: 332 ± 160 seconds; competition: 457 ± 233 seconds; control 2: 
379 ± 180 seconds; P < 0.05).  Interestingly, however, no differences (P > 0.05) in 
physiological measures, V
．
E, V
．
O2max and HR, were identified between conditions.  The 
authors suggested that the improvements reported, with competition introduced, were 
likely due to improved anaerobic metabolism and may also involve an enhanced tolerance 
to exercise induced pain.  Unfortunately, the authors did not assess circulating metabolites 
(e.g. lactate concentrations) or markers for pain to support their suggestions.  Nevertheless, 
competition significantly influenced exercise performance.  
 
More recently, Corbett and colleagues (Corbett et al., 2012) assessed the influence of 
believing that one is competing against another individual, in a head-to-head  manner, on 
performance during a 2000 metre cycling time trial.  The authors reported that participants 
completed the 2000 metre cycling time trial faster when they believed they were 
competing, in an head-to-head manner, than when completing the time trial alone 
(familiarisation time: 187.7 ± 8 seconds; time trial alone: 188.3 ± 9.5 seconds; and head-to-
head competition: 184.6 ± 6.2 seconds).  The head-to-head competition time trial time was 
reported as significantly faster than either familiarisation (P = 0.003) or time trial alone 
(P = 0.021).  The authors also concluded that this was a result of, primarily, an enhanced 
anaerobic energy yield.  
 
Interestingly, in a recent study by Viru and colleagues (Viru et al., 2010) the introduction 
of competition not only resulted in the improvement (when compared to non-competition) 
of exercise performance during incremental treadmill running to exhaustion (by 4.2%; +49 
seconds; P < 0.05), but this was in addition to  noticeable differences in the physiological 
measure of V
．
O2peak (by 4.4%; +2.5 ml·kg
−1·min−1; P < 0.05).  The authors concluded that 
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in competitive situations, the added motivation experienced by athletes can enhance 
exercise performance and leads to an increase in V
．
O2peak.  Further, an enhancement in 
sympatho-adrenal system activation has been suggested to occur under such conditions 
which in turn may be a contributor to enhancing performance (Viru et al., 2010).  
 
Thus, it is clear that to truly elucidate what limits exercise capacity or endurance 
performance, as previously described, research has to replicate scenarios of reality.  That 
is, moving away from laboratory based tests to assessing performance as it is truly carried 
out in the field, where possible, in a competitive environment.  This is a scenario where 
true maximal effort will most likely be given resulting in a truer fatigue response.   As 
previously highlighted, there is convincing evidence to support this notion where 
differences between field and laboratory based assessments and, in addition to, the impacts 
of competition on performance outcome have been indicated.  However, a challenge with 
attempting measurements in the field is the potential restriction based on available 
technologies, and with available technologies, the ability to obtain satisfactory accuracy in 
the measurements that are obtained. 
 
A modern technological development in portable metabolic systems is one area which has 
enabled traditional laboratory based practices to be taken in to the field.  However, there 
are few published studies examining the performance of such commercially available 
devices during real life, field-based activities.  For example, there is no published research 
on the validity of one of the most popular models currently available, the Cosmed K4b2 
portable breath-by-breath system (K4b2, COSMED s.r.l., Rome, Italy) (Figure 1.16), for 
use during running outdoors.  Therefore, the assessment of such devices particularly during 
real life field-based activities is of key importance. The K4b2 is one of several 
commercially available systems and has been previously described (McLaughlin et al., 
2001), but the assessment of its performance in the field is very limited as highlighted in 
Table 1.4.  Overall, studies have found the validity of the K4b2 to be quite variable often 
dependent on the exercise protocol employed. 
 
 
 
Chapter 1. General Introduction  82 
______________________________________________________________________________ 
82 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.16:  The K4b2 breath-by-breath gas with description of components  
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Table 1.4:  Summary of studies assessing Cosmed K4b2 validity and/or reliability 
 
Study Participants Description Environment & Comparison 
Method 
Exercise Protocol Study Summary Results & Conclusions 
     
McLaughlin 
et al., 2000 
10 healthy males (age: 27.6  
± 6.4 y; height: 180.9 ± 6.2 
cm; weight: 75.3 ± 5.6 kg; 
mean ± SD)   
Indoor laboratory.  
Douglas Bag method. 
Cycle ergometry 
exercise at 50W, 
100W, 150W, 200W 
and 250W 
No significant differences (P > 0.05) in V
．
O2 
between K4b2 and DB at rest and 250W.  K4b2 
values significantly higher (P < 0.05) than DB 
values at 50, 100, 150, and 200W.  Magnitude of 
differences small (0.088, 0.092, 0.096, and 0.088 
l.min-1, respectively).    
Parr et al., 
2001 
7 healthy males (age: 27.5 ± 
6 5.6 y; 
height: 181.8 ± 3.3 cm; 
weight: 74.9 ± 7.1 kg; mean 
± SD) 
Indoor laboratory.  
Douglas Bag method. 
Cycle ergometry 
exercise at 50W, 
100W, 150W, 200W 
and 250W 
No significant differences (P > 0.05) for V
．
O2 , 
V
．
CO2, V
．
E, and R at work rates from rest to 200W 
despite significant differences in FEO2 (P < 0.01) 
and FECO2 (P < 0.05). 
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Doyon et al.,  
2001 
6 male and 2 female 
competitive cross-country 
skiers (subject demographic 
details not disclosed.) 
Indoor laboratory and Field-
based (640-m paved asphalt 
course). Mixing box system. 
Incremental 
treadmill running 
test. Field test: 3 x 
roller ski maximal 
effort  
No significant differences (P < 0.05) were found 
across the full range of V
．
O2 measures.   
Pinnington et 
al., 2001 
12 males (age: 26.5 ± 11.2 y; 
height: 177.3 ± 5.5 cm; 
weight: 76.4 ± 15.3 kg).  8 
females (age: 23.5 ± 4.5;  
height: 162.2 ± 4.5 cm; 
weight: 55.2 ± 4.8; mean ± 
SD) 
Indoor laboratory.    
CPX metabolic cart. 
Treadmill running at 
self-selected speed 
for 12-15 mins to 
assess FEO2, FECO2 
and V
．
E. 
K4b2 FEO2 and FECO2 measures were 
significantly lower (P < 0.001) than CPX 
metabolic cart.   
Littlewood et 
al., 2002 
4 males and 5 females (group 
average age: 28.2 ± 4.7 y; 
height: 168.7 ± 79.2 cm; 
weight: 73.2 ± 22.6 kg; mean 
± SD) 
Indoor laboratory.  
Deltatrac II metabolic cart   
Resting energy 
expenditure  
Bland and Altman analysis revealed a mean bias 
for REE, RQ, V
．
CO2, V
．
O2 between K4b2 and 
Deltatrac II metabolic cart of 268 ± 702 kcal/day, 
-0.0 ± 0.2, 26.4 ± 118.2 and 51.6 ± 126.5 ml.min-
1, respectively.  Variability between the two 
devices was very high and a degree of 
measurement error was detected. 
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Maiolo et al.,  
2002 
9 healthy male footballers 
(age: 18.3 ± 2.2 y; height: 
1.77 ± 0.57 m; weight: 67.3 
± 4.6 kg) 
Indoor laboratory.    
Airspec QP9000 mass 
spectrometer. 
Resting measures 
and treadmill 
incremental & 
exercise running test 
8 km/h to 18 km.h-1 
in increments of 2 
km.h-1.  
No significant differences were found between 
V
．
O2 (P > 0.05) and V
．
CO2 (P > 0.05) at rest or 
during exercise. 
Duffield et 
al.,  2004 
12 male athletes (age: 
23.3±3.2 y; height: 181.0 ± 
5.6 cm; weight: 76.3 ± 7.6 
kg; mean ± SD)   
 
 
Indoor laboratory.    
Metabolic cart. 
Treadmill running: 
easy for 10 min, 
hard for 3 min and 1 
min sprint.   
The K4b2 measured significantly higher V
．
O2 (P < 
0.05) and V
．
CO2 (P < 0.05).   
McNaughton 
et al. 2005 
8 males (age: 23.7 ± 1.1 y; 
height:1.78 ± 0.01 m, 
weight: 74.4 ± 2.1 kg; mean 
± SD) 
Indoor laboratory.   
Morgan EX670 mass 
spectrometer  
Cycle ergometer 
based V
．
O2max test & 
submaximal exercise 
test at 150W, 200W, 
250W and 300W 
K4b2 significantly higher than Morgan EX 670 
for both V
．
O2 and V
．
CO2 at 250 W (P < 0.05 and P 
< 0.002, respectively), and 300 W (P < 0.002 and 
P < 0.005, respectively). Unsystematic bias varied 
between 1% and 16% and systematic bias 
between 3% and 8%.   
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Schrack et 
al.,  2010  
10 men and 9 woman (group 
average age: 39.8 ± 13.8 y; 
height: 181.2 ± 4.8 cm, 
weight 86.90 ± 29.71 kg; 
mean ± SD) 
Indoor laboratory.   Medgraphics 
D-Series  stationary gas 
exchange system 
Treadmill 400 m 
walk 
The K4b2 not significantly different for V
．
O2 (P = 
0.16) and V
．
CO2 (P = 0.08) during steady-state 
and submaximal exercise. 
Min: minutes; W: watts, ICC: intraclass correlation coefficient, V
．
O2: oxygen uptake, V
．
CO2: carbon dioxide production, REE: resting energy expenditure, 
RQ: respiratory quotient, R: respiratory exchange ratio, FEO2: fractional expired oxygen, FECO2: fractional expired carbon dioxide, V
．
E: expiratory 
ventilation, DB: Douglas bag method.  Values are indicated as mean ± SD. 
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In the only study to assess the K4b2 in the field, Doyon and colleagues (Doyon et al., 
2001) compared the K4b2 in eight competitive cross-country skiers where each carried out 
one field- and one laboratory-based test to determine a number of variables including peak 
oxygen uptake (V
．
O2peak).  Field tests involved maximal roller skiing efforts on a straight 
640 m long, with 2% gradient, paved asphalt course.  Oxygen uptake was measured using 
the K4b2.  The laboratory comparison test was carried out on a motorised treadmill where 
speed and gradient increased incrementally until exhaustion.  Field K4b2 measures were 
compared to a standard laboratory mixing box system.  The authors reported that V
．
O2peak 
was not significantly different during indoor treadmill running and outdoor diagonal stride 
roller skiing (62 ± 2.9 ml.kg-1.min-1 and 60.4 ± 2.8 ml.kg-1.min-1, respectively; P > 0.05).  
This sole study provides some indication as to performance of the K4b2 in an outdoor 
environment; however, the field test employed only took 2 to 3 minutes to complete.  
Further, the results are only truly applicable to roller skiing activity.   
 
It is surprising that 364 studies (according to the K4b2 bibliography on  the manufacturer 
website: http://www.cosmed.com/images/pdf/bibliography/k4b2_Bibliography.pdf 
[Accessed: 25th September 2012] have been carried out using the K4b2, of which several 
were used for assessments in varying field-based environments e.g. (Devienne and 
Guezennec, 2000, Billat et al., 2003), yet only 1 study has attempted to assess its validity in 
the field.  Furthermore, there are no published studies (to the best of knowledge) assessing 
the accuracy of the K4b2 during running activities, specifically, in outdoor environments.    
Therefore, there is a clear need for the K4b2 to be assessed during running exercise, at 
submaximal and maximal speeds, in the field.  Having an accurate portable metabolic 
device for measuring gas exchange variables in the field would enable the assessment of 
endurance performance in a ‘truer’ environment (i.e. running on a track). 
  
1.12 Psychosocial and Anti-doping Considerations in the use of 
Performancee Enhancing Drugs 
Psychosociology is the study of the interaction between psychological effects and social 
environments (Hemingway and Marmot, 1999).  This has been a key approach in research 
assessing factors contributing to an individual’s motivation and decision to engage in 
doping activity.  Reports suggest that the motivation to dope can be triggered by a range of 
factors including: the growing cultural emphasis to ‘win at all costs’, the potential financial 
benefits of success, the lack of emphasis on sportsmanship and teamwork, the 
unwillingness to train hard over prolonged periods of time and the lacking of confidence in 
ones abilities (Petroczi, 2007) (Donovan et al., 2002).  Such examples indicate a variety of 
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potential ‘triggers’ and emphasises the importance of understanding both psychological 
and social factors, if we are to obtain a full understanding of doping behaviours.   
Several studies have provided useful insights into athlete viewpoints on drugs, sporting 
performance, doping in sport (Rossi and Botre, 2011, Waddington et al., 2005).   Studies 
have also identified key psychosocial challenges associated with sports participation, 
competition and, consequently, the development of  key coping strategies in order to 
improve how individuals deal with such psychosocial challenges (Reeves et al., 2011).  In 
addition, researchers have attempted to assess, under laboratory conditions, the potential 
relationships between competition, performance enhancement and cheating (Schwieren and 
Weichselbaumer, 2008), where it has been reported that the ability of an individual to carry 
out a task, determined how they reacted to competition, with less skilled individuals being 
more likely to resort to cheating behaviours.  Furthermore, the relationship between social 
support systems and use of performance enhancing drugs have also been discussed where, 
for example, steroid use has been reported as being more prevalent in users who had poorer 
relationships with their parents (Skarberg and Engstrom, 2007).   
This information is important for improving anti-doping intervention strategies.  However, 
two important limitations exist in the available evidence base.  Firstly, the majority of data 
– generally from interviews and/or questionnaires – are obtained from users a number of 
months or years after drug use has taken place (Yesalis and Bahrke, 2000, Bahrke et al., 
2000, Calfee and Fadale, 2006, News, 2005).   Secondly, it is difficult to ascertain whether 
responses are truthful.  For example, methodological problems have included the poor 
stability of results (Yesalis, 1988) as well as a high, yet unknown, degree of 
underestimation in relation to the use of doping substances (Pedersen, 2005). 
One key problem of obtaining information ‘after the fact’ relates to the passage of time 
where, according to the Decay Theory, memories fade and the related information becomes 
harder to retrieve, with the accuracy of recall becoming less accurate (Berman et al., 2009).  
Furthermore, the Interference Theory suggests that stored memories are interfered with as a 
result of newly stored memories (Tomlinson et al., 2009).  In addition, the importance of 
contemporaneous statements or notes in the court of law and in healthcare also provides 
evidence as to the quality of recall from memory (National Health Service, 2013).  
Regardless of the theory, however, it is clear that stored memories related to behaviour 
prior and during doping is likely to be distorted when asked to recall after a period of 
time/after the behaviour has taken place.   
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One obvious solution involves attempting to obtain information from users of performance 
enhancing substances while they are taking them.  However, in reality, the task of trying to 
obtain information as doping behaviour is taking place is challenging, because doping 
practices are extremely secretive and dopers generally want to evade detection.  Therefore, 
studies employing the use of performance enhancing drugs in a research context provide a 
unique opportunity to assess psychosocial factors associated with use of such substances 
contemporaneously (i.e. immediately taken down notes, audio recordings and interviews).  
Potential areas of interest may include:  how participants behave when training with team-
mates and/or coaches (i.e. do they discuss their involvement in such a research study?) and 
if participants aren’t sharing their experience with team mates do they feel guilty, 
particularly if they are performing better during training. 
A final issue to consider is whether use of performance enhancing substances alters an 
individual’s perception of fairness and cheating.  Cheating is a word often heard in debates 
regarding doping, however, defining what constitutes as cheating can, at times, be 
complex.  The Oxford Dictionary (Oxford Dictionaries, 2013) defines cheating as follows:  
• act dishonestly or unfairly in order to gain an advantage: she always cheats 
at cards 
• gain an advantage over or deprive of something by using unfair or deceitful 
methods; defraud: he had cheated her out of everything she had 
• be sexually unfaithful: his wife was cheating on him 
• avoid (something undesirable) by luck or skill: she cheated death in a spectacular 
crash 
 
The ethics behind the action of stealing provides an interesting parallel.  Stealing is 
generally viewed as being a socially unacceptable act; however, this view can change if the 
act of stealing was perceived to have been performed for a ‘good’ reason (e.g. stealing to 
feed one’s family).  Such reasoning can also be applied in the context of drug taking in 
sport.  There is evidence to suggest that cheating is often carried out by individuals because 
of the perception that other competitors are doing the practice and thus there is a need to 
‘level the playing field’ (McCabe, 2009, McCabe, 1999).  This notion of ‘levelling the 
playing field’ has increasingly been cited as justification for drug use by caught users of 
performance enhancing drugs.  Examples include Dwain Chambers, Lance Armstrong and 
Tyler Hamilton (BBC, 2007, Guardian, 2013, CBS, 2013).   
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However, it is very difficult to determine whether such a justification was genuinely felt at 
the time of drug use or was a post hoc justification to mitigate their drug use after getting 
caught. Recent reports of widespread doping in Italy (Paoli and Donati, 2013), Australia 
(Australian Crime Commission, 2013) and the case of Lance Armstrong (BBC Sport 
Cycling, 2013) suggest that doping in sport may be more widespread than previously 
appreciated, adding weight to the ‘levelling the playing field’ argument. 
Thus, there is a clear need for further research to understand the thought processes and 
more general experiences of individuals at the time that (or immediately after)  
performance enhancing substances are being taken.   
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1.13 Aims and Objectives 
The aims of this PhD were therefore: 
 
i. To determine the validity of the K4b2 in the measurement of V
．
O2 during outdoor 
running at submaximal and maximal intensities (Chapter 3).   
 
ii. To determine the effect of r-HuEpo administration on performance in a field-based 
setting and quantitative psychological factors, and to confirm its haematological effects 
(Chapter 4). 
 
iii. To determine the effect of r-HuEpo administration on psychosocial factors (Chapter 5). 
 
iv. To determine the effect of a subcutaneously injected placebo, purporting to be a legal 
substance with similar effects to r-HuEpo: on field-based performance, haematological 
measures, and psychological responses (Chapter 6).  
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2.  General Methods 
2.1 Participants 
Participants were recruited using various methods and this depended on the experimental 
study.  For the study in Chapter 3, posters were placed in appropriate advertising locations 
such community health centers, gymnasiums and sports clubs across Glasgow city. In 
addition, digital advertisements were circulated via emails and online forums of sports 
clubs, as well as within the University of Glasgow.  
In Chapters 4, 5 and 6, such a relatively open public advertising approach was not pursued 
due to the sensitive nature associated, in the experimental studies, with the use of illegal 
and legal performance enhancing drugs.  As a result, potential participants were identified 
either through Glasgow City Council (i.e. Sport and Events, Culture and Sport Glasgow), 
or by personal contact or direct advertisement. Athletes (with their respective coaches 
and/managers) were asked to meet with the investigators to discuss the project and to 
ascertain whether they would be suitable participants.   
In all cases, an information sheet was also provided to all potential candidates (Chapter 3: 
Appendix A; Chapter 4: Appendix B, Chapter 5: Appendix B, Chapter 6: Appendix C).  
The information sheets provided a description of the purpose, procedures, potential risks 
and benefits of the study involved.  All participants were encouraged to ask questions prior 
providing informed consent.   
After informed consent was obtained (with the option to withdraw from participation at 
any point without reason), all recruited participants completed an exercise participation and 
health questionnaire (Appendix F).  Participants were then recruited based on specific 
criteria for each experimental Chapter: 
Chapter 3:  
i. Male aged 18-35 years  
ii. Endurance trained (i.e. more than 6 hours of planned endurance training per week) 
iii. Non-smokers 
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iv. Non-diabetic  
v. No previous history of established coronary heart disease 
vi. No family history of early cardiac death 
Chapters 4 and 5: 
In this instance, the extent of any illnesses, medication or nutritional supplementation was 
noted, as well as the incidence of familial haemoglobinopathies (e.g. sickle cell trait) which 
could have a substantial effect on measured haematological parameters. All participants 
were then required to pass a comprehensive medical examination where the 'good health’ 
of each participant was established prior starting the study by a qualified medical 
practitioner (Appendix H).  Specifically, participants were recruited based on the following 
criteria:  
i. Male aged 18-35 years (addendum later submitted and approved for ages 18-38) 
ii. Endurance trained (i.e. more than 6 hours of planned endurance training per week) 
iii. Not involved in sporting competition for the duration of the study 
iv. No current illness 
v. No injury which impacts on the capacity to exercise  
vi. No disorders or history of disorders of the haematopoietic system 
vii. No family history of premature cardiovascular disease 
viii. No musculoskeletal conditions 
 
Chapter 6: 
After informed consent was obtained (with the option to withdraw from participation at 
any point without reason) all participants were instructed to complete a health and sports 
participation questionnaire (Appendix F) and have blood pressure measured. Participants 
were recruited based on the following criteria:  
i. Male aged 18-35 years  
ii. Endurance trained (i.e. more than 6 hours of planned endurance training per week) 
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iii. Non-smokers 
iv. Non-diabetic  
v. Body mass index < 35 kg.m-2 
vi. No uncontrolled hypertension (> 160/90 mm Hg on anti-hypertensive medication) 
vii. No previous history of established coronary heart disease (e.g. myocardial 
infarction, coronary artery bypass graft surgery, coronary angioplasty) 
viii. No family history if early cardiac death (< 40 years) 
ix. All participants in good health at the time of testing 
 
2.2 Anthropometric Measures 
2.2.1 Body Mass 
In Chapters 3 and 4, body mass was measured to the nearest 0.05 kg using a beam balance 
scale (Avery, England).  In Chapter 6, body mass was measured using a pre-calibrated 
standard digital weighing scale (SECA, Hamburg, Germany).  On all occasions, 
participants were measured after voiding of the bladder and wore minimal clothing (i.e. 
generally light-weight shorts and t-shirt) with shoes and jewellery accessories (e.g. 
watches, heavy necklaces) removed. Participants stood on the scales with feet planted on 
the platform, facing forward and with arms relaxed to the sides of their body.   
2.2.2 Height 
Height was measured to the nearest 0.1 cm using a standard stadiometer (Invictus Plastics 
Ltd., Leicester, England).  On all occasions, participants stood barefoot, with both feet 
alongside one another, and with their back against the vertical measuring rod.  The head 
was positioned in a horizontal manner with the stadiometer headpiece rested on top of the 
individuals head and, when necessary, a slight downward pressure was applied to minimize 
the potential additive effect of hair.  In order to account for daily variations in height, a 
slight upward pressure was applied to the head in an attempt to alleviate any potential 
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spinal compression.  This was then immediately followed by recording the final 
measurement on the vertical measuring rod.  
2.3 Respiratory Gas Exchange Analysis 
2.3.1 Breath-by-Breath Exchange 
Automated gas exchange systems were used in exercise protocols employed in Chapters 3 
and 4 during.  Chapter 3 featured a portable metabolic unit (K4b2, Cosmed, Italy) whilst 
Chapter 4 featured a laboratory based metabolic cart (Quark b2, Cosmed, Italy).  Such 
systems enabled the determination of V
．
O2, carbon dioxide output (V
．
CO2) and minute 
ventilation (V
．
E) during the maximal incremental exercise tests.  The laboratory based 
Quark metabolic cart has been shown to be valid and reliable for use in indoor 
environments during submaximal and maximal exercise intensities (Bowles et al., 2011).  
For both K4b2 and Quark systems, participants were required to wear a face mask 
connected to a 28 mm bi-directional turbine digital volume sensor and a capillary gas 
sampling line.  These were held in place via a facemask which provides a lower resistance 
to breathing and allows for more natural breathing (i.e. allows participants to breathe 
through the nose and mouth) as opposed to when using a mouthpiece.  The turbine features 
impellers (as part of the rotor makeup) which measure inspired and expired flow and 
volume by the recording of the number of impeller interruptions of an infra-red laser beam 
located within the turbine.  The frequency of interruptions determines impeller velocity 
which is then used to determine both inspiratory and expiratory flow rates as impeller 
velocity and gas flow are proportional to each other.  The turbine used, in both the K4b2 
and Quark, featured low resistance characteristics with a resistance of <0.07 kPa.L-1.s-1 at a 
flow rate of 14 L.s-1. 
The capillary sample line used in the K4b2 and Quark systems, extracts a small sample of 
gas (20 ml.min-1) into a vacuum, within the respective units, where then concentrations of 
O2 and CO2 are then measured. Extracted samples are measured within the vacuum every 
20 ms by the respective O2 and CO2 analysers.  
The O2 analyser type differs between the K4b and Quark systems in that the K4b2 has an 
electro-galvanic fuel cell sensor whilst the Quark has a paramagnetic sensor.  The electro-
galvanic sensor involves a chemical reaction between potassium hydroxide (located inside 
the fuel cell) and oxygen which, in turn, creates an electric current between the anode and 
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cathode.  The current produced is proportional to the concentration of oxygen present.  
Alternatively, the paramagnetic sensor utilizes the paramagnetic properties of oxygen in 
order to distinguish it from other gases.  Oxygen molecules are attracted to the strong 
magnetic field and this exhibits a force which is proportional to the oxygen content of the 
surrounding gases.  The CO2 infrared analyser is based on infrared absorption where higher 
concentrations of CO2 results in higher infrared absorption rates.  Thus, the resulting 
infrared absorption rate is related to concentrations of CO2 which is measured electro-
optically.  Once fractional concentrations of O2 and CO2 are analysed and determined by 
the sensors, using specified manufacturer algorithms, V
．
O2 and V
．
CO2 are calculated, 
respectively.  In addition, an algorithm is also used to calculate V
．
E.   
2.3.1.1 Calibration of Breath-by-Breath Systems 
For all tests involving the K4b2 and Quark systems, the device was warmed up for one 
hour prior the pre-test calibration procedure (conducted according to manufacturer 
guidelines) which was then started approximately 15 to 30 minutes prior each test.  Both 
systems were calibrated according to manufacturer guidelines which involved a 3-step 
calibration process: 
 
1. Calibration to ambient conditions. 
2. Flow-volume sensor calibration. This involves the connection of a 3 litre volume 
syringe (Hans Rudolph Inc., Kansas City, MO, USA) where this known volume is 
pumped though the turbine mimicking inspiratory and expiratory flow.  A series of 
6 complete pumps were carried out and values were accepted within a range of 2.9 
to 3.1 litres.  
3. Gas analyser and time-delay calibration.  This automated process involves the 
analysis of room air and calibration tank gases (16% O2 and 5% CO2) in order 
sample a range of concentrations that would be observed during exercise.  The 
time-delay calibration component involves the delay between volume and gas 
concentration signals by each respective analyser.  
 
2.3.1.2 Data analysis and Data Reduction 
All data collected using the K4b2 and Quark systems was checked and edited with the 
exclusion of breath-by-breath V
．
O2 values that exceeded four standard deviations from the 
average value for the last 30 seconds of each work rate.  Values excluded indicated ‘false’ 
or ‘artifactual’ breaths; typically caused by swallows, sighing, coughing, or any other 
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reason that would end a breath prematurely (Beaver et al., 1973, Lamarra et al., 1987). The 
use of four deviations from the mean (i.e. 99.9% confidence interval) provides a 0.005 
probability that the identified ‘artifactual’ or ‘false’ breath is in fact a genuine breath 
(Lamarra et al., 1987). The typical error of measurement was also calculated in order to 
assess the mean difference error for the measure of V
．
O2 (i.e. the typical error in values 
from measurement to measurement).  The typical error of measurement was calculated by 
dividing the standard deviation, for the data set, by the square root of two (Hopkins, 2000) 
 
2.3.2 Douglas Bag Method 
As Chapter 3 involved the validation of the K4b2 unit, thus the Douglas bag method was 
also used as the gold standard comparison.  Expired gases were collected via a mouthpiece 
connected to a Hans-Rudolph 2700 series large 2-way valve (Hans-Rudolph Inc., Kansas 
City, MO, USA) and wide-bore Falconia tubing.  Expired gas was collected over the last 
30 sec of each 3 minute running increment.  Each Douglas bag was analysed within 10 
minutes for expired volume in litres (Harvard dry gas meter, Harvard appliances Ltd, UK), 
FEO2 and FECO2 (Servomex 4100 Gas purity analyser, Servomex, UK).  The gas analyser 
was calibrated prior to each test with known reference gases (i.e. room air calibration, 
reference 16% O2 and 5% CO2) and the gas meter calibrated with a known volume (i.e. 3L 
Hans Rudolph calibration syringe, Kansas City, MO, USA).  Barometric pressure was 
measured using a standard mercury barometer and the volume, temperature and flow rate 
of the sample to the Servomex were noted.  These were used along with fractional expired 
oxygen (FEO2) and carbon-dioxide concentrations (FECO2) to calculate oxygen uptake 
(V
．
O2) and carbon dioxide production (V
．
CO2), respectively, and ventilation (V
．
E) according 
to the Haldane transformation (Parr et al., 2001).  As an example, the calculation for V
．
O2, 
via the Douglas bag method, is provided: 
  V
．
O2 = (V
．
I x FIO2) - (V
．
E x FEO2) 
V
．
O2 = (33.9 l
.min-1 x 0.2093) - (33.8 l.min-1 x 0.1658) 
V
．
O2 = 1.49 l
.min-1 
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2.4 Exercise Tests 
Depending on the experimental Chapter, participants performed exercise tests as follows: 
1. Chapter 3 – Manually controlled treadmill (Woodway PPS55 Med, Weilam Rhein, 
Germany) and on an outdoor 400 m running track (Bellahouston Park, Glasgow, 
UK) 
2. Chapter 4 - Manually controlled treadmill (Woodway PPS55 Med, Weilam Rhein, 
Germany) and on an indoor 200 m running track (Kelvin Hall Arena, Glasgow, 
U.K) 
3. Chapter 6 - Indoor 200 m running track (Kelvin Hall Arena, Glasgow, U.K) 
 
2.4.1 Maximal Incremental Exercise Testing  
Maximal incremental exercise tests were used in Chapters 3 and 4 and were manually 
controlled using a treadmill (Woodway PPS55 Med, Weilam Rhein, Germany).  However, 
the protocol varied slightly between the experimental Chapters 3 and 4.      
Chapter 3 featured two indoor and one outdoor continuous maximal incremental test per 
participant.  The indoor tests comprised participants running on a treadmill set at 1% 
gradient with 2 km.h-1 continual incremental increases in speed, every 3 minutes, starting 
from 8 km.h-1 to the individual’s maximal attainable speed (Figure 2.2) (Appendix I).  A 
1% gradient was used during treadmill tests as it has previously been demonstrated that 
this most accurately reflects the energetic cost of running outdoors (Cureton et al., 1978).  
Once the participant reached maximal capacity, the speed was reduced according to 
participant preference for a cool down for a minimum duration of 5 minutes.   
The outdoor test was similar except participants were requested to run on a running track 
(Figure 2.1) where velocities were set by an experimenter cycling a road bike fitted with a 
calibrated speedometer (Cateye Velo 5, Osaka JAPAN).  The participant was strictly told 
to run alongside the middle of the bike in line with the experimenter’s leg.  The experiment 
was stopped by the cycling experimenter once the participant could no longer run as 
instructed.  This, in turn, was used as a marker for the end of the test.  
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14 km.h-1 
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Figure 2.2: Continual maximal incremental running protocol 
Cool  
down 
X 
 Figure 2.1: Participant undergoing the K4b2 outdoor test 
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Chapter 4 featured four discontinuous maximal incremental treadmill tests per participant. 
Similar to the test employed in Chapter 3, participants were required to run on a treadmill 
set at 1% gradient with 2 km.h-1 incremental increases in speed every 3 minutes (between 
running speeds of 8 and 12 km.h-1) and, from then onwards, with 1.5 km.h-1 incremental 
increases, every 3 minutes, to the individual’s maximal attainable speed.  However, in this 
instance, every increment was separated by up to 3 minutes at walking pace (i.e. 3-4 km.h-
1) in order to obtain a capillary blood sample for the determination of blood lactate 
concentration (see section 2.5.2 below).  Essentially, the aim was to obtain the sample 
whilst minimising the break time.  Such breaks were employed to facilitate ‘clean’ blood 
sampling and to ensure that lactate analysis was complete prior moving on to the next 
intensity level.  Such breaks have been shown not to have a significant influence on the 
blood lactate curve (Gullstrand et al., 1994).  Once the participant reached maximal 
capacity, the speed was reduced according to participant preference for a cool down for a 
minimum duration of 5 minutes (Figure 2.3). 
A verification test was then carried out and this involved participants running at a 
supramaximal constant speed (i.e. 1 stage higher than what was achieved during the 
incremental phase) to exhaustion, after completion of the incremental phase (Midgley et 
al., 2007).  Establishing V
．
O2max / V
．
O2peak initially involved the removal of non-breaths as 
previously described in section 2.3.1.2.  The V
．
O2 values of the final 30 seconds of the 
incremental test were averaged to determine the maximal or peak value.  If there was less 
than 2% difference between this value and the V
．
O2peak, obtained in the verification test, 
then the incremental value was accepted as a V
．
O2max value (Midgley et al., 2007).  
  
 
 
 
 
 
 
 
 
 
Time (minutes) 
3 6  9 12  15  18    
Warm-up 
8 km.h-1 
10 km.h-1 
12 km.h-1 
Maximal 
Figure 2.3: Discontinuous maximal incremental running protocol followed by a verification test 
Cool  
down 
Supra-maximal 
13.5 km.h-1 
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2.4.1.1 Criteria for determination of V
．
O2max / V
．
O2peak  
Maximal oxygen uptake is defined as the highest rate at which O2 can be taken up and used 
by the body during severe exercise (Bassett and Howley, 2000).  Researchers in the first 
half of the 20th century first observed that a high V
．
O2max was a key physiological 
characteristic of elite endurance athletes (Hill and Lupton, 1923, Robinson et al., 1937). 
Traditionally, a widely used criterion in order to identify whether or not V
．
O2max has been 
achieved involves the attainment of two or more of the following criteria: 
1. A plateau in V
．
O2 – no change in V
．
O2 over 250 ml 
2. A respiratory exchange ratio of 1.15 at the point of exhaustion 
3. A peak heart rate within 10 b.min-1 of the age predicted maximum which is 
calculated by subtracting age from 220 
4. A minimum blood lactate concentration of 8 mmol.l-1 at the point of exhaustion 
Recent issues have, however, been identified surrounding the use of such criteria for the 
identification of V
．
O2max (Rossiter et al., 2006) and some authors have even deemed it 
unnecessary (Poole et al., 2008).  For example, Rossiter and colleagues (Rossiter et al., 
2006) have shown that not all individuals achieve a plateau in V
．
O2 and when such 
individuals then carried out a following supramaximal exercise (i.e. at a higher intensity 
than what was achieved in the incremental test), no differences in V
．
O2 were identified 
between tests. Thus, in order to ensure the determination of V
．
O2max, the use of such criteria 
was used in addition to a supramaximal verification test (as previously described in section 
2.4.1) immediately post each maximal incremental test in Chapter 4. 
2.4.2 Assessment of Running Economy  
As previously discussed in section 1.7.2, running economy related to the amount of energy 
expended at a given submaximal running velocity, can be expressed in V
．
O2 either in litres 
per minute or according to body mass (i.e. ml.kg-1.min-1).  This was assessed in Chapter 4.  
For reliable measures of running economy, it has been demonstrated that V
．
O2 values 
obtained during running speeds below 85% of V
．
O2max should be utilised for running 
economy comparison purposes (Saunders et al., 2004a).  Accordingly, for the group of 
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participants recruited in Chapter 4, a running speed of 12 km.h-1 was used as this ensured 
that all participants were below 85% of V
．
O2max. 
 
2.4.3 Time Trial Testing 
In Chapters 4 and 6, as part of the exercise testing protocol, field-based 3 km time trials 
were performed by participants on a 200 m indoor running track at the Kelvin Hall Arena, 
Glasgow. 
Participants refrained from alcohol, caffeine and strenuous exercise on the day before 
testing.  For the measurement of heart rate during each 3 km time trial, in Chapter 4, a 
Garmin watch (Garmin Forerunner 405, Garmin, Kansas, USA) and heart rate belt were 
worn by participants.  During the time trial itself, participants were only informed about 
the number of laps remaining and were asked not to look at the watch for timing 
information.  In order to ensure this, after the participant started the watch they were 
instructed to flip the watch round their wrist in order to hide the front display.  Individual 
lap times and total times were taken by one of either two trained experimenters and were 
noted on each occasion (Appendix J).   
Chapter 6 also featured 3 km time trials carried out on the same 200 m indoor running 
track, however, the protocol varied slightly in comparison to Chapter 4.  The key 
difference involved ensuring that the 3 km races were competitive, thus, participant 
starting times were handicapped based on the times achieved during the individual 3 km 
time trial familiarisation runs (i.e. a participant with an achieved 3 km time of 11:00 would 
start 30 seconds before a participant with a predicted 3 km time of 10:30).  In this instance, 
lap completion times were taken by experimenters for each participant during each 
competition run using standard stopwatches.  Heart rate measurements were also recorded 
and monitored on a real time basis using Fitpulse technology (Fitpulse, TT Sport S.R.L, 
Italy).  Competition prizes (maximum value £35) were provided depending on overall 
competition finishing positions (i.e. on completion of all four competition runs).  This was 
added to encourage competition between competitors.  All participants were positively 
motivated during each competition run and only received information on the number of 
laps remaining.  Participants were not given any further information or results until 
completion of the study. 
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2.5 Blood Collection  
2.5.1 Venous Blood Sample Collection 
Chapters 4 and 6 involved the collection and analysis of venous blood.  Prior any blood 
samples being extracted, either a cannula (Vasofix, Braun, Melsungen, Germany) was 
inserted or a venipuncture (BD Vacutainer, Becton Dickinson, USA) carried out into the 
antecubital vein of the inner forearm.  Following a 10-minute resting period, in a supine 
position, a 10 ml sample was extracted into an ethylenediamine tetra-acetic acid (EDTA) 
containing vacutainer (BD Vacutainer, Plymouth, UK) with the vacutainer gently mixed 
for 2 minutes.  Where several blood samples were required, this involved an adapter (BD 
Vacutainer Multiple Sample Luer, Plymouth, UK) being connected to a three-way valve 
which pierced the EDTA vacutainer to allow for direct and quick blood collection.  Once 
the required amount of blood was obtained, a 0.9% sterile sodium chloride solution (B. 
Braun, Melsungen, Germany) was inserted and flushed through the cannula in order to 
keep it clean and free from blood clots.  During the venepuncture procedure, an EDTA 
tube was directly punctured when the hypodermic needle was attached to a vacutainer 
(Bectin Dickinson, Helsinborg, Sweden), and blood was directly collected upon insertion 
of the needle into the antecubital vein of the inner forearm.  In both blood collection 
methodologies, upon the completion of blood sampling, the needle was removed and 
pressure was applied at the insertion site for a minimum of 3 minutes in order to minimise 
any potential bruising.  All venous blood samples were collected by the author or another 
qualified phlebotomist.  
2.5.2 Capillary Blood Sample Collection  
Chapter 4 involved the determination of lactate concentrations during the discontinuous 
maximal incremental exercise protocol (Bentley et al., 2007) as previously described in 
section 2.4.1.  The collection of capillary blood samples involved the disinfection (using an 
alcohol wipe) of one of the participant’s fingertips which was then punctured with a lancet 
(Accu-Check Safe-T-Pro Plus, Roche, Mannheim, Germany).  The first drop of blood was 
discarded and capillary blood samples were collected in pre-heparinized glass capillary 
tubes (Clinitubes, Radiometer, Copenhagen, Denmark) and were filled in under 10 
seconds.  A magnetic rod was then placed inside the blood-containing capillary tube as this 
allowed for the sample to be mixed with the use of an external magnet before being 
analysed for lactate concentration using the Radiometer ABL 725 analyser.  
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2.6 Blood Analysis  
Blood samples were analysed using flow cytometric erythrocyte analysis performed on a 
portable Sysmex XT-2000i (Sysmex, Norderstedt, Germany) haematological analyser.  
Flow cytometry involves a laser beam, of a single wavelength, being directed on a 
hydrodynamically focused (i.e. cells are forced to pass through a specific ‘tunnel’ or 
pathway) stream of liquid of which a sample of blood is suspended.  Each suspended 
particle (i.e. located in the blood sample), from 0.2 to 150 micrometeres, is then 
hydrodynamically focused and moved through and perpendicular to the laser beam.  This 
results in the formation of scattered and fluorescent lights of varying wavelengths, due to 
the excitation of suspended particles, which is then picked up by detectors and analysed for 
physical and chemical properties (Duffield et al., 2004).  In Chapter 4, samples were 
immediately analysed (in-house) after mixing within 10 minutes, whilst in Chapter 6 
samples were analysed within 30 minutes at the Western Infirmary Hospital in Glasgow 
city. 
 
In both Chapters 4 and 6, direct erythrocyte measurements included red cell count (RBC), 
haemoglobin concentration [Hb], haematocrit Hct, mean cell volume (MCV) and 
percentage reticulocyte (%retic).  The analyser was calibrated against Sysmex™ 
diagnostics reference materials, before samples were processed, according to manufacturer 
guidelines.   
 
2.6.1 Capillary Blood Sample - Lactate Analysis 
The Radiometer ABL 725 measures lactate concentrations using amperometric electrodes 
with enzymatic membranes.  This has an accuracy bias of -2.0% when compared to the 
reference method of spectrophotometry using a lactate dehydrogenase (LDH) method 
measured on serum (Radiometer Medical ApS., 2009) .  The amperometric electrodes with 
enzymatic membranes measurement is based on an enzyme that recognises blood based 
lactate which results in a biochemical reaction.  This, in turn, results in flow current 
changes (i.e. electrochemical changes) which is then transduced into a concentration signal 
(Thompson and Krull, 1991).  Lactate threshold values were determined, by two 
investigators, using the visual inspection method (Wasserman et al., 1973) where the 
lactate threshold was defined as the work rate beyond which the lactate concentration 
increased more rapidly from baseline measures by 1 mmol.l-1 (Goodwin et al., 2007).  The 
criteria used for OBLA was the work rate which corresponded to a lactate concentration of 
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4 mmol.l-1, and these were also visually determined and independently verified by two 
investigators (Goodwin et al., 2007). 
The determination of MLSS, as previously described in section 1.7.1, was not directly 
assessed in experimental Chapter 4.  However, studies have shown the LTP, as previously 
described in section 1.7.1, as providing a good approximation of the work rate at MLSS 
(Pringle and Jones, 2002).  The authors however do indicate that the blood lactate 
concentration measure, at LTP, is typically under-estimated when compared to those 
obtained at MLSS.   
2.6.2 Optimised Carbon Monoxide (CO)-rebreathing method 
The optimised CO-rebreathing is an easy to handle and minimally invasive laboratory 
method to determine total haemoglobin mass.  The accuracy and reliability of this method 
is similar to the well-established Chromium release (51Cr) method, which is considered to 
be the gold standard by the International Committee for Standardization in Haematology 
(Saunders et al., 2004a) .  According to published recommendations and via personal 
correspondence with the Jon Werhlin research group (Swiss Federal Institute of Sport), 
who are current experts in the optimised CO-rebreathing method, the following operating 
procedures were employed. 
2.6.2.1 Carbon Monoxide Dose Determination 
As part of the optimised CO-rebreathing method, participants were instructed to inhale a 
bolus of chemically pure CO (99.97%) (BOC Gases, Surrey, UK), during an initial 
inspiration, from a custom-made spirometer (University of Glasgow, UK) made according 
to previous instructions (Schmidt and Prommer, 2005a).  A dose of 1.0 ml.kg-1 (at room 
temperature and pressure) was administered and has been shown to effectively elicit a 
~6.5% change in carboxy-haemoglobin (∆HbCO), in turn, ensuring a good degree of 
sensitivity (i.e. 1.5% of Hb mass) whilst not compromising safety (Schmidt and Prommer, 
2005a, Nilsson et al., 2002).  To emphasise the uncompromised approach to safety, even 
increasing the CO dose beyond the state dose (e.g. up to 100 ml.kg-1) should not cause any 
substantial undesirable effects (Schmidt and Prommer, 2005a) and so a wide safety margin 
is present.  Nevertheless, participants were constantly monitored for any signs of early CO 
toxicity such as weakness, confusion, headache, nausea, disorientation and for any visual 
disturbances (Opie et al., 1976). 
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2.6.2.2 Optimised Carbon Monoxide -rebreathing Procedure 
Prior the measurement of tHb, the Radiometer ABL 725 was calibrated and made ready for 
the measurement of carboxy-haemoglobin (HbCO) (Radiometer Medical ApS., 2009) .  
The Radiometer ABL 725 measures HbCO using principles of visible absorption 
spectroscopy.  Visible absorption spectroscopy involves the interaction between light, from 
the visible electromagnetic spectrum (i.e. wavelengths of 380 to 720 nm), and its 
absorption by a solution.  The Beer-Lambert Law states that the absorbance of light, by a 
solution, is directly proportional to the concentration of the absorbing species in the 
solution (Kocsis et al., 2006).  The Radiometer ABL 725 has an HbCo measurement range 
of 0 to 100% with a +0.03 bias in measurement, when compared to the reference gas 
chromatography method, for determining HbCO (Radiometer Medical ApS., 2009). 
Following this, the netting bag of the spirometer was filled with 10 g of soda lime in order 
to absorb excess carbon dioxide, the rebreathing bag was filled with 4 litres of pure oxygen 
and carbon monoxide analysers (Fluke CO-220, Fluke, Norwich, UK and Draeger Safety, 
Northumberland, UK) were switched on.  The participant’s body weight was measured and 
the required CO dose was calculated based on 1 ml.kg-1 and filled into a 100 ml syringe.  
Ambient barometric pressure and temperature was then noted.  A baseline venous blood 
sample was collected as instructed in section 2.5.1 and analysed using the Radiometer ABL 
725.  Participant’s end-tidal CO concentration was then analysed using the Draeger 
Pac7000 CO analyser.  The Pac 7000 Draeger CO-analyzer was connected to the specific 
adapter and mouthpiece provided by Draeger Safety using a piece of tubing (~9 cm long).  
The participant was then, whilst wearing a nose-clip, instructed to hold their breath for 20 
seconds followed by exhalation into the mouthpiece over a 20 second period after which 
the maximal value of end-tidal carbon monoxide observed was recorded.  Measurements of 
HbCO were made in triplicates with baseline values not exceeding a < 2% difference.  
 
During the tHb measurement, the participant was then instructed to exhale; initially out 
with the spirometer, but completing the exhalation in the spirometer beyond residual 
volume (i.e. cannot exhale any further).  Only once the participant has exhaled beyond 
residual volume, were they instructed to open the rebreathing bag by turning a specified 
valve.  At the same instance, the individualised CO dose was administered via the pre-
filled 100 ml syringe, a standard digital stopwatch was started and the individual inhaled 
deeply and held the breath for 10 seconds.  The participant was then instructed to breathe 
normally (i.e. neither too deeply nor too superficially) into the spirometer for 1 minute and 
50 seconds.  At the end of the 2 minute period, the participant was instructed to exhale to 
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residual volume and to then try to fully inflate the rebreathing bag.  Following this the 
participant was disconnected from the spirometer by letting go of the mouthpiece and 
questions were asked, by the experimenter, regarding potential signs of early CO toxicity 
(e.g. headache, dizziness).  Once no sign of CO toxicity has been established, the end-tidal 
CO concentration at minute 4 was repeated and a venous blood sample was taken at minute 
8 and immediately measured for HbCO as previously described.  The rebreathing bag was 
then measured in order to assess any potential remaining CO using the Draeger Pac7000 
CO analyser. 
 
Prior to actual testing each participant was familiarised with the rebreathing procedure 
where the CO dose was replaced with an equivalent dose of ambient air.  In addition, 
during actually rebreathing measurements a portable CO analyser (Fluke CO-220, Fluke, 
Norwich, UK) with parts-per-million sensitivity, was placed beside the mouth piece and 
nose-clip to monitor any potential gas leakages.  If this did occur, noted values were used 
to correct calculated values.  Further, the reproducibility of the employed method was 
quantified by calculating the typical error of measurement (Hopkins, 2000). Precision was 
good, with a typical error <2%, for the determination of total haemoglobin mass and blood 
volume performed on consecutive days (Durussel, 2011).  
 
2.6.2.3 Optimised Carbon Monoxide (CO)-rebreathing Calculations 
Total haemoglobin mass was calculated as:  
 
tHb (g) = K x MCO x 100 x (∆HbCO x 1.39)-1 
 
where K = (current barometric pressure (mmHg) x 273.15oK) x (current temperature (oK) x 
760 mmHg)); ∆HbCO% = the difference between basal haemoglobin carbon monoxide 
percentage (HbCO%) and HbCO% in blood samples after CO administration; 1.39 = 
Hufner’s number of CO binding capacity for Hb (ml.CO.Hb-1) (Gorelov, 2004);  
  
Myoglobin carbon monoxide content (MCO) (ml), the volume of CO bound to Hb = 
volume of CO administered (ml) - (the amount of CO remaining in the spirometer and lung 
after disconnection (ml)) + the amount of CO exhaled after rebreathing until blood 
sampling (ml) + the amount of CO diffused to myoglobin (ml)).   
 
The amount of CO remaining in the spirometer and the lung (ml) = [CO] in the rebreathing 
bag (ppm) x (spirometer volume (ml) + lung residual volume (ml) x 10-6.  The lung 
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residual volume was estimated according to a prediction equation (Withers and Ball, 
1988).  Estimated instead of measured residual volume was considered sufficient since an 
error of 500 ml would lead only to a ~2 g deviation of tHb for a given subject with 900 g of 
tHb and inhaling 70 ml of CO.  The amount of CO exhaled after disconnection (ml) = 
difference between end-tidal [CO] measured before and after the rebreathing procedure 
(ppm) x alveolar ventilation (ml.s.-1) x time (s) x 10-6.  
 
The amount of CO diffused to myoglobin from the vascular bed (ml) = 0.3% x volume of 
CO administered (ml) x time (min) (Nilsson et al., 2002).  As myoglobin is another 
potential binding site for CO, this amount has to be considered to avoid overestimating tHb 
(Garvican et al., 2010, Nilsson et al., 2002).  The calculation of the amount of CO lost to 
myoglobin, derived by Prommer and Schmidt (2007), was deemed sufficient as a ±10 kg 
change of lean body mass and therewith myoglobin content would lead only to a ~3 g error 
of tHb for a given subject with 950 g of tHb.  
 
Finally, blood volume (BV), erythrocyte volume (EV) and plasma volume (PV) were 
derived from tHb, [Hb] and Hct measures via formulae: 
 
BVA (l) = tHb (g) x [Hb]
-1 (g.dl-1) x 10-1 
EVA (l) = BVA (l) x Hct (%) x 0.91 x 10
-2 
PVA (l) = BVA (l) - EVA (l) 
 
These formulae have been frequently used in previous research (Christensen et al., 1993, 
Saunders et al., 2004a, Pottgiesser et al., 2007, Schumacher et al., 2008, Thomsen et al., 
1991).  
 
2.7 Blood Pressure 
When blood pressure measurements were taken participants were instructed to lay in a 
supine position for at least 10 minutes prior the automated measurement being taken 
(Omron HEM705 CP, Omron Healthcare UK Ltd, Milton Keynes, UK).  This automated 
blood pressure monitor has been validated according to the European Society of 
Hypertension International Protocol (El Assaad et al., 2003).  Each occasion involved three 
measurements taken, of which values were averaged and then used for analysis (Appendix 
G).  Participants were familiarized with the blood pressure taking protocol during the 
initial screening process.  
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2.8 Recombinant Erythropoietin Storage, Preparation, Self-
administration and Placebo Self-administration  
2.8.1 Recombinant Erythropoietin Storage 
The r-HuEpo (Neorecormon, Basel, Switzerland) was stored in a refrigerator between 2°C 
– 8°C (Roche, 2009) and this was monitored and logged on a daily basis.  Care was taken 
to ensure that the reconstituted solution was made in an ambient temperature below 25°C 
and away from sunlight.  
2.8.2 Recombinant Erythropoietin Preparation 
The experimenter first washed their hands and wore protective gloves in order to minimise 
the chance of contamination.  The lyophilisate vial was removed from the packing and the 
date of reconstitution and expiry were written on the label (expiry is 1 month after 
reconstitution).  The protective plastic cap was then removed from the lyophilisate vial and 
the rubber seal was disinfected using an alcohol wipe.  The reconstitution solution and 
withdrawal device (which allows sterile air exchange) was taken out and the protective 
cover from the spike was removed.  The withdrawal device was attached to the vial until 
the snap lock clicked into place.  A needle and syringe, contained in the packaging, was 
then lifted and the needle cover removed. The solvent containing One-Point-Cut ampoule 
was then shook/tapped in order to get any fluid, in the stem, into the body of the ampoule. 
The stem was then snapped off away from the experimenter.  All the solvent was 
withdrawn into the syringe.  The rubber seal of the withdrawal device was then disinfected 
using an alcohol wipe.  The seal was penetrated with the needle, to a depth of about 1 cm, 
and the solvent was slowly injected into the vial. The syringe (with needle) was then 
disconnected from the withdrawal device.  The reconstituted vial was swirled gently until 
the lyophilisate dissolved.  The solution was then checked to ensure that the solution was 
clear, colourless and free of particles.  If this was not the case, the injection was discarded.  
 
2.8.3 Recombinant Erythropoietin Self-administration Instructions 
Participants were instructed that they were to self-administer the injection subcutaneously 
at the abdomen.  The injection was warmed, by the experimenter, by rolling the filled 
syringe between the hands for a few minutes. This was a comfort measure for the person 
receiving the injection.  The injection site was then exposed by the participant and the area 
Chapter 2.  General Methods  110 
______________________________________________________________________________ 
110 
 
was clean in a circular motion with an alcohol swab, beginning at the centre and moving 
outwards.  The area was then allowed to dry for approximately ten seconds. 
 
Participants were instructed to remove the needle cap and hold the syringe, as though 
holding a pencil, and were instructed to pinch the skin where the injection is to be made 
with the other hand.  Participants were instructed to hold the syringe at a 45-90 degree 
angle and about two inches from the skin surface.  Participants were instructed to insert the 
needle with a quick jab with the needle going all the way into the skin.  If no blood was 
identified in the syringe, the participant was then instructed to slowly push down on the 
plunger until all the solution was injected.  A clean alcohol swab was then placed over the 
needle and the skin site, without pressing down, and the needle was pulled out.  Pressure 
was then applied to the injection site. Participants were instructed to remove the swab after 
five to ten seconds and an adhesive bandage or plaster was placed over the site in case of 
any bleeding. 
 
The exact same procedure was followed in Chapter 6 for the self-administration of placebo 
except r-HuEpo was replaced by saline.  
 
2.8.4 Recombinant Erythropoietin Dosages and Iron Supplementation 
In Chapter 4, each participant received 50 U.kg-1 body mass subcutaneous injections of r-
HuEpo (Neorecormon, Roche, Switzerland) every 2 days over a 4-week period and this is 
in line with previous studies (Parisotto et al. 2000).  Participants also received daily iron 
tablets providing approximately 105 mg of elemental iron derived from 350 mg of dried 
ferrous sulphate (Abbott Ltd, Maidenhead, UK).  This was carried out as studies have 
shown oral iron supplementation to be more effective than intravenous in assisting with red 
blood formation and development (Parisotto et al., 2000a).  
Saline (NaCl 0.9% BP, Baxter, Glasgow, UK) injections were substituted for r-HuEpo 
injections if a pre-determined haematocrit (Hct) limit of 55% was reached in response to r-
HuEpo.  Participants resumed the standard r-HuEpo regimen once Hct dropped below 
55%.  The American College of Sports Medicine position on Epo and blood doping 
(Sawka et al. 1996) refers to an Hct greater than 55% as “dangerous”.  However, ceasing r-
HuEpo injections if Hct reaches 55% is a medical safeguard which in-line with previous 
studies commissioned by the World Anti-doping Agency (WADA) and the International 
Olympic Committee (IOC) with no untoward events recorded (e.g. Parisotto et al. 2001).  
The dangers associated with elevated Hct values relates to blood viscosity and, in turn, the 
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increased risk of thrombosis and related events.  There have been no reports of significant 
side effects as a result of r-HuEpo injections in normal healthy individuals and, in athletes, 
there has been one report of elevated systolic blood pressure (from 177 to 191 mmHg) 
during moderate-intensity exercise (compared with mild or low intensity exercise) 
following treatment with r-HuEpo at doses of ~30 units per kilogram body weight over 6-7 
weeks.  Other potential side effects include flu like symptoms (mild and of short duration), 
suppression of natural r-HuEpo production, a burning sensation associated with 
subcutaneous injection of r-HuEpo, joint pains, rashes, and one case of a hypotensive 
episode associated with r-HuEpo injection.  
The management of side effects including allergy and arthalgia, and those listed above, 
included the cessation of r-HuEpo treatment and withdrawal from further participation in 
the study.  It is important to highlight that higher doses of r-HuEpo per kilogram body 
weight per week have been safely used in previous studies (Audran et al., 1999).  Further, 
athletes typically have Hct levels lower than those of non-exercising populations.  With 
values around 40-45% (compared with “normal” values of 45-50%) and the lower Hct 
values have been associated with training-induced haemodilution (Szygula, 1990). 
This effect of training should minimise the risks of hyperviscosity associated with r-HuEpo 
administration.  In addition, throughout the study period, participants were encouraged to 
maintain normal hydration practices.  Finally, the administration of the first r-HuEpo dose 
was carried out under medical supervision because of the very low but possible risk of 
anaphylaxis (Goodnough et al., 2000). 
2.9 Psychological and Psychosocial Measures 
Prior the use of psychological and psychosocial measures, an expert in the field was 
contacted (at Swansea University).  Based on expert advice and on what quantitative scales 
and qualitative interview questions have been previously used in similar type of research, it 
was concluded that the following quantitative and qualitative measures should be carried 
out:   
2.9.1 Quantitative measures 
The profile of moods (POMS) and cognitive-state anxiety (CSAI-2) (Appendix D) 
questionnaires were used in Chapters 4 and 6.  The POMS and CSAI-2 questionnaires 
contained 24 and 27 self-report items with a 4-point scale, respectively.  Participants were 
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instructed to choose from 0 (not at all) to 4 (extremely/very much) as to how they felt in 
response to the question.  The questionnaires took a combined time of approximately 3 to 7 
minutes to complete.  Participants were familiarised with each questionnaire prior 
experimental use.  
2.9.2 Qualitative measures 
In Chapters 4 and 6, participants individually took part in one and two semi-structured 
interviews, respectively. In the case of experimental Chapter 6, one interview was carried 
out prior the placebo deception being revealed and one after the placebo deception being 
revealed.  In each case, the interviews were carried out on the final day of each respective 
experimental protocol (Appendix E). All interviews involved participants answering 
questions in relation to the trial.  In Chapter 6, upon completion of interview one, subjects 
were given a scripted debriefing document to read after the initial interview was completed 
and this revealed that a deception had taken place with further information explaining the 
rationale behind the study.   
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3. The Evaluation of the Cosmed K4b2 Portable 
Metabolic System during Running Outdoors 
3.1 Introduction 
Modern technological developments in portable metabolic systems have enabled traditional 
laboratory based practices to be taken into the field and many research studies have used 
these systems (Strath et al., 2000, Billat et al., 2000, Sheel et al., 2003, Roels et al., 2005, 
Abel et al., 2008, Thornton et al., 2011, Bertuzzi et al., 2012). One widely used system is 
the Cosmed K4b2 system (K4b2, COSMED s.r.l., Rome, Italy). 
 
Several studies have examined the validity and reliability of the K4b2 portable metabolic 
system (McLaughlin et al., 2001, Pinnington et al., 2001, Eisenmann et al., 2003, Duffield 
et al., 2004, Hodges et al., 2005, Schrack et al., 2010) however, all but one study have 
considered a static indoor testing environment (i.e. treadmill or cycling ergometer).  The 
only study to investigate K4b2 accuracy in an outdoor environment used roller skiing 
exercise (Doyon et al., 2001).  There have been no published studies (to the best of the 
author’s knowledge) on the accuracy of the K4b2 during running activities in outdoor 
environments.  Given the differences between the static laboratory setting and the often 
dynamic outdoor setting, it does not necessarily follow that validity will transfer to the 
latter. 
 
The main potential problem that may be incurred during outdoor testing is interference of 
facing head winds with the K4b2 flow-meter and sampling line.  The extent to which this 
theoretical factor may influence oxygen uptakes, calculated by the K4b2 during outdoor 
running is unclear and thus there is insufficient data available to determine whether the 
K4b2 is reliable and accurate for use during testing outdoors.  Despite this, the K4b2 has 
been used for data collection in outdoor environments in a number of studies (Devienne 
and Guezennec, 2000, Billat et al., 2003).  
 
The purpose of this study was therefore to determine the validity of the K4b2 for 
determining oxygen uptake during treadmill and outdoor running.  
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3.2 Methods 
3.2.1  Participants 
Nineteen trained male volunteers (age: 22.9 ± 1.0 years; weight: 74.1 ± 1.8 kg; height: 
179.2 ± 1.4 cm; V
．
O2max 59.4 ± 0.30 ml
.kg-1.min-1 mean ± SD) were recruited as described 
in section 2.1 with inclusion and exclusion criteria also described.  
 
3.2.2  Experimental Design and Procedures 
Each participant completed three continuous maximal incremental running tests in random 
order:  K4b2 indoors, K4b2 outdoors and Douglas bag (DB), as previously described (see 
section 2.4.1).  Cardiopulmonary measurements obtained using the K4b2 were compared 
to the DB.     
 
K4b2 indoor tests were carried out in a mean ambient temperature of 21oC (Comark 
N8006, Hertfordshire, UK) and were performed on a motorised treadmill (Woodway 
PPS55 Med, Weilam Rhein, Germany).  Douglas bag indoor tests were carried out under 
the same conditions.  K4b2 outdoor tests were carried out on a 400 m concrete running 
track (Bellahouston Park, Glasgow, UK) with a mean ambient temperature of 18oC and 
with no to slight winds (<2 m·s-1, Skymaster Wind Meter SM-28, Speedtech Instruments, 
Great Falls, VA, USA).   
 
Running tests for each individual were separated by at least two days for appropriate 
recovery and were scheduled at approximately the same time of day to avoid the influence 
of diurnal variation on the metabolic response to exercise.  Each participant completed the 
trial within a 2-week period.  Participants were requested to wear the same athletic clothing 
and footwear for all tests.  
 
Participants reported to the laboratory on the day of testing following a 3-hour fast and 
having refrained from alcohol, caffeine and strenuous exercise the day before.  
Participants’ height and weight were measured at the start of the study and body weight 
(Avery, England, UK) and height (Invicta Plastics Ltd, Leicester, UK) were measured prior 
each test as previously described.  Participants wore a heart rate transmitter belt (Polar NV, 
Polar Oy, Kempele, Finland) and were asked to perform their usual warm-up before 
commencing each test.   
Chapter 3.  The Evaluation of the Cosmed K4b2 Portable Metabolic System during Running 
Outdoors.   115 
______________________________________________________________________________ 
115 
 
3.2.3  Statistical Analysis 
Statistical analysis was completed using Statistica statistical software (Release 6.0, 
Statistica, StatSoft, Inc., Tulsa, OK, USA).  Differences in V
．
O2, V
．
CO2, FEO2, FECO2, V
．
E 
and respiratory exchange ratio (RER) between conditions were compared by a 2-way 
Analysis of Variance (condition x running speed) with Tukey post hoc tests used to 
identify where differences lay.  Linear regression analyses were used to determine the 
relationships between V
．
O2 measured under the three different conditions.  A limits of 
agreement approach (Bland and Altman, 1986, Bland and Altman, 1996) was used to 
determine agreement between V
．
O2 measured under the three different conditions.  All 
continuous data were checked for normality utilising the Anderson-Darling test and 
transformed where appropriate.  All data are presented as mean ± SEM unless otherwise 
stated.  
 
3.3 Results 
Figures 3.1, 3.2, 3.3 , 3.4, 3.5, 3.6 and 3.7 show the data obtained for V
．
O2, V
．
CO2, FEO2, 
FECO2, V
．
E, RER and HR, respectively, for K4b2 indoors, K4b2 outdoors and Douglas bag 
method conditions.   
 
Oxygen uptake, when measured by K4b2 indoors, was significantly higher than when 
measured using the Douglas bag method or K4b2 outdoors at all running speeds (P = 0.03) 
(Figure 3.1).  No statistically significant differences were found between K4b2 outdoors 
and the Douglas bag method for V
．
O2 at any running speed (P > 0.05).  K4b2 indoors V
．
CO2 
measures were significantly higher than the Douglas bag method (P = 0.03) and K4b2 
outdoors (P = 0.02) at a running speed of 12 km.h-1.  No statistically significant differences 
were found between K4b2 outdoors and the Douglas bag method for V
．
CO2 at any running 
speed except at 16 km.h-1 (P = 0.01) (Figure 3.2).    
 
No statistically significant differences were found between K4b2 indoors and K4b2 
outdoors for FEO2 at any running speeds except at 8 km
.h-1 (P < 0.05).  K4b2 FEO2 
measures, both indoors and outdoors, were significantly lower when compared to the 
Douglas bag method at all running speed (P < 0.05) (Figure 3.3).  No statistically 
significant differences were found between K4b2 indoors and K4b2 outdoors for FECO2 at 
any running speeds.  The Douglas bag method was significantly lower for FECO2 when 
compared to K4b2 indoor and K4b2 outdoor measures at all running speed (P < 0.05) 
except at 16 km.h-1 (Figure 3.4). 
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No statistically significant differences were found between K4b2 indoors and the Douglas 
bag method for V
．
E at any running speed.  The K4b2 indoors was significantly higher, for 
V
．
E, than the K4b2 outdoors at all running speeds (P < 0.05) except at 8 km
.h-1(Figure 3.5).   
 
No statistically significant differences were found between the K4b2 indoors and K4b2 
outdoors for RER at all running speed.  The K4b2 indoors was statistically lower from the 
Douglas bag method for RER at all running speeds (P < 0.05) except at 10 km.h-1.  The 
K4b2 outdoors was statistically lower from the Douglas bag method for RER at all running 
speeds (P < 0.05) except at 8 and 10 km.h-1 (Figure 3.6).  Heart rate measurements were 
not significantly different between any conditions and at any running speeds (Figure 3.7). 
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Figure 3.1: V
．
O2 values at different running speeds for K4b2 indoors (In), K4b2 outdoors 
(Out) and Douglas Bag (DB) conditions. * K4b2 indoors significantly different (P < 0.05) 
from K4b2 outdoors and Douglas bag method. 
Figure 3.2: V
．
CO2 values at different running speeds for K4b2 indoors (In), K4b2 outdoors 
(Out) and Douglas Bag (DB) conditions. * K4b2 indoors significantly different (P < 0.05) 
from K4b2 outdoors and Douglas bag method. # K4b2 outdoors significantly different (P < 
0.05) from the Douglas bag method. 
*
*
*
*
*
*
#
Chapter 3.  The Evaluation of the Cosmed K4b2 Portable Metabolic System during Running 
Outdoors.   118 
______________________________________________________________________________ 
118 
 
      
 
 
 
 
 
 Figure 3.4: FECO2 values at different running speeds for K4b2 indoors (In), K4b2 outdoors 
(Out) and Douglas Bag (DB) conditions. * K4b2 indoors and K4b2 outdoors significantly 
different (P < 0.05) from Douglas bag method. 
Figure 3.3: FEO2 values at different running speeds for K4b2 indoors (In), K4b2 outdoors 
(Out) and Douglas Bag (DB) conditions. * K4b2 indoors and K4b2 outdoors significantly 
different (P < 0.05) from Douglas bag method. # K4b2 indoors significantly different (P < 
0.05) from K4b2 outdoors. 
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Figure 3.6: RER values at different running speeds for K4b2 indoors (In), K4b2 outdoors 
(Out) and Douglas Bag (DB) conditions. * K4b2 indoors significantly different (P < 0.05) 
from Douglas bag method.  # K4b2 outdoors significantly different (P < 0.05) from Douglas 
bag method.     
Figure 3.5: V
．
E values at different running speeds for K4b2 indoors (In), K4b2 outdoors (Out) 
and Douglas Bag (DB) conditions. * K4b2 indoors significantly different (P < 0.05) from 
K4b2 outdoors. 
*
*
*
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Figure 3.7: Heart rate values at different running speeds for K4b2 indoors (In), K4b2 outdoors 
(Out) and Douglas Bag (DB) conditions.  No significant differences found between conditions 
at any running speed. 
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Figure 3.8: Scatterplot of K4b2 indoors (In) and Douglas bag method (DB) for V
．
O2 (solid line: line 
of identity; dashed line: line of best fit.  
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Figure 3.9: Scatterplot of K4b2 indoors (In) and K4b2 outdoors (Out) for V
．
O2 (solid line: line of 
identity; dashed line: line of best fit.  
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Figure 3.10: Scatterplot of K4b2 outdoors (Out) and Douglas bag method (DB) for V
．
O2 (solid 
line: line of identity; dashed line: line of best fit.  
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Figure 3.8 shows the relationships between V
．
O2 measured using the Douglas bag method 
and V
．
O2 measured using the K4b2 indoors.  The shared variance (r
2) between the Douglas 
bag method and K4b2 indoors was 85.9%.  The gradient of the line was 0.92 with an 
intercept of 0.36 ml.kg-1.min-1.  This indicates that the intercept was very close to zero 
(only a 0.36 ml.kg-1.min-1 offset), but the K4b2 indoors systematically overestimated V
．
O2 
when compared to Douglas bag by 8.4% (i.e. 1/0.9225).   
   
Figure 3.9 shows similar data for K4b2 indoors versus the K4b2 outdoors.  The shared 
variance (r2) between the two methods was 88.6%.  In contrast to Figure 3.8, a substantial 
offset is shown between the two methodologies with the K4b2 outdoor intercept being 
systematically 3.32 ml.kg-1.min-1 lower than K4b2 indoor measurements.  Furthermore the 
gradient of the line was very close to 1 (exactly 0.99) so there was only a 0.85% (i.e. 
1/0.9916) difference in the increment in V
．
O2 between these two conditions.  Thus, in 
contrast to the previous comparison, when comparing K4b2 indoors and K4b2 outdoors, 
the gradient was the essentially the same with a change in intercept.  
 
Figure 3.10 shows the relationships between V
．
O2 measured using the Douglas bag method 
and V
．
O2 using the K4b2 outdoors.  The shared variance between the two methods was 
85.9%.  The gradient of the line was 0.88 with an intercept of 5.2 ml.kg-1.min-1.  This 
intercept indicates (i.e. a 5.2 ml.kg-1.min-1) a K4b2 outdoors negative offset by 5.2 ml.kg-
1.min-1, but this was coupled with a K4b2 outdoors overestimation of V
．
O2 by 14.2% (i.e. 
1/0.8754).  The direction of these errors were opposite, thus for values towards the middle 
of the V
．
O2 range these errors appear to cancel out.  
 
This is further seen when we consider the Bland Altman plots (Figures 3.11-3.13) where 
mean biases and levels of agreement between conditions, for V
．
O2, are also shown.   
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Mean V
．
O2 was 4.2 ml
.kg-1.min-1 higher with the K4b2 indoors than when compared to the 
Douglas bag method.  95% confidence interval limits of agreement range from -3.7 and 
12.1 ml.kg-1.min-1.  This is equivalent to a typical measurement error of 6.7% (i.e. √2 x SD) 
or 2.9 ml.kg-1.min-1. 
 
Figure 3.11: Bland and Altman plot of K4b2 indoors (In) and the Douglas bag method (DB).  
   
Line of equality 
Mean bias 
95% Confidence Interval 
95% Confidence Interval 
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Mean V
．
O2 was 1.9 ml
.kg-1.min-1 higher with the K4b2 indoors than when compared to the 
K4b2 outdoors.  95% confidence interval limits of agreement range from -5.7 and 9.4 
ml.kg-1.min-1.  This is equivalent to a typical measurement error of 6.3% (i.e. √2 x SD) or 
2.7 ml.kg-1.min-1. 
 
 
 
 
Figure 3.12: Bland and Altman plot of K4b2 indoors (In) and the K4b2 outdoors (Out).  
Line of equality 
Mean bias 
95% Confidence Interval 
95% Confidence Interval 
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Mean V
．
O2 was 2.3 ml
.kg-1.min-1 higher with the K4b2 outdoors than when compared to the 
Douglas bag method.  95% confidence interval limits of agreement range from -6.1 and 
10.7 ml.kg-1.min-1.  This is equivalent to a typical measurement error of 6.5% (i.e. √2 x SD) 
or 3.0 ml.kg-1.min-1. 
 
 
 
 
Figure 3.13: Bland and Altman plot of K4b2 indoors (In) and K4b2 outdoors (Out).  
 
Line of equality 
Mean bias 
95% Confidence Interval 
95% Confidence Interval 
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3.4 Discussion 
The primary purpose of this study was to assess the accuracy of the K4b2 in measuring 
V
．
O2 during running in an outdoor environment.  To the author’s knowledge this is the first 
study to do so.  In summary, V
．
O2 measured using the K4b2 outdoors appeared to provide 
similar values to those obtained using the Douglas bag method.  However, this apparent 
agreement was a consequence of two different errors which acted in opposite directions 
(i.e. a 5.2 ml.kg-1.min-1 negative offset in V
．
O2 coupled with a 14.2% higher gradient in the 
relationship between the K4b2 outdoors and the Douglas bag method for measuring V
．
O2). 
 
This is further illustrated from the Bland Altman plot (Figure 3.13) which indicates a 
typical measurement error in V
．
O2 between the K4b2 outdoors and the Douglas bag method 
of 6.5%.  In other words, on average, values between the K4b2 outdoors and the Douglas 
bad method will differ by 6.5%.  The 95% confidence interval range for agreement 
between these two methods was 16.8 ml.kg-1.min-1.  This degree of error is substantial and 
thus limits the potential for using the K4b2 for the measurement of potentially subtle 
differences in performance measures such as V
．
O2max, V
．
O2 at lactate threshold or running 
economy. 
 
As there are two methodological changes when moving from the Douglas bag method to 
the K4b2 outdoors (i.e. change in device and change in condition), it is logical to consider 
these two aspects separately in order to further assess the sources of these observed errors. 
 
The first aspect to consider is the difference between the Douglas bag method and K4b2 
when both were used under the indoor treadmill condition.  In this instance, one 
methodological difference is the added ~1.5 kg weight that wearing the K4b2 device adds.  
For the average person in the group (i.e. weighing 74.1 kg), this represents a 2% increase 
in weight, which would in turn be expected to increase V
．
O2 by 2%.  Thus, the added ~1.5 
kg weight that the K4b2 indoors contributes cannot solely explain the 8.4% difference in 
V
．
O2 found.  Although not statistically different, heart rate values during K4b2 indoor tests 
were numerically higher by an average of 3% when compared to both the Douglas bag 
method. This may indicate a small additional workload during the K4b2 indoor condition.  
This could conceivably reflect the additional weight and potentially breathing resistance 
from the K4b2 mask.  Ventilation rates were also numerically higher during K4b2 indoor 
tests when compared to the Douglas bag method by an average of 6.2%.  Interestingly, in 
previous literature examining K4b2 measured V
．
O2 with various reference methods, indoor 
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cycling ergometer based assessments have, more often, shown good agreement 
(McLaughlin et al., 2000, Parr et al., 2001).  However, there seems to be discrepancies 
where treadmill running is involved with at least one study (Duffield et al., 2004) showing 
an over-estimation of V
．
O2 by the K4b2 device; similar to the findings reported here.  A key 
difference between cycling and running exercise is that the exercising individual does not 
need to support their own body weight in cycling, thus the weight of the K4b2 should not 
influence V
．
O2 values.  The fact that the V
．
O2, during running, was higher by more than 
what would be expected by the weight of the device suggests that wearing the K4b2 may 
have a negative impact on biomechanical efficiency which may, in turn, have reduced 
running economy.  Another interesting point to consider would be the potential 
psychological impacts, on performance, of the device physically attached to the individual.   
 
Looking at Figure 3.5, V
．
E was on average 6.2% higher with K4b2 indoors than when 
compared to the Douglas bag method.  Thus, given similar levels of FEO2, V
．
E could 
explain approximately two-thirds of the difference in V
．
O2 (8.4%) between the two 
methods.  Thus, about a third of the difference must be explained by differences in oxygen 
extraction (i.e. FEO2).  The average FEO2 measures for the Douglas bag method and K4b2 
indoor conditions was 16.47% and 15.72%, respectively.  Assuming an ambient O2 
concentration of 20.93%, a 4.46% and 5.21% extraction of O2 occurred with the Douglas 
bag method and K4b2 indoor conditions, respectively.  Thus, the percentage difference 
(i.e. ((5.21-4.46) / 4.46)*100) between these averages was 16.8% which is much higher 
than what is needed to explain the remaining difference (i.e. 2.2%) in V
．
O2 between the two 
methodologies.  Thus, due to such large FEO2 discrepancies, in seems logical to assess 
potential differences in how FEO2 is measured and used for the calculation of V
．
O2 between 
the K4b2 device and the Douglas bag method. 
 
Both the K4b2 and Servomex gas analysers (used during the Douglas bag method) were 
calibrated and checked prior use and were reading within their respective range of 
tolerance (both manufacturers claim an error of 0.02% for measured O2 and 0.01% for 
measured CO2).  However, the K4b2 indoors still measured significantly lower FEO2 at all 
running speeds when compared to the Douglas bag method by an average of 0.7%.  For 
FECO2, a similar pattern emerged, however in this instance; the K4b2 indoor values for 
FECO2 were significantly higher, by 0.5%, than those measured by the Douglas bag 
method.   
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One difference between the Douglas bag method and the K4b2 is that the latter excludes 
the initial 70 ml of each breath in order reduce the occurrence of ‘double-breaths’ (i.e. 
where a single breath may be measured as two breaths as a result of an interruption to the 
breath).  This results in the calculation of lower FEO2 and higher FECO2 values (Parr et al., 
2001) (i.e. only after 70 ml of air passes through the flow meter are air gas fractions 
measured).  In contrast, the Douglas bag method includes each entire breath, including 
apparatus dead space, which also contributes to Douglas bag measures being inherently 
higher when compared to the K4b2.  The difference between the two methods is illustrated 
in Figure 3.14.  
 
 
 
 
 
 
 
 
 
 
Figure 3.14: An illustration of the difference between the K4b2 and Douglas bag 
method in determining metabolic variables (extracted from Parr et al., 2001)  
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This special K4b2 characteristic, as well as differences in how V
．
O2 is calculated by the 
K4b2 and Douglas Bag, has been previously described (Parr et al., 2001) using the 
following example formulae comparison:   
 
Douglas Bag - 
V
．
O2 = (V
．
I x FIO2) - (V
．
E x FEO2) 
V
．
O2 = (33.9 L
.min-1 x 0.2093) - (33.8 L.min-1 x 0.1658) 
VO2 = 1.49 L
.min-1 
 
K4b2 - 
V
．
O2 = (V
．
I x FIO2) - (V
．
E x FEO2) - (VD x (FIO2- FETO2)) 
V
．
O2 = (33.9 L
.min-1 x 0.2093) - (33.8 L.min-1 x 0.1618) - (2.0 L.min-1 x (0.2093 - 0.1427)) 
V
．
O2 = 1.49 L
.min-1 
 
The K4b2 uses the equation, based on the above, where V
．
O2 is calculated using the volume 
of O2 inspired (V
．
I x FIO2) subtracted from the volume of O2 expired (V
．
E x FEO2).  This is 
similar to how V
．
O2 is calculated by the Douglas Bag method.  The key difference, 
however, is related to the expulsion of the initial 70 ml measured by the K4b2 which aims 
to reduce the occurrence of ‘double-breaths’.  In addition, the 70 ml expulsion, in turn, 
corrects for the small amount of oxygen located in the dead space (VD) of the breathing 
apparatus, at the start of inspiration and expiration (VD x (FIO2- FETO2)), as such dead-
space is flushed out prior the calculation of air gas fractions.  This mechanisms and/or 
correction, therefore, aim to improve K4b2 measures as to match measures by the Douglas 
bag method, despite K4b2 measuring lower FEO2 values.  Similar findings have also been 
reported previously (McLaughlin et al., 2001, Pinnington et al., 2001, Mc Naughton et al., 
2005).  Although this algorithm seems logical, large discrepancies in V
．
O2 measures were 
still present between the K4b2 indoor and the Douglas bag method.  Thus, the fact that the 
difference was bigger than 3.3% (i.e. V
．
O2), it is due to the way the K4b2 measures FEO2, 
which therefore is not comparable to the Douglas bag method due to the differences 
highlighted.     
 
The next consideration is potential changes in V
．
O2 when moving from an indoor to an 
outdoor running environment.  One major difference between running outdoors and 
indoors involves facing air velocities encountered during running outdoors versus running 
on a treadmill.   
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One major difference between running indoors and outdoors involves facing air velocities 
and how this impacts the determination of V
．
E and FEO2 (and FECO2) at the sampling level.  
This is yet to be conclusively determined.  Minute ventilation was lower in the K4b2 
outdoor condition in comparison to the K4b2 indoor condition (Figure 3.5).  This may be a 
consequence of head-winds which in turn impacts the rotation of the internal turbine, used 
to calculate V
．
E, by the expiratory breaths.  As a result of this finding, a potential dilution 
effect on FEO2 (and FECO2) values, as a result of the interfering ambient air head winds, 
might also be expected.  However, FEO2 values were not significantly different between 
K4b2 indoor and K4b2 outdoor conditions.  Thus, an explanation as to the discrepancies in 
V
．
O2 between the K4b2 indoors and outdoors remains to be elucidated, but the reduction 
found outdoors in V
．
E will likely have contributed.  Furthermore, it remains unclear as to 
how well the sampling line and turbine of the K4b2 are protected, from both head and 
environmental winds, when considering that participants ran in an angular fashion, round 
track bends, in the outdoor condition.     
 
Another consideration may be related to the impact of the 1% gradient used during indoor 
tests as to better resemble the energetic costs of running outdoors (Cureton et al., 1978).  
The gradient contribution to V
．
O2 was assessed using an American College of Sports 
Medicine formula for the calculation of V
．
O2 during running indoors 
(speed*3.334+0.15*speed*grade+3.5) (American College of Sports Medicine, 2000).  This 
may have been a contributing factor to the statistically higher K4b2 indoor values when 
compared to the K4b2 outdoors.  The formula indicates a constant multiplied by speed 
which suggests a divergence in the relationship between speed and V
．
O2 as speed is 
increased.  However, this was not the case as indicated in Figure 3.9, where the lines of 
identity and best fit are parallel with one another (i.e. a K4b2 indoor systematic bias of 3.3 
ml.kg-1.min-1).  Thus, there are a number of potential errors in the measurement of V
．
O2 
between the Douglas bag method and K4 outdoors. Taken together this leads to a typical 
error of 3 ml.kg-1.min-1 and 95% confidence interval range of -6.1 and 10.7 ml.kg-1.min-1.  
This is substantial and is not suitable for measuring potential subtle differences in 
performance measures (equivalent to typical measurement error of 6.5%). 
 
Another point of concern is in relation to K4b2 derived RER values.  Statistically 
significant differences were found for RER values between both K4b2 conditions and the 
Douglas bag method at various running speeds (Figure 3.6).  Furthermore, measurements 
made by the K4b2 both indoors and outdoors, during maximal running speeds, were 
unusually low when considering a frequently used criterion of RER > 1.15 for V
．
O2max 
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(Rossiter et al., 2006).  This may have been due to the numerically lower V
．
CO2 
measurements made by the K4b2 during maximal exercise where a greater plateau is 
present for V
．
CO2 compared to V
．
O2. 
 
In summary, the degrees of error for the measurement of V
．
O2, as reported in this 
experimental chapter, are unacceptable when considering the level of accuracy required for 
physiological measures such as V
．
O2max and running economy, amongst others.  Such 
differences can have significant impacts on data interpretation and conclusions in research 
studies.  Overall, it is clear that no single factor is responsible for the results found in this 
experimental Chapter.  It is most likely the case that several errors found in various sub-
component variables (i.e. FEO2 and V
．
E), from which V
．
O2 is derived,  as well as the 
potential negative impact wearing the K4b2 may have on running economy, all contributed 
to the physiologically meaningful differences reported.  It is acknowledged that portable 
metabolic devices for use in the field will always have an inherently higher error in 
comparison to laboratory based technologies.  However, it is also clear that improvements 
are required to improve the accuracy of field based measures in order for such technologies 
to be more readily employed with confidence in the results obtained. 
 
3.4.2  Study Limitations  
Theoretically, the ideal experimental design would have been to use both the K4b2 and the 
Douglas bag method simultaneously (Atkinson et al., 2005).  However, previous reports 
have found that simultaneous use proved too problematic as a result of interferences 
between the two measuring devices (McLaughlin et al., 2001).  This, alongside practicality 
issues (i.e. using the Douglas Bag outdoors), warranted the design employed in this study.  
As a result, testing on different days did incur a 48 hour resting period between tests and so 
a day-to-day variation in V
．
O2 was expected to be in the region of 4% (Armstrong and 
Costill, 1985).  To add, although experimenters did their utmost best to ensure that speeds 
during the outdoor trials were maintained as closely as possible, this could potentially be a 
source for variation in measured variables.   
 
3.5 Conclusion 
The present investigation (to the best of the author’s knowledge) is the first to attempt the 
assessment of the K4b2 device during submaximal and maximal running velocities 
outdoors.  The K4b2 metabolic device appears valid for measuring V
．
O2 during 
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submaximal and maximal running velocities in an outdoor environment.  However, a K4b2 
outdoors mean bias of 2.3 ml.kg-1.min-1 with a 95% confidence interval limits of agreement 
range from -6.1 and 10.7 ml.kg-1.min-1 (equivalent to a measurement typical error of 6.5%) 
indicates unacceptable degree of error.  Furthermore, the K4b2 significantly overestimated 
V
．
O2 indoors when compared to the Douglas bag method.  As a result, users must seriously 
consider the level of measurement accuracy required prior using the K4b2 portable device.  
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4. The Effects of Human Recombinant Erythropoietin on 
Exercise Performance, Haematological and 
Psychological Variables 
4.1 Introduction 
The use of r-HuEpo in clinical practice is common and includes the administration to 
anaemic patients due to chronic renal failure (Eschbach et al., 1989) and to cancer patients 
undergoing chemotherapy (Platanias et al., 1991).  The administration of r-HuEpo has also 
been widely reported to improve athletic performance (Ashenden et al., 2001, Ninot et al., 
2006, Ashenden et al., 2006, Lundby et al., 2007, Robach et al., 2008, Lundby et al., 
2008b, Boning et al., 2008, Lundby, 2008) and such improvements are largely as a result 
of changes in the haematological profile resulting in improvements in aerobic fitness.  
Some studies have also shown improvements in physical strength scores immediately post 
r-HuEpo treatment (Ninot et al., 2006).  As a result, the use of r-HuEpo is speculated to 
frequently occur amongst the athlete population and high profile convictions such as Lance 
Armstrong have shown that this may indeed be the case (United States Anti-doping 
Agency (USADA), 2012). 
 
Endogenously present erythropoietin, primarily produced by the kidneys, is the main 
regulator of erythropoiesis in the human body and is regulated by the renin-angiotensin 
system (Dunn et al., 2007).  The administration of additional recombinant erythropoietin, 
exogenously, directly targets red blood cell progenitors and precursors which further 
stimulates pluripotent stem cell proliferation, differentiation and maturation of red blood 
cells as they enter the circulatory system (Jelkmann and Wolff, 1991, Ng et al., 2003).  It is 
by this mechanism that r-HuEpo administration can increase blood [Hb] and blood Hct, in-
turn increasing blood oxygen-carrying capacity.  This can lead to enhancements in key 
endurance performance determinants, such as V
．
O2max, and such improvements have been 
shown to improve endurance performance (Egrie et al., 1986, Ashenden et al., 2001).    
 
Several clinical studies have also examined the psychological effects of r-HuEpo 
administration and clinical outcomes have included improvements in cognitive function 
(Nissenson, 1990), decreases in the fatigue (Nissenson, 1990, Johansen et al., 2011) and 
improvements in perceived physical conditioning (Ninot et al., 2006).  However, there is 
still a lack of research assessing the effects of repeated r-HuEpo injections on 
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psychological measures in well-trained endurance individuals and how this may contribute 
to changes in exercise performance. 
  
The assessment of psychological changes in athletes is often problematic.  Under normal 
circumstances (i.e. assessing well-trained endurance individuals pursuing normal training 
approaches), detecting psychological changes can be problematic due to potential changes 
being very small (due to the high initial physical fitness levels) (Ninot et al., 2006).  In 
addition, any potential psychological changes associated with training will require 
relatively long periods of time in order for training adaptations to occur (Fox, 2000).  The 
use of r-HuEpo, however, can overcome such limitations as it induces noticeable 
performance enhancing effects over a substantially shorter timeframe (Lundby et al., 
2007).  As a result, this may trigger significant changes in psychological measures related 
to motivation, such as mood and anxiety, particularly during and immediately post the r-
HuEpo period of administration.  This may, in turn, contribute to the positive performance 
enhancing effect which previous studies have solely explained from a physiological 
standpoint (Ashenden et al., 2001, Ninot et al., 2006, Ashenden et al., 2006, Lundby et al., 
2007, Robach et al., 2008, Lundby et al., 2008b, Boning et al., 2008, Lundby, 2008).  In 
addition, this is the first study to assess whether results obtained from laboratory based 
performance tests, after the administration of r-HuEpo, are transferable to the field via 3 
km time trial assessments.  
 
Therefore, the aims of this study were to: 
 
1. Confirm the erythropoietic effect of r-HuEpo administration on haematological 
measures. 
2. Determine the effects of r-HuEpo administration on performance in an outdoor 
field setting. 
3. Determine which endurance performance-related physiological factors are changed 
by r-HuEpo administration. 
4. Determine whether r-HuEpo administration influences psychological measures, 
such as mood and anxiety, which may be attributable to potential changes in 
running performance.   
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Figure 4.1 illustrates the key factors that influence endurance performance and how r-
HuEpo administration may influence such factors with those measured, in Chapter 4, also 
indicated.  
Chapter 4. The Effects of Human Recombinant Erythropoietin on Exercise Performance, Haematological and Psychological Variables   138 
______________________________________________________________________________ 
138 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Hb] %SaO2 
COmax 
Maximum Velocity 
in Distance Race 
Oxidative 
Enzymes 
Velocity at LT 
V
．
O2max 
Capillary 
Density 
%V
．
O2max at LT 
Running 
Economy 
(Ca-CvO2)max 
SVmax HRmax 
Muscle Fibre 
Recruitment? 
- Mood? 
- Anxiety? 
Coronary Flow 
r-HuEpo 
r-HuEpo 
r-HuEpo 
r-HuEpo 
r-HuEpo 
r-HuEpo 
r-HuEpo? 
Figure 4.1:  Summary of the major cardiovascular variables (black lines), with the addition of the Central Governor Model (CGM) (orange lines), related to V
．
O2max 
and the maximal velocity that can be maintained in distance races. The documented (red arrows) and potential effects (red arrows with question mark) of r-HuEpo are 
also included.  Variables measured in Chapter 4 (green border). HRmax = maximal heart rate; SVmax = maximal stroke volume; [Hb] = haemoglobin concentration; %SaO2 = 
percent oxygen saturation; COmax = maximal cardiac output; (Ca-CvO2)max = maximal arterial-venous difference; V
．
O2max = maximal oxygen uptake; %V
．
O2max at LT = percentage 
of maximal oxygen uptake at lactate threshold.   
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4.2 Methods 
4.2.1  Participants 
Seven men (age: 25.7 ± 2.2 years; BMI 22.5 ± 0.7 kg.m-2; V
．
O2max: 57.7 ± 2.9 ml
.kg-1.min-1; 
mean ± SD) participated in the study.  Inclusion and exclusion criteria are described in 
section 2.1. 
 
All participants had been training regularly for several years, and during the study period 
were asked to continue their normal training activities (actual training durations of 8-18 
h·wk-1).  Participant 10 km running personal best (PB) times (average for this group was 
36.0 ± 1.8 min; mean ± SD) were directly obtained from the individual and, where 
possible, was cross-checked using an official athlete profiling website approved by United 
Kingdom Athletics (http://www.thepowerof10.info/).  For two participants a 10 km time 
was not available, therefore a 10 km completion time equivalence was calculated using one 
participant’s 3 km PB and another’s 5 km PB via an online running distance converter 
(http://www.runningtimes.com). 
 
All participants came from middle-class socioeconomic backgrounds and none were facing 
or had faced major negative life events that would have affected psychological responses 
over the study period.  Haematological measures were obtained for all seven participants.  
One participant’s exercise performance data was excluded from the study due to an illness 
not associated with r-HuEpo administration.  Thus, maximal oxygen uptake, running 
economy, ratings of perceived exertion, maximal respiratory exchange ratio (RERmax) and 
maximal heart rate measures (HRmax) were obtained for six participants during the V
．
O2max 
tests.  Running speed at LT, OBLA, LTP and %V
．
O2max at LT were obtained for five 
participants at all time points (i.e. at weeks 2, 6 and 10), with one participant’s data not 
collected at the immediately post r-HuEpo time point due to technical problems.  
Psychological measures, CSAI-2 and POMS, were obtained for six participants.  Three 
kilometre time trial results were obtained for six participants.   
 
This study was approved by the University of Glasgow and performed according to the 
World Medical Association (Declaration of Helsinki) code of ethics. 
Chapter 4. The Effects of Human Recombinant Erythropoietin on Exercise Performance, 
Haematological and Psychological Variables   140 
______________________________________________________________________________ 
140 
 
4.2.2  Experimental Design 
Participants took part in a 10-week protocol divided into three phases; baseline (2 weeks), 
r-HuEpo administration (4 weeks) and post administration (4 weeks) (Appendix K).  Fifty 
IU.kg-1 subcutaneous injections of r-HuEpo were administered every two days during the 4 
week administration phase and this was supplemented by daily oral iron tablets (Parisotto 
et al., 2001) (~100 mg of elemental iron, Ferrous Sulphate, Almus, Barnstaple, UK.) as 
previously described in section 2.8.  If [Hct] rose above 55%, the administration of r-
HuEpo would have been stopped and replaced by the administration of saline (0.9% NaCl).    
 
4.2.3  Haematological Measures 
Standard haematological analyses were made using a haematology analyser (Sysmex XT-
2000i, Norderstedt, Germany), as described in section 2.6, and measures included [Hb], 
Hct and %ret.  Samples were collected and immediately analysed at baseline (2 weeks), 4 
weeks during r-HuEpo administration and 4 weeks post r-HuEpo administration as 
described in section 2.8.  The haematology analyser was calibrated against diagnostic 
reference materials prior the measurement of collected samples as described in section 2.6.  
Total haemoglobin mass was also determined once a week using the optimised carbon 
monoxide rebreathing method (Schmidt and Prommer, 2005a, Schmidt and Prommer, 
2005b, Gore et al., 2006) as described in section 2.6.2.2.      
 
4.2.3.1 Blood Lactate Determination 
Capillary blood samples were taken from the fingers of participants during recovery phases 
of the discontinuous incremental exercise protocol, as previously described in section 
2.5.2.  Capillary blood samples were immediately analysed upon collection (Radiometer 
ABL 700, Copenhagen, Denmark) for blood [Lac] and measures were consequently used 
to assess any changes in running speed at the points of LT, OBLA, LTP and %V
．
O2max at 
LT (as previously described in section 2.6.1).  
 
4.2.4  V
．
O2max and 3 km Time Trials 
Maximal oxygen uptake and 3 km time trial performance was assessed at baseline (2 
weeks), immediately post (6 weeks) and 4 weeks post the r-HuEpo administration phase 
(10 weeks) (see section 2.4.1).  All 3 km time trial assessments were carried out on an 
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indoor 200 m running track located at the Kelvin Hall Arena (Glasgow, U.K) in a mean 
ambient temperature and humidity of 21.5 ± 1.8oC and 48.1 ± 8.0% (Comark, UK), 
respectively (Figure 4.2). 
  
4.2.5  Psychological Measures 
The CSAI-2 and POMS were used to assess anxiety and mood, respectively, at baseline (2 
weeks), immediately post (6 weeks) and 4 weeks post (10 weeks) the r-HuEpo 
administration phase (see section 2.9).  The CSAI-2 questionnaires were administered 
approximately 20 to 30 minutes (Craft et al, 2003) prior V
．
O2max and 3 km time trial 
performance tests (Appendix D).   
 
4.2.6  Data Analysis 
A one-way ANOVA for repeated measures with Tukey post hoc analysis was used to 
locate differences between all variables and time points.  Statistical significance was 
accepted at P < 0.05.  All values are reported as mean ± SEM unless otherwise shown.  
Relationships between variables were determined using Pearson correlations. 
 
 
 
 
 
 
 
 
 
 
  Figure 4.2: The Kelvin Hall Arena and Running Track 
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4.3 Results 
4.3.1  Haematological Measures 
The r-HuEpo administration was tolerated by all participants with no adverse effects 
reported and/or observed, and with no participants reaching an Hct of 55% or above.  
Table 4.1 shows haematological results at baseline (2 weeks), immediately post r-HuEpo 
administration (6 weeks), and 4 weeks post r-HuEpo administration (10 weeks).  
Immediately post r-HuEpo administration, [Hb], Hct, ret and tHb significantly increased (P 
< 0.05) by 21.2%, 21.3%, 75.0% and 11.7%, respectively.  At 4 weeks post r-HuEpo 
administration, [Hb], Hct and tHb decreased compared to immediately post but remained 
significantly elevated compared to baseline by 7.9%, 9.3% and 6.9%, respectively (P < 
0.05).  Reticulocytes decreased to below baseline levels (by 41.7%) 4 weeks post r-HuEpo 
administration (P < 0.05).        
 
 
 
 
Table 4.1: Haematological measures at Baseline, Immediately Post and 4 weeks Post 
r-HuEpo administration 
Haematological measures (n = 7) Baseline Immediately Post 4 weeks Post 
   
14.0 ± 0.3 16.9 ± 0.5* 15.1 ± 0.3*# 
40.8 ± 0.6 49.5 ± 1.0* 44.6 ± 0.8*# 
1.2 ± 0.1 2.1 ± 0.3* 0.7 ± 0.1 *# 
 
[Hb] (g/dl) 
Hct (%) 
Ret (%) 
tHb (g) 1003.1 ± 40.7 1120.0 ± 43.7* 1072.2 ± 39.9* 
Values are mean ± SEM.  Significant differences between groups (P < 0.05) are denoted 
as follows: * different from baseline, # different from immediately post 
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4.3.2  Performance Measures 
Table 4.2 shows performance results at baseline, immediately post r-HuEpo 
administration, and 4 weeks post administration.  Maximal oxygen uptake did not 
significantly change (P = 0.07) over the course of the protocol, but was numerically 5.2% 
higher immediately post r-HuEpo administration when compared to baseline.   
 
Running speed at which the LT occurred was significantly higher by 6.4% (P < 0.05) 
immediately post r-HuEpo administration when compared to baseline.  Running speed at 
OBLA was significantly higher immediately post r-HuEpo administration when compared 
to baseline by 5.9% (P < 0.05) and this remained elevated 4 weeks post, by 5.3%, when 
compared to baseline (P < 0.05).  The %V
．
O2max at LT was significantly higher 
immediately post r-HuEpo administration when compared to baseline by 6.6% (P < 0.05).  
Lactate turn-point values were also significantly higher (P < 0.05) immediately post r-
HuEpo administration when compared to baseline and 4 weeks post by 9.6 and 7.6%, 
respectively.  Running economy and maximal heart rate measures were not significantly 
different between any of the time-points (P > 0.05).   
 
Three kilometre time trial performance significantly improved immediately post r-HuEpo 
administration by 4.9% (P < 0.05) when compared to baseline.  Faster times were sustained 
4 weeks post r-HuEpo administration, when compared to baseline, by 3.9% (P < 0.05).  
 
Table 4.3 shows correlations, using the difference between measured values at baseline and 
immediately post r-HuEpo administration, between measured haematological variables 
(i.e. [Hb], Hct, Ret and tHb), physiological performance-related variables (i.e. LT running 
speed, OBLA running speed, LTP running speed, %V
．
O2max at LT and Running Economy) 
with performance related outcome measures (i.e. V
．
O2max and 3 km time trial completion 
times).  Changes in [Hb] significantly correlated with changes in V
．
O2max (r = 0.985; P = 
0.016) (Figure 4.3).  There was a tendency for changes in Hct to correlate with changes in 
V
．
O2max (r = 0.807; P = 0.053) (Figure 4.4).   
 
No significant relationships were found between any changes in haematological variables 
and changes in 3 km time trial performance (Table 4.3).  No significant relationships were 
found between changes in any of the other measured variables (i.e. V
．
O2max, LT running 
speed, OBLA running speed, LTP running speed, %V
．
O2max at LT and Running Economy) 
and 3 km time trial performance (Table 4.3).  No significant relationships were found 
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between changes in haematological variables and changes in LT, LTP, OBLA running 
speeds or with running economy (Table 4.3).  However, a significant negative relationship 
was found between changes in %V
．
O2max at LT with changes in [Hb] (r = -0.882; P = 0.048) 
and Hct (r = -0.926; P = 0.024) immediately post r-HuEpo administration.         
 
 
 
 
Table 4.2: Performance measures at Baseline, Immediately Post and 4 weeks Post r-
HuEpo administration 
Performance measures (n = 6) Baseline Immediately Post  4 weeks Post  
V
．
O2max (ml
.kg-1.min-1) 57.9 ± 2.9 60.9 ± 3.0 59.7 ± 1.8 
LT Running Speed (km.h-1)^ 13.8 ± 1.0 14.7 ± 0.8* 14.0 ± 0.7 
OBLA Running Speed (km.h-1)^ 15.2 ± 1.0 16.1 ± 1.0*  16.0 ± 1.0* 
LTP Running Speed (km.h-1)^  15.6 ± 0.6 17.1 ± 0.8*#  15.9 ± 0.9 
%V
．
O2max at LT^  70.8 ± 2.6 75.5 ± 2.2* 68.0 ± 4.7 
Running Economy - V
．
O2 at 12 
km.h-1 (ml.kg-1.min-1)  
37.5 ± 1.0 39.8 ± 1.3 38.5 ± 0.9 
RPEmax  19.2 ± 0.2 19.2 ± 0.2 19.3 ± 0.2 
RERmax  1.1 ± 0.0 1.1 ± 0.0 1.1 ± 0.0 
HRmax (bpm)  188.3 ± 1.7 189.8 ± 1.8 186.8 ± 1.4 
3 km Time Trial (s)  607.8 ± 28.5 577.9 ± 25.4*# 583.8 ± 26.7* 
 
Values are mean ± SEM.  Significant differences between groups (p < 0.05) are denoted as 
follows: * different from baseline. # different from 4 weeks post. LT = lactate threshold. 
OBLA = onset of blood lactate. LTP = lactate turn-point.  RPEmax = maximal rate of 
perceived exertion. RERmax = maximal respiratory exchange rate. HRmax = maximal heart 
rate.  ^ n = 5. 
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Table 4.3:   Pearson correlations showing relationships between change in V
．
O2max 
and change in 3 km time trial performance with changes in haematological and 
physiological variables from baseline to immediately post r-HuEpo administration  
 
 
 
 
 
 
 
 
 
 
 
 
 
 V
．
O2max          
(ml
.
kg
-1.
min
-1
) 
3 km Time Trial  
(s) 
Hb (g/dl) 0.895* -0.544 
Hct (%) 0.807 -0.574 
Ret (%) 0.101 -0.187 
tHb (g) 0.050 0.509 
LT Running Speed (km.h-1) 0.272 -0.380 
OBLA Running Speed (km.h-1) -0.031 0.219 
LTP Running Speed (km.h-1) -0.363 0.183 
%V
．
O2max at LT 0.610 -0.129 
Running Economy - V
．
O2 at 12 
km.h-1 (ml.kg-1.min-1) 
0.512 -0.055 
V
．
O2max (ml
.kg-1.min-1)  -0.532 
LT = lactate threshold. OBLA = onset of blood lactate. LTP = lactate turn-point. 
* P < 0.05. 
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Figure 4.3: Pearson correlation showing a strong positive relationship between ∆V
．
O2max 
and ∆[Hb] from baseline to immediately post r-HuEpo administration. r = 0.985; P = 0.016. 
Figure 4.4: Pearson correlation showing a positive correlation tendency between ∆V
．
O2max 
and ∆Hct from baseline to immediately post r-HuEpo administration. r = 0.807; P = 0.053.   
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4.3.3  Psychological Measures 
Table 4.4 shows psychological results at baseline, immediately post r-HuEpo 
administration and 4 weeks post administration.  The CSAI-2 cognitive subscale decreased 
significantly immediately post r-HuEpo administration by 18% (P < 0.05) compared to 
baseline.  The POMS tension subscale decreased significantly immediately post r-HuEpo 
administration compared to baseline by 61% and this was also sustained 4 weeks post r-
HuEpo administration by 50% (P < 0.05).  Tables 4.5 and 4.6 show correlations, using the 
difference between measured values at baseline and immediately post r-HuEpo 
administration, between POMS and CSAI-2 sub-scales with performance related outcome 
measures (i.e. V
．
O2max and 3 km time trial completion times).  A significant relationship 
was found between the POMS confusion sub-scale and V
．
O2max (r = 0.894; P = 0.016).  
There was a tendency for changes in CSAI-2 somatic anxiety sub-scale and V
．
O2max (r = 
0.800; P = 0.058).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4. The Effects of Human Recombinant Erythropoietin on Exercise Performance, 
Haematological and Psychological Variables   148 
______________________________________________________________________________ 
148 
 
Table 4.4: Psychological measures at Baseline, Immediately Post and 4 weeks Post r-HuEpo 
Psychological measures 
(n = 6) 
Subscales Baseline Immediately Post 4 weeks 
Post 
CSAI-2  Cognitive 21.6 ± 1.7 17.7 ± 1.9*# 19.2 ± 1.8 
 Somatic 15.1 ± 1.0 13.9 ± 0.8 14.2 ± 1.7 
 Self-confidence 21.3 ± 0.9 20.9 ± 1.8 21.0 ± 2.0 
     
POMS  Tension 2.8 ± 0.7 1.1 ± 0.7*# 1.4 ± 0.4*# 
 Depression 0.4 ± 0.3 0.7 ± 0.5 0.7 ± 0.4 
 Anger 1.2 ± 0.7 0.5 ± 0.3 0.7 ± 0.5 
 Vigour 8.8 ± 1.3 9.2 ± 1.5 8.9 ± 1.7 
 Fatigue 4.1 ± 1.0 2.0 ± 0.7 3.1 ± 0.7 
 Confusion 0.9 ± 0.5 0.4 ± 0.3 0.7 ± 0.4 
Values are mean ± SEM.  Significant differences between groups (P < 0.05) are denoted as 
follows: * different from baseline. # considered as positive changes. 
 
Subscale considerations: Decreases in: cognitive, somatic, tension, depression, anger, fatigue and 
confusion = positive change.  Increase in: self-confidence and vigour = positive change.  
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Table 4.5:   Pearson correlations showing relationships between change in V
．
O2max and 
change in 3 km time trial performance with changes in POMS sub-scales from 
baseline to immediately post r-HuEpo administration 
 V
．
O2max         
(ml
.
kg
-1.
min
-1
) 
3 km Time Trial  
(s) 
Tension 0.124 0.217 
Depression 0.544 -0.123 
Anger 0.625 -0.489 
Vigour -0.262 0.723 
Fatigue 0.522 -0.358 
Confusion 0.894* -0.319 
  V
．
O2max = maximal oxygen uptake. * P < 0.05. 
 
 
 
 
 
  
Table 4.6:   Pearson correlations showing relationships between change in  V
．
O2max       
and change in 3 km time trial performance with changes in CSAI-2 sub-scales from 
baseline to immediately post r-HuEpo administration 
 V
．
O2max         
(ml
.
kg
-1.
min
-1
) 
3 km Time Trial  
(s) 
Cognitive 0.118 -0.360 
Somatic 0.800  -0.008 
Self-confidence -0.179 0.564 
  V
．
O2max = maximal oxygen uptake. * P < 0.05. 
 
 
 
 
Chapter 4. The Effects of Human Recombinant Erythropoietin on Exercise Performance, 
Haematological and Psychological Variables   150 
______________________________________________________________________________ 
150 
 
4.4 Discussion 
All variables found to be significantly influenced, immediately post r-HuEpo 
administration, are indicated in Figure 4.5.  Furthermore, variables found to be related to 
changes in haematological factors, as well as changes in 3 km time trial performance, are 
also indicated.  In line with previous studies (Audran et al., 1999, Parisotto et al., 2000b, 
Birkeland et al., 2000, Ashenden et al., 2001, Russell et al., 2002a, Ashenden et al., 2006) 
[Hb], Hct, ret and tHb increased (by 21.2%, 21.3%, 75.0% and 11.7%, respectively) and 
V
．
O2max values were numerically higher immediately post r-HuEpo administration (by 
5.2%).  This change in V
．
O2max was lower than values reported in previous studies, however 
the present findings confirmed that changes in [Hb] and Hct, elicited by r-HuEpo 
administration, are associated with changes in V
．
O2max as indicated in Figure 4.3 and Figure 
4.4, respectively.  This has previously been reported elsewhere (Audran et al., 1999, 
Parisotto et al., 2000b, Birkeland et al., 2000, Ashenden et al., 2001, Russell et al., 2002a, 
Ashenden et al., 2006, Ninot et al., 2006).   
 
Interestingly, treadmill running speeds at LT, OBLA and LTP were significantly higher 
immediately post r-HuEpo administration when compared to baseline by 6.4%, 5.9% and 
9.6%, respectively (Table 4.2).  Furthermore, %V
．
O2max at LT were also significantly higher 
immediately post r-HuEpo administration when compared to baseline by 6.6% (Table 4.2).  
In addition to the change reported in V
．
O2max, it would be logical to suggest that such 
changes would contribute to the 4.9% improvement found in 3 km time trial performance 
immediately post r-HuEpo administration.  However, there was no significant relationship 
between changes in 3 km time trial performance and changes in [Hb] (r = -0.544; P = 
0.265) or Hct (r = -0.574; P = 0.234).  Furthermore, no significant relationships were found 
between changes in 3 km time trial performance and changes in V
．
O2max (r = -0.532; P = 
0.278), LT (r = -0.380; P = 0.528), OBLA (r = 0.219; P = 0.723), LTP (r = 0.183; P = 
0.769) or running economy (r = -0.055; P = 0.918).   This may be the consequence of a 
type 2 statistical error as the small sample size in the present study limits the ability to 
detect significant relationships between variables.  Indeed, with n = 5 – as was the case 
with many of the variables measured due to missing data – only correlations of r = 0.81 or 
higher would have achieved statistical significance.  Thus it is very likely that real 
relationships between variables affecting performance were missed in this study.  
Nevertheless, it is also possible that the performance improvements observed in this study 
were not mediated by effects of r-HuEpo on haematological variables, as is classically 
reported, and this warrants further investigation.   
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The assessment of haematological variables with other performance related variables 
revealed no significant relationships between changes in [Hb] and changes in LT (r = 
0.438; P = 0.460), LTP (r = -0.159; P = 0.798), OBLA (r = 0.300; P = 0.624) or running 
economy (r = 0.453; P = 0.367).  In addition, no significant relationships were observed 
between changes in Hct and changes in LT (r = 0.456; P = 0.440), LTP (r = -0.063; P = 
0.920), OBLA (r = 0.353; P = 0.560) or running economy (r = 0.389; P = 0.446).  
Interestingly, however, a significant negative relationship was found between changes in 
%V
．
O2max at LT and changes in [Hb] (r = -0.882; P = 0.048) and Hct (r = -0.926; P = 
0.024).  In other words, those who experienced the greatest increases in [Hb] and Hct 
experienced the smallest changes in %V
．
O2max at LT.   Closer observation of the data 
reveals that a negative (albeit not statistically significant) relationship between changes in 
%V
．
O2max at LT and changes in V
．
O2max (r = -0.610; P = 0.274) which would have been 
expected given the closer associations between [Hb], Hct and V
．
O2max, than between [Hb], 
Hct and LT.  Thus, increases in % V
．
O2max at LT increased V
．
O2max more than LT, leading to 
a fall in %V
．
O2max at LT in those with the biggest [Hb] and Hct changes.  Additional 
considerations could be made with regards to the potential use of non-parametric based 
statistics (e.g. Spearman rank correlation). However, parametric statistics were solely 
preferred as clear numerical interpretations were required to be made.  Also, when 
considering the small sample size present, larger sample sizes are often required (when 
using non-parametric statistics) to draw conclusion with the same degree of confidence (in 
comparison to parametric statistics.  
 
Regardless of the associations reported in this study, however, it is clear that 3 km time 
trial performance significantly improved immediately post r-HuEpo administration by 
4.9% and faster times were sustained for 4 weeks post r-HuEpo administration (by 4.0% 
compared to baseline).  It is not clear, however, as to what factors likely caused this and to 
what degree.  Potential differences in physical effort (i.e. HRmax and RPEmax) did not 
contribute to this effect as measures were not significantly different between any of the 
time-points.  However, this study does show r-HuEpo induced changes in [Hb] and Hct 
that were only strongly related to V
．
O2max with no clear association between changes in 
[Hb], Hct or V
．
O2max and changes in 3 km time trial performance.  This suggests that, 
subject to statistical caveats outlined above, factors other than [Hb], Hct and V
．
O2max 
changes are likely to have influenced 3 km time trial performance.  Furthermore, this is the 
first study (to the best of the author’s knowledge) to demonstrate the sustained nature of 
improvement in a field-based performance assessment following r-HuEpo administration. 
Three km running performance remained 4% faster than baseline 4-weeks (a decline of 
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~1% from immediately post-administration).  In contrast the increase in [Hb] and Hct had 
declined by more than 50% from the immediately post-administration time-point over this 
4-week period, again suggesting a disconnect between the haematological and 
performance-related changes seen in this study.   
 
4.4.1  Psychological Effects 
A significant decrease in cognitive anxiety, by 18.3%, was found immediately post r-
HuEpo administration when compared to baseline (Table 4.4).  This suggests that the 
mental component of anxiety, caused by negative expectations about success or by 
negative self-evaluation (Martens, 1971), was reduced immediately post r-HuEpo 
administration.  However, none of these sub-scales were related to changes in either 
V
．
O2max or 3 km time trial performance (Table 4.6).  A previous meta-analysis on CSAI-2 
and sport performance (Craft, 2003) reported mixed results for the relationship between 
CSAI-2 subscales and sport performance.  However, cognitive and somatic anxiety were 
reported as being more influential in individual rather than team sports; possibly due to the 
greater pressures inflicted onto a single person as opposed to a team.  In contrast, Jones and 
colleagues (Jones et al., 1993) reported no significant group differences in cognitive 
anxiety, state anxiety or self-confidence in 48 gymnasts who were categorised into poor 
and good performance groups.  Interestingly, these authors reported that the good 
performance group viewed cognitive anxiety to be more facilitative than debilitative when 
compared to the poor performance group.  The 3 km time trial performance tests carried 
out in this study were on an individual basis and, in contrast to previous literature, it 
appears that a reduction in cognitive anxiety may have facilitated, not debilitated, the 
improvement found immediately post r-HuEpo administration in 3 km time trial 
performance. 
 
The POMS tension (i.e. a form of stress) subscale was also significantly lower, by 61%, 
immediately post r-HuEpo administration when compared to baseline and this remained 
lower by 50% for 4 weeks post r-HuEpo administration (Table 4.4).  However, this was not 
related to changes in either V
．
O2max or 3 km time trial performance (Table 4.5).   A POMS 
and sport performance meta-analysis reported tension and anger as having small 
performance debilitating effects and is also associated with both positive and negative 
performance outcomes (Beedie, 2000).  This present study would suggest that a reduction 
in tension may have facilitated the improvement found immediately post r-HuEpo 
administration in 3 km time trial performance.  As to why only tension and cognitive 
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anxiety proved significant in comparison to other subscales such as self-confidence (which 
did not) remains to be elucidated.  Furthermore, the relationships found between POMS 
confusion sub-scale and CSAI-2 somatic anxiety subscale with V
．
O2max also remains to be 
elucidated.  
 
The notion that r-HuEpo may influence central components (i.e. the brain) and, in turn, 
influence exercise performance outcome is supported by recent evidence which suggests 
possible r-HuEpo mediated effects on the CNS (Ehrenreich et al., 2004, Core et al., 2011).  
The findings reported are also in line with the fact that no clear associations were found 
between [Hb], Hct or V
．
O2max and 3 km time trial performance suggesting, in turn, that 
factors other than [Hb], Hct and V
．
O2max changes likely influenced 3 km time trial 
performance.  Thus the endurance performance enhancing effect, of r-HuEpo 
administration, may not solely be due to peripheral physiological changes, but may indeed 
be more complex with central mechanisms, psychology (Noakes, 2007) and the placebo 
effect being key potential mediators (Zhang et al., 2008).   
 
4.4.2  Anti-Doping Considerations 
The r-HuEpo administration of 50 UI.kg-1 three times a week over a 4-week period is in 
line with previous studies (Parisotto et al., 2000b, Parisotto et al., 2001).  These authors 
have reported a continued elevation in [Hb] and Hct for 21 days after the cessation of r-
HuEpo injections and a return to baseline for tHb within one month of the cessation of r-
HuEpo injections.  Similar findings are found here for the continued elevation in [Hb] and 
Hct.  However this present study found that 4 weeks (i.e. 28 days) post r-HuEpo 
administration [Hb], Hct and tHb decreased compared to immediately post r-HuEpo 
administration, but these remained significantly elevated when compared to baseline 
measures.  
 
This has important connotations for the field of anti-doping.   It is acknowledged that 
alternative dosage protocols (Russell et al., 2002b, Ashenden et al., 2006), in contrast to 
moderate doses of r-HuEpo over a 4 week period, more likely reflect how r-HuEpo is 
utilised by athletes who choose to ‘dope’ in an attempt to evade detection.  However, the 
haematological results are indeed very similar (Ninot et al., 2006). The variation in 
haematological measures post the cessation of r-HuEpo injections between this and 
previous studies (i.e. ~30 days return to baseline reported by Parisotto and colleagues 
(Parisotto et al., 2000b), in contrast to the 28-day continued significant elevation compared 
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to baseline reported in this study), further exemplifies this.  In agreement with Parisotto 
and colleagues (Parisotto et al., 2000b), the analysis of blood data using a models based 
approach may indeed be a more effective deterrent than simply attempting to detect current 
r-HuEpo use.   
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Figure 4.5:  Summary of the major cardiovascular variables (black lines), with the addition of the Central Governor Model (CGM) (orange lines), related to V
．
O2max and 
the maximal velocity that can be maintained in distance races. The documented (red arrows) and potential effects (red arrows with question mark) of r-HuEpo are also 
included.  Variables measured in Chapter 4 (green border).  Variables found to be of significance immediately post r-HuEpo administration (red tick).  Variables not 
found to be of significance immediately post r-HuEpo administration (red cross). No definitive evidence for effect immediately post r-HuEpo administration (red 
question mark). HRmax = maximal heart rate; SVmax = maximal stroke volume; [Hb] = haemoglobin concentration; %SaO2 = percent oxygen saturation; COmax = maximal cardiac 
output; (Ca-CvO2)max = maximal arterial-venous difference; V
．
O2max = maximal oxygen uptake; %V
．
O2max at LT = percentage of maximal oxygen uptake at lactate threshold.  
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4.4.3  Study Limitations and Future Considerations 
This study has two important limitations.  The first is the relatively small sample size, 
which limits statistical power and increases the chances of type 2 statistical error: this issue 
has been discussed above.  Although several key variables were found to be significantly 
different after the period of r-HuEpo administration, V
．
O2max was not found to be significant 
(very likely to be as a result of a type 2 statistical error given previous evidence).  Based on 
a V
．
O2max improvement of 5.2% (as present in this chapter) and an SD of 1.8%, 8 
participants will provide 80% power to detect a significant effect at p < 0.05.     
 
The second is the absence of a control group.  As a result of this, it is not possible to 
discount the possibility of a placebo effect influencing the study findings.  It is therefore 
imperative that further studies are carried out to assess the effect of placebo injections on 
running performance in individuals who believe (i.e. deceptive studies) they are receiving 
r-HuEpo or equivalent injections.  A final consideration is that the effect of training was 
not strictly controlled across all phases of the study – participants were asked to maintain 
their usual training programmes. Although these athletes were well-trained and followed 
strict training regimes, this lack of tight control may have influenced the performance 
results to some small degree.      
 
4.5 Conclusions 
This study confirmed r-HuEpo increases [Hb] and Hct, and these were associated with 
improvements in V
．
O2max.  Three kilometre time trial performance improved immediately 
post r-HuEpo administration by 4.9%.  However, no clear association was found between 
[Hb], Hct or V
．
O2max and 3 km performance, suggesting that factors other than changes in 
[Hb], Hct and V
．
O2max are likely to have influenced running performance.  Furthermore, the 
improvement in 3 km time trial performance persisted for 4 weeks post r-HuEpo 
administration, despite the r-HuEpo mediated changes in [Hb] and Hct declining by more 
than 50% over this interval.  Positive changes were also observed in anxiety and tension 
which warrant further investigation as a potential contributor to enhancing performance.  
Finally, this study is the first (to the best of the author’s knowledge) to demonstrate 
performance enhancing effects r-HuEpo administration, both, in laboratory and in a field-
based performance test. 
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5. Psychosocial and Doping Effects: Viewpoints from 
Well-trained Individuals after using an Illegal 
Performance Enhancer 
5.1 Introduction  
He won numerous medals on the international stage including winning bronze in the 1999 
World Championships (www.iaaf.org).  He is one of Europe’s fastest ever over the 100 m 
distance holding the second fastest time in British history (www.iaaf.org).  In October 
2002 he received a two-year ban from athletics as well as a life ban from competing in the 
Olympics for taking an anabolic steroid derivative - tetrahydrogestrinone (aka THG). 
 
In an in-depth interview on BBC radio in 2008, he was asked, ‘…but when you took drugs 
for the first time, when people came up to you afterwards and said that you had run 
brilliantly, didn’t you feel just so incredibly guilty?”  He responded, “when I got home, not 
during, you’ve got to put on a brave face.  Again, that was pretty hard for me to deal with, 
but eh, you know, we’re going back a long time, it’s difficult for me to be open about those 
views…I wish I’d never done it”, Dwain Chambers responded.  He was then asked, 
“…how would you have felt if you had gone through and fulfilled yourself and won an 
Olympic title?  How would you have felt knowing that it wasn’t really true?”  Dwain 
Chambers responded: “…it would have been bitter sweet…there would have been a part of 
me, that yes, I would have got my goals, but at the same time I knew I would have been 
cheating myself and others…”.   
 
The use of substances to enhance sporting performance has been prevalent in sport for 
decades, with some reports dating the practice back to the 1890s where cyclists were 
supplemented with caffeine, cocaine and sometimes even strychnine (Bloodworth and 
McNamee, 2010).  Many studies have attempted to measure athlete viewpoints on drugs 
and sport as well as attempt to measure the prevalence of doping in sport (Rossi and Botre, 
2011, Waddington et al., 2005).  Varying methodologies have been employed and include 
observational studies, interview based studies and questionnaire based studies; each 
possessing limitations (Laure et al., 2004).   
 
A common problem that is incurred with such methodologies is that one can never ensure 
the honesty of participants with regards to their own personal experiences concerning 
illegal substances.  For example, review articles, predominantly in North American studies, 
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have reported that 3 to 12% of male and 1 to 2% of female adolescents as having used 
anabolic-androgenic steroids at some point in their lives and, of these individuals, 40% 
were not involved in competitive sport (Yesalis and Bahrke, 2000, Bahrke et al., 2000, 
Calfee and Fadale, 2006). The fact that this study suggests that 60% were actually involved 
in competitive sport and admitted their interactions with illegal performance enhancers 
remains of serious concern.  Further, one could realistically suggest that these figures may 
indeed be under-estimating the true prevalence of drug use in sport as it is likely that some 
participants, in such studies, may simply be providing researchers with false information 
either intentionally or unintentionally.  
 
In a recent publication, Lentillon-Kaestner and Ohl (Lentillon-Kaestner and Ohl, 2011) 
suggested that in order to obtain more reliable data on the prevalence of doping in sport, it 
is important to utilise various methods including: using various ways of questioning 
athletes, observing the usage of substances, cross checking data collected, taking into 
account the aim of substances used, as well as utilising various definitions on what 
constitutes as doping.  Thus, the same approach should also be used when attempting to 
identify and understand, not only, the underlying reasons behind doping behaviour, but 
also when obtaining and assessing athlete views on doping (past and present).  This is also 
in addition to approaches on the psychosocial factors and consequences that may be 
involved and experienced.   
 
In a previous study by Bloodworth & McNamee (Bloodworth and McNamee, 2010) the 
authors carried out several focus groups on a total of 40 talented male and female British 
athletes and these sessions were intended to investigate athletes’ attitudes towards doping.  
They reported that, in general, ‘the athletes embraced those values promoted in anti-doping 
educational programmes, although there were some notable exceptions’.  Further, it was 
reported that the social emotion of ‘shame’ was the most significant deterrent not to dope.  
Although there were a few notable exceptions identified in this study, a major limitation in 
such studies is that it is unknown if some viewpoints were actually being given by an 
individual who is potentially on or who has previously taken an illegal performance 
enhancing substance.  As the authors indicated, the most likely reason being to avoid 
capture or the reported shame associated with the practice of doping (Bloodworth and 
McNamee, 2010).   
 
The 2008 BBC interview with Dwain Chambers is useful and unique as it sheds further 
light on the psychosocial reasons not only behind doping, but also, the psychosocial effects 
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of carrying out ‘doping’.  The difficulties associated with this type of research is 
acknowledged; however the assessment of individuals that have utilised a substance that is 
illegal in competitive sport (in the confines of research) and who have experienced the 
associated effects of the substance on sporting performance, as well as on psychosocial 
factors, would further enhance our understanding in this field.  
 
In this unique study, participants participated in private, individualised semi-structured 
interviews after completing a trial involving the use of the illegal performance enhancing 
drug r-HuEpo (according to the WADA code).  This WADA approved study (as part of a 
larger study) assessed the effect of r-HuEpo use on psychological and social (i.e. 
psychosocial) factors associated with the practice.   
 
5.2 Methods 
5.2.1  Participants 
The present qualitative study involved six well-trained men (age: 26 ± 2 y; BMI: 22 ± 1; 
V
．
O2max: 58 ± 3 ml
.kg-1.min-1) who individually participated in semi-structured interviews 
(Appendix E) after completing a research trial involving the administration of r-HuEpo by 
subcutaneous injection for 4 weeks.  The 4 weeks of r-HuEpo administration was preceded 
by a 2 week baseline period and was followed by a 4 week post r-HuEpo administration 
period.  Participants individually participated in semi-structured interviews which were 
carried out within 1 week of completing the study. 
 
5.2.2  Experimental Procedures  
The semi-structured interviews consisted of a series of questions (Appendix E) designed to 
assess participant psychosocial experiences during the trial as well as their viewpoints on 
doping and anti-doping prior and after completing the trial.  The use of focus groups 
(Bloodworth et al., 2012) has been suggested to be a more attractive method for 
participants as it may induce a more relaxed environment as opposed to the more 
intimidating one-to-one interview.  Although focus groups may potentially be a useful 
means to extract more truthful and open responses, when discussing sensitive issues such 
as these (Kitzinger, 1995, Bloodworth and McNamee, 2010), it was decided that private 
interviews would be carried out as confidence and trust was obtained between participants 
and researchers throughout the 10 week trial period prior the interview stage.  In all cases 
participants knew and interacted with the interviewee for a prolonged period (i.e. over 10 
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weeks).  In all cases, it was made clear and understood by both parties that the contents of 
the discussion would only be made public in an appropriately anonymous form.   
 
Participants were happy to discuss their psychosocial experiences during the trial and any 
issues relating to doping and anti-doping practices.  All participants signed a declaration 
stating that they would not take part in any sporting competitions whilst participating in the 
trial.  It is acknowledged that a degree of caution must always be taken when assessing 
participant responses, however the development of an atmosphere of trust was crucial, and 
the researchers believed that this was achieved.  
 
5.2.3  Data Analysis  
The semi-structured interviews were recorded and transcribed.  Transcriptions were 
manually analysed and coded (Express Scribe v 5.45, NCH Software and Microsoft Office 
Excel 2003).  For consistency, the interviewee also carried out the transcription (exactly as 
spoken) and coding processes.  
 
5.3 Results 
5.3.1  Overall Thoughts on r-HuEpo Trial Participation 
All the participants were happy about taking part in the study.  The general consensus was 
that it was an enjoyable and informative experience and participants particularly enjoyed 
the learning of new aspects on their physiology and psychology.  Two individuals made 
more exceptional comments:  
 
Participant 1: ‘…interesting for myself to go through these 10 weeks, try 
something that’s banned.  Definitely yes”.   
 
  
 Participant 2: “…it was really interesting to see what potential I have 
whilst on EPO”.  
 
In general, all participants were intrigued to experience the effect of r-HuEpo 
administration on exercise performance.  All participants showed a belief that r-HuEpo 
administration would elicit a positive change, and in some cases reveal ones ‘true ability’ if 
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they were to pursue their training further with a legal alternative to doping, for example, 
altitude training.  
 
5.3.2  Thoughts, Expectations, Anticipations, Anxieties Prior r-HuEpo 
Administration 
Participants were asked how they came to their final decision to participate in the trial and 
how they evaluated the potential risks.  All participants understood the potential risks 
involved in the trial as described in the trial information sheet (Appendix B) and from 
discussions held prior study participation.  However, it became apparent that the 
environmental setting of a research facility was what ultimately persuaded and comforted 
all the participants to participate.  Interestingly, no participants commented on any 
potential health risks.   A notable response was: 
 
Participant 3: “I was quite excited by it to be honest. Em… the other stuff 
was obviously legal [in reference to other substances that this individual 
has previously used], haha, whereas this stuff could get you banned…yeah 
I was excited.  To do it in a controlled environment such as this was a 
good opportunity…comfortable with it here…I’ve read the horror stories 
of cyclists dying, but I trusted that you would do a good job.”  
 
There was one individual who showed more concern prior deciding to participate in the 
trial.  However this was not in relation to potential health implications, but more associated 
with the fear that others would ‘find out’ and the resulting potential social stigma that may 
occur even after completing the trial and being ‘clean’ again:   
 
Participant 2:“Yeah, I remember at the start being a bit unsure and I 
needed a couple of weeks to think about it, but at the end of the day I 
wouldn’t take it professionally…nah…nah.  I totally trust you and 
everything else, it was more the fact that if somebody found out about it, 
they would tell everybody and people at a race would say oh he’s done 
that. Just because some, well most…won’t understand this, so…” 
 
When participants were asked about their anticipated feelings when taking r-HuEpo, all six 
participants believed that r-HuEpo would improve their endurance exercise capability; 
Chapter 5. Psychosocial and Doping Effects: Viewpoints from Well-trained Individuals after using 
an Illegal Performance Enhancer  162 
______________________________________________________________________________ 
162 
 
however, five participants were unsure as to how and what feelings would manifest.  A 
representative response was: 
 
Participant 3: “I don’t know what I expected really…”  
 
In contrast to this feeling, one individual felt the opposite and was more specific with 
regards to how r-HuEpo would make the individual feel: 
 
Participant 1 “…I was really interested to see how EPO would affect, eh, 
how I will run. I thought yeah, I thought maybe I’d find something 
completely different when I would be running…to see if it would be easier 
or if I would be stronger”.   
 
When participants were asked whether or not they had any anxieties about taking such a 
substance (in reference to the point where participants were about to start self-
administering r-HuEpo), 5 participants developed a concern closer to the action of self-
administering r-HuEpo.  These individuals started to mention, more adamantly, how they 
wanted their participation in the trial to be kept private.  Most participants told nobody 
outwith the testing environment, whilst those who regularly trained with a trusted coach 
informed their coach of their participation.  Participants were not asked specifically how 
they felt with regards to needles and self-injecting the substance; however, one individual 
commented: 
 
Participant 5: “…I think the only doubt was the injection really…never 
had a problem with needles before, but it was maybe the self-injection 
thing…that was the only part I was worried about.  Yeah, the fact that I 
wasn’t a trained professional, me and my chubby fingers and that…”  
 
More notably one participant commented on the initial concern regarding the self-
injections, but elaborated further how quickly this became a non-issue: 
 
Participant 3: “beforehand it was quite…I was quite excited, but also 
apprehensive about it, ‘cause I have never taken any performance 
enhancer like that before, there was some apprehension, but when I 
started, I was…felt quite strange about giving myself an injection, it was I 
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don’t know, there’s a kind of a stigma attached to that. But I was surprised 
how quickly I just slipped in… just how quickly it became normal”.  
 
Further, although this aspect was not mentioned by all participants during the final 
interview stage, it was clear that prior starting the trial, all participants sought comfort with 
regards to the self-injection process as none had self-injected any substance before.  It was 
clear to the researcher, who observed participants self-inject, that participants showed 
notable anxiety during the first injection but this anxiety was not present during the 
remaining injections.  Participants quickly became less concerned with the action of self-
injecting. 
 
5.3.3  Experiences of Effects during r-HuEpo Administration 
All participants expected to experience a physiological and/or psychological change whilst 
taking r-HuEpo; although the majority were unsure in what form exactly.  Participants 
were asked questions with regards to how they felt during r-HuEpo administration in 
general, but also how they felt during training / performing / running.  More specifically, 
participants were then asked whether recovery was different in any way.  Participants were 
also asked to what degree they felt any changes, that may have occurred, were down to the 
substance itself or down to the individuals own hard work. 
 
All participants described feeling different or commented that taking the substance had an 
effect; however the magnitude of the perceived effect varied between participants.  Five of 
the participants described an achievement that they have never managed before and this 
ranged from maintaining greater work rates during training, for longer periods, to 
achieving certain fitness targets at a much quicker rate.  Notable comments include: 
 
Participant 4: “One day, just, I was running with the same people I 
would normally, they would finish the run and I would be the back of the 
group, but half way through the run they were running fast, and as they 
were running fast they were saying ‘you know we are running pretty fast’ 
and I was with them.  They started to struggle and then I took off and left 
them, it was ridiculous, I got quite embarrassed, and you know it was like 
where the hell did that come from.  I thought that must be the EPO.  You 
could see people in the group when they came in at the end, they are like 
‘how you doing?’  I was like, ‘I’m off’ [laughs].  I was embarrassed. I felt 
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like that was....but then again, since then, I have had experiences where I 
have run as well, so I don’t know of that was a special day, or were they 
struggling…but that was one occasion where I took off”. 
 
Participant 3: “… certainly I would say looking at the times I was running, 
I mean that was certainly what I would expect from a much longer period 
of training. So something’s done something for sure”. 
 
With regards to recovery, 5 participants referred to recovery periods either in between 
training intervals or between training days as being either ‘quicker’ or ‘better’.  For 
example: 
 
Participant 3: “…and the recovery was something that I noticed, the 
recovery sessions felt so much better…quicker”. 
 
More specifically, all participants commented on how they felt peripheral components of 
fatigue (i.e. legs) were limiting factors, whilst respiratory components felt fine.  One 
individual commented on a notable occasion during training: 
 
Participant 2: “That was the day, when I came in, my heart rate fell down 
quickly, massively, within a couple of minutes, I probably was thinking 
that must be the EPO kicking in.  I think yeah, anytime I did run like that, I 
must have thought yeah that must be the EPO”. 
 
Conversely, one participant mentioned feeling more fatigued; one throughout the 4 week r-
HuEpo administration period, and the other more specifically at the end of the r-HuEpo 
administration phase.   
 
Participant 4: “I found that I became quite tired at the end of EPO, I don’t 
know, maybe ‘cause I was trying to do .....maybe I knew I was on EPO, so 
I thought I could do much more so I went out hard, but at the end of it was 
taking more days to recover.  I just remember, getting quite tired”. 
 
Participants were then asked to what degree were any of the performance enhancing effects 
down to the substance itself versus the individuals own hard work.  In addition, they were 
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also asked if there was a possibility of a placebo effect.  Two participants were sure that it 
was solely down to the substance itself.  A notable response included: 
 
Participant 6: “I would say that was down to the substance, like, feeling 
floored for a week and then running a PB.  I can still remember being 
float-like during the whole 15 laps and, like, it was pretty weird…” 
 
Participant 6 continued to describe how the substance itself had impacted on his feelings as 
well as how the substance had changed his behaviour with no reference to a potential 
placebo effect: 
 
Participant 6: “I think that when you’re training so hard and then still be 
able to recover and then still train really quick that your confidence is 
high so your confidence plus EPO has a big boost and then the fact that 
you are willing to risk in training, like running faster, ‘cause you think 
during training, I’m on this drug and going to get better, so I’m going 
faster...let’s take more risks, let’s run ‘til you drop...  See where this will 
take you, so maybe you feel a bit more I would say ‘immortal’ in training.  
You would feel as if like, I felt, there sessions where I could feel I could 
run so fast where I would generate no lactate, but didn’t know why, but at 
the end of the sessions you would feel lactate, but during the first few reps 
you’re still running really quick. And you got lots of confidence, your 
running going like you can’t feel the burn yet –brilliant! And people 
behind you chasing you. Gives you a massive boost 
psychologically…that’s something that I’ve not got in my locker usually. 
I’m not such a confident person normally, I feel quite a lot of athletes are 
better than me and that’s the reason why I train really hard to become 
better than them.  People say the hard way isn’t the right way all the time, 
but when on EPO I was training hard and running fast, felt like nobody 
could stop me.  I had something that I’ve never had before”. 
 
One participant was less adamant and suggested that it was a combination of both 
substance and hard work, but with no reference to a placebo effect: 
 
Participant 5: “…I would say to a good degree the substance, but there’s 
been a lot of effort into that”. 
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The remaining participants showed uncertainty in response to this question.  An example 
response included: 
 
Participant 4: “Placebo side… I don’t know, I think knowing that I had it 
in me, should be able to do something, and I must have enough energy to 
do more.  It sometimes pushed me out when I didn’t feel too keen; I went 
out because I thought I would be fine due to having it in me”. 
 
Interestingly, participant 4 also commented specifically that he felt more of a performance 
enhancing effect on the training days that coincided, specifically, with the days of r-HuEpo 
administration. 
 
Participant 4: “But I think I was just, I don’t know, once I really noticed 
that I felt wow, it was at the running club, 7 mile run, 8 miles we were 
running, during the EPO phase, and I think I also found that, I think, I 
performed better the day I took EPO rather than the next day” [EPO was 
administered every second day]. 
 
5.3.4  Viewpoints After r-HuEpo Administration 
Participants were asked a series of questions regarding their feelings since the cessation of 
r-HuEpo administration 4 to 5 weeks after the last r-HuEpo injection.  All participants 
acknowledged their performances had slowed over the 3 km distance performance measure 
employed in the trial 4 weeks after the final r-HuEpo injection.  Three participants 
provided a more in-depth description: 
 
Participant 3: “…it was quite exciting the whole way through to see what 
kind of changes would take place, and then afterwards I don’t know, I 
suffered a mental withdrawal....I need more!” 
 
Participant 4: “…and EPO  to post, post was the slowest, yeah, so yeah, 
you know good in the sense that how the training has gone.  As long as 
I’ve, even though I was feeling horrific here [in reference to post phase 3 
km time trial], so even though that’s a bit slower than this, I’m happy, 
‘cause I felt really bad then [post EPO].  I’m happy that I was faster than 
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the pre-race.  From pre to post, a 3% difference...interesting, so training 
must have been going well too”. 
 
Participant 6: “…now getting further away from taking EPO, my body, it’s 
getting more fatigued, more easily, but could be many factors…it’s a wee 
[i.e. little] bit frustrating, I could and now can’t.  I would be lying in 
saying it’s me just going back to being normal, but no I do feel a bit 
frustrated that I’ve not got that same leg turnover and I’m no [i.e. not] just 
now, I’m not so confident as what I was...because I’m no running, I’m 
almost running the same times though the constant training, but I’m no 
running the same as on EPO.  I’m finding it harder to achieve things 
now”. 
 
5.3.5 Viewpoints on whether athletes should be able to use such a substance as 
a component of their training 
All participants generally showed an anti-doping sentiment, however some more 
convincingly than others.  Thee participants demonstrated outright objection and 
associated sporting performance with one’s natural ability and hard work: 
 
Participant 4: “I think anything [in relation to substance abuse] that’s 
going to enhance your performance, I think should be banned, I think, 
there’s, I’d rather see everyone play on the same playing field...I guess.  
The best ultra-runner in GB would run in the Chamonix race, and has to 
work a full-time job as opposed to others who don’t.  Would it be okay for 
semi-pro Scottish athletes to take EPO to catch full timers up?  I think it’s 
up to the individual to make time, like people in my running club, to make 
time to fit it, or change your lifestyle according to what is priority.  I'd 
rather, I think it’s, what else could they use?  It would go out of control; if 
you’re allowed to use EPO then people would find another drug to make 
people go faster.  I don’t know, I would say, I think it’s very interesting, 
but at the same time one of the reasons as well that I took part in this, 
when you said you would be also looking at detecting methods, that’s 
probably one of the reasons why I participated in something to clamp 
down on drug use.  I was a part of this effort, say 10 years down the line, I 
was a part of this work.  Great! One of my main reasons probably”. 
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Participant 1: “…I still don’t think so, because you should put limits and 
boundaries for everybody and I do think taking injections like this 
shouldn’t be allowed.  Saying this, we know that current tests are not very, 
I would say, efficient.  We have to find a solution…other solutions must be 
found”. 
 
Participant 2: “I’m still very much against it, it is just cheating…I just, it is 
cheating, like, you are using something that’s not naturally made from 
your body, it’s not right.  It should be all the athlete’s work.  People say 
that there’s not much difference between this and altitude training, but at 
altitude you’re still putting in the work, it’s not just putting in EPO into 
your body.  If I was, if I was at that level, and like everybody else was 
doing it, I would probably, but yeah I can see the sort of draw to it for 
athletes.  Like I said when I was training it did feel amazing, just to be 
honest.  I can appreciate it a wee bit more why people would do it, but I 
don’t really think it…my view hasn’t really changed on it. If somebody 
else was taking it to try and cheat, I would still be against them”. 
 
The other three participants described the situation as ‘complex’ or ‘difficult’.  Particular 
reference was made to what was perceived as their competitors, from countries such as 
Kenya, who live in conditions more favourable.  More specifically, references were made 
with regards to the benefits of living at high altitude for endurance athletes.  These 
participants perceived that r-HuEpo use essentially provided similar performance 
enhancing properties to training models utilising high altitude as a component.  Notable 
comments include: 
 
Participant 3: “It’s a tough one because, I mean, I have had this 
conversation before with others where athletes are fortunate enough to 
live at altitude and they get similar results, eh, whereas in this country we 
don’t have that kind of advantage.  I don’t know, I think my views have 
changed since being involved in the trial.  If these guys are allowed to 
create these results just by sleeping in a certain place, just by taking 
advantage of their surroundings, I think we are disadvantaged in this 
country [i.e. UK] simply because the place is the way it is, and if… I don’t 
know…where can you draw the line.  I don’t know…if you can sleep in a 
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tent to give you the same results? Is that cheating? Is it cheating when you 
introduce a needle, or not?  It’s a tough one, as you are achieving the 
same results, yet artificially”. 
 
Participant 5: “…well, it’s hard to say because there are so many illegal 
substances out there that could maybe do similar things, but I don’t think 
would give you such a great improvement. But, if you took a proper 
athlete and it did the similar effect, that’s un-heard off.  How do you 
eradicate drugs?  I mean, what’s the difference between coffee and EPO 
you know....really deep question.  A similar reaction will be brought about 
by blood transfusions...emm....ehhh...no, very much against drugs in sport, 
but I think they’ve got a tough job on their hands”[in reference to anti-
doping agencies]. 
 
Participant 6: “…tough question, personally you would go yeah because I 
would then be allowed to take it and train even better, but could be many 
factors.  As you’ve said, doesn’t mean just ‘cause blood profiles go up, 
doesn’t mean your performance will go up.  Yeah, like what happens if 
you’ve got a higher haematocrit level then the guy standing next to you in 
the line, but he can utilise it better then you.  So if everybody could use it 
on a level playing field then maybe, but that wouldn’t happen due to 
money, it’s really expensive, like the poorer and going to run bad and the 
rich going to run well.  Like poor runners in European countries, not 
Kenya and that.  Like the well-off families are going to be able to buy this 
substance and run well, em…then you’ve got your poor runners in Kenya 
that have altitude, so they’re going to run well anyway.  It would kind of 
off-set the imbalance.  I would say, keep it banned, there’s so many like, 
you want people to be running races and showing excitement because well 
they’ve done hard work to get there...people think that somebody that has 
run fast might be on drugs, thinking on my god, that’s amazing, but like 
what’s really going on.....a big report comes out saying they’ve taken 
drugs...oh that’s how he’s run fast.  Too much to lose kinda, so if you can 
train hard and run fast clean, you’ve got people that will look up to you 
and follow you, it’s so  much more.  Taking drugs takes a bit of pride away 
you know. I’d say keep it banned, but the effects are good, but I think keep 
it banned”. 
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5.4 Discussion 
The information obtained in this experimental chapter has overcome two important 
limitations which exist in currently available literature, regarding psychosocial insights and 
experiences felt by users whilst ‘doping’.  Firstly, issues regarding the truthfulness and 
accuracy of responses have been overcome as participants were given a platform on which 
they could discuss issues open and freely, without risk, whilst using a banned substance.  
Furthermore, this study also provided useful insights into athlete viewpoints on drugs (as 
well as potential contrasts before and after using a banned substance), impacts on sporting 
performance as well as doping in sport. This, in turn, has also provided potentially useful 
insights for anti-doping strategies. 
Overall, all participants reported experiencing a performance enhancing effect as a result 
of r-HuEpo administration and participants described an achievement that they have never 
managed before, ranging from being able to maintain greater work rates during training for 
longer periods to achieving certain fitness targets at a much quicker rate.  All but one 
participant referred to recovery periods either in between training intervals or between 
training days as being either ‘quicker’ or ‘better’.  All participants commented on how they 
felt peripheral components of fatigue (i.e. legs) were limiting factors, whilst respiratory 
components felt fine.  All participants generally maintained an anti-doping sentiment, 
however some more convincingly then others especially when comparing to those deemed 
to be privileged with living at altitude.  
 
Interestingly, a key psychosocial implication that emerged involved the feelings and/or 
emotions of guilt, shame and/or embarrassment.  The difference between the two emotions 
of shame and guilt as well their relationship has long been debated (Tangney et al., 2011).  
Typically however, shame can be described as an emotion where the social norm is not 
adhered to whereas guilt is an emotion experienced after carrying out an act against 
socially accepted rules (Morris, 1971).  One could argue that participants were protected 
from committing a shameful act due to participation in the name of science, however as 
previously highlighted; all participants refrained from telling peers and those who did 
choose to tell anyone, told a very small number of individuals.  This was due to two 
factors, firstly the fear that public perception would not  believe the individuals true motive 
for being part of the trial involving an illegal substance, and secondly, that the person did 
not want to be perceived as willing to carry out a shameful act.  
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Five participants showed a degree of guilt or in one case ‘embarrassment’ as result of the 
performance enhancing effects of r-HuEpo.  
 
Participant 3: “I didn’t tell anybody at my club that I was doing this, one 
thing that I hadn’t considered is that we all gauge our fitness on other 
people.  I didn’t realise that it could have a negative effect on other people 
when they see how quickly I am improving.  They are doing the same 
training and same sessions, but they aren’t getting the same results.  On a 
couple of occasions people did say like they just weren’t improving the 
way they should be…that kind of thing.  Obviously it was noticed, it was 
noticed by coaches in club…you’ve gained shape quite quickly, but I 
didn’t say anything, although, it is kind of funny from my point of view…it 
must be quite dispiriting for others.  I just attributed to the miles of 
running...yeah never even considered it until I was in the situation. Maybe 
not ashamed, but I felt bad for those kinds of people...” 
 
Participant 4: “One day, just, I was running with the same people I would 
normally, they would finish the run and I would be the back of the group, 
but half way through the run they were running fast, and they were 
running fast they were saying you know we are running pretty fast and I 
was with them.  They started to struggle and then I took off and left them, 
it was ridiculous, I got quite embarrassed…you know it was like where the 
hell did that come from.  I thought that must be the EPO.  You could see 
people in the group when they came in at the end, they are like how you 
doing?  I was like, I’m off. I was embarrassed”. 
 
Participant 2: “Just mentally, sometimes I think eh, one of the sessions I 
thought about...I was running with a guy and coach, and was told to tuck 
in behind, but in the last straight, even between reps…my legs and 
breathing felt amazing and I flew past this guy on the last stretch.  Wasn’t 
even funny how easy it was. It was 4 x 600 reps, 800 pace, towards the 
second week of EPO.  When I finished that, I thought it was, I felt I was 
like cheating...that’s when I thought there’s no way I could do this 
properly, to cheat people, if I was racing…just didn’t feel right, felt like an 
unfair advantage”. 
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However, one particular individual clearly stated that no guilt was experienced and 
entertained the idea of using r-HuEpo again and/or alternative performance enhancing 
methods:  
 
Participant 6: “Even though it was illegal, I didn’t really have that guilt or 
anything, no anxiety, at the same time without taking it I was running 
really well.  I was like well...aye [i.e. yes], like that’s probably maybe my 
personality but sometimes while, quite a lot of the time I care a lot about 
what people think.   I did keep it to just a very, very, very few people that I 
knew.  EPO is illegal, and I would say that if say… I’ll be really honest…I 
would do your trial again to go back on it.  I would make sure I was out of 
competition, in a way I’m still cheating, but I’m not competing, so one way 
I’m not allowed to compete, but I’m still taking a banned substance which 
I was fine in doing during the trial and I would still do it again…just to 
boost my performance.  I know that there’s a certain time limit or time 
where it would go out the system, so I would do the trial and take EPO 
and then wait till it was out, carry on training hard, keep working through 
a hard training phase which I’m sure this is what some athletes do 
through their phase of [being] on EPO and wait till it’s out their system.  
I’ve actually looked into altitude generators that you can get, like you can 
get the tent over your bed, it’s a lot of money....like just under £3500”. 
 
 
Not only does limited research exist assessing psychosocial factors, attitudes and values of 
athletes towards performance enhancing drugs, but even less exists examining those who 
have been truly known to ‘cheat’ or those who are in the process.  The reasons for this are 
obvious.  However, assessments of those individuals who have used illegal means for 
enhancing performance would enable us to further understand more factually, as opposed 
to most studies which are often hypothetical, about the beliefs and complications of doping 
practices and also the likely psychosocial implications of doing so.    
 
Although alternative methods, such as questionnaires and/or focus groups, could have been 
employed, the quality and depth of the data obtained as a result of one-to-one interviews 
suggests that this method is effective when a strong rapport has been established between 
the interviewer and volunteer.  In this case, the interviewer had closely interacted 
(physically, and via email and telephone) with all participants on a very regular basis to 
ensure a trusting and open relationship was established.  
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It is acknowledged that, due to the small number of participants in this study, one must be 
careful to extrapolate views as being general to the greater population.  Further, it could be 
argued that these individuals are already of a certain ‘personality type’ as they have 
willingly put themselves forward to participate in such a trial.  However, even when taking 
these points into consideration, the data still shows varied responses to questions which, in 
itself, indicate the complexity behind human attitudes and personalities.  There may be 
certain attributes that may make an individual more likely to dope; for example an 
individual who is less susceptible to the emotion of guilt as may be the case with one 
participant in this study.  However, in this case for example, if the environmental setting 
was outwith the confines of a ‘controlled’ and ‘safe’ research facility and more associated 
with the ‘underground’ or ‘black market’, this individual may have felt differently about 
participating.  This may be because the health risks, associated with inappropriate use of 
the substance, would have become more possible or real in that situation.  
 
In five cases, the individual’s personal performance enhancement expectations were 
generally fulfilled, but to varying degrees, as a result of r-HuEpo administration.  
However, in one case, although there was a measured performance improvement from 
baseline to immediately after r-HuEpo administration, this particular individual’s 
expectations were not fulfilled; this individual expected ‘more’ of an effect.  Interestingly, 
this particular individual showed the least enthusiasm or excitement that r-HuEpo would 
elicit a great change in performance throughout the trial.    
 
Five of the participants did not change their stance with regards to doping in sport and, of 
them, one individual entertained the idea that doping should be allowed, and four 
individuals stood by their initial stance of ‘drugs should be banned in sport’.  These five 
individuals provided a range of reasons against the use of such substances for performance 
enhancing purposes upon varied emotions from guilt and shame to the unfair advantage 
that may be obtained against fellow competitors.  Interestingly, participant 6 suggested that 
he had changed since being involved in the trial stating: 
 
Participant 6: “I think we are disadvantaged in this country simply 
because the place is the way it is” [referring to Great Britain].  
 
This individual perceived the geographical advantages in certain other countries, where 
altitude can be more readily and more effectively incorporated into training, as simply 
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being an unfair advantage.  However, this particular individual did not condone the use of 
substances such as r-HuEpo as long as they were still categorised as being illegal. 
 
The highlighted psychosocial consequences of using an illegal performance enhancing 
drug, as previously indicated, may also assist in acting as a deterrent to doping.   If the 
public are made more aware of such potential psychosocial implications, which could 
potentially seriously affect relationships and psychological well-being, then those tempted 
by doping may be encouraged to think twice.   
 
5.5 Further studies 
This study adds useful insights into athlete viewpoints on drugs (as well as potential 
contrasts before and after using a banned substance), impacts on sporting performance as 
well as doping in sport.  In agreement with previous authors (Reeves et al., 2011), these are 
useful for incorporation into the development of key coping strategies in order to improve 
how individuals deal with such related psychosocial challenges.  Further research is needed 
to assess how such psychosocial impacts can be dealt with in order to help athletes better 
cope with the many pressure associated with elite sport (e.g. to educate athletes on the 
psychosocial consequences of doping and also provide coping strategies in order to deal 
with scenarios where athletes might be encouraged to dope). 
5.6 Conclusions  
All participants reported experiencing a performance enhancing effect as a result of r-
HuEpo administration and participants described an achievement that they have never 
managed before, ranging from being able to maintain greater work rates during training for 
longer periods to achieving certain fitness targets at a much quicker rate.  All but one 
participant referred to recovery periods either in between training intervals or between 
training days as being either ‘quicker’ or ‘better’.  All participants commented on how they 
felt peripheral components of fatigue (i.e. legs) were limiting factors, whilst respiratory 
components felt fine.  Psychosocial implications included the feelings and/or emotions of 
guilt, shame and/or embarrassment and these were prominent themes that emerged.  These 
feelings and/or emotions may also, in turn, be an effective deterrent to doping.  All 
participants generally maintained an anti-doping sentiment, however some more 
convincingly then others especially when comparing to those deemed to be privileged with 
living at altitude.  
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6. The Effects of an Injected Placebo on Endurance 
Running Performance in Simulated Race Conditions 
6.1 Introduction 
The placebo effect is acknowledged as a key factor in medical research and, as a 
consequence, its effect has been controlled in clinical trials for over 50 years (Price et al., 
2008).  The placebo effect has also been recognised in the context of sports performance, 
where researchers have reported statistically significant performance improvements with 
placebo interventions (Price et al., 2008, Beedie and Foad, 2009).  Studies, mostly in 
laboratory conditions, have shown the positive effects a placebo intervention can have on 
physical performance where athletes have been shown to improve performance by either 
exceeding performance limitations and/or by diminishing the perception of fatigue/pain 
(Ariel and Saville, 1972, Maganaris et al., 2000, Foster et al., 2004b, Beedie et al., 2006, 
Beedie, 2007a, Beedie and Foad, 2009).  However there are few studies which have 
assessed how the placebo effect impacts on self-paced running performance, during field-
based head-to-head competition scenarios, as opposed to tests confined to the laboratory.  
Such an approach is likely to provide a better measure, than can be determined from lab-
based studies, of the likely magnitude of the placebo effect on sporting performance in real 
competition environments (Wilmore, 1968). 
 
There are reports of increasing use of performance enhancing drugs in both elite and 
recreational level sport (Waddington et al., 2005, Carpenter, 2007, Pitsch, 2009, Holt et al., 
2009, Cakic, 2009, Rossi and Botre, 2011) and in recent years a growing body of research 
has been undertaken into the health and performance implications of taking such 
substances (Wagner, 1991, Bahrke et al., 1998, Goldberg et al., 2000, Dawson, 2001).  One 
such drug is r-HuEpo, a recombinant form of the endogenously present glycoprotein based 
hormone primarily secreted by the kidneys in humans (Egrie et al., 1986).  
Pharmaceutically engineered r-HuEpo was first developed in the 1980s and is now used in 
clinical applications; including the administration to patients suffering from anaemia due to 
chronic renal failure (Eschbach et al., 1989) and to cancer patients undergoing 
chemotherapy (Platanias et al., 1991).  Research studies have also demonstrated that r-
HuEpo administration increases Hct and oxygen-carrying capacity which often results in 
the improvement of endurance performance in athletes (Egrie et al., 1986, Ashenden et al., 
2001).  However, r-HuEpo is banned for use in sport by the World Anti-Doping Code and 
in recent years a number of elite athletes have received bans for its use.  
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A key feature of r-HuEpo administration is that it is given by injection, and there is clear 
evidence from clinical medicine that the route of delivery is a key mediator of the size of a 
placebo effect.  Further, placebos administered by injection have been shown to induce a 
larger effect than placebos administered orally (Zhang et al., 2008).  In the context of 
sports performance, one study has demonstrated a greater placebo effect on pain tolerance 
with use of intramuscular injections compared to oral administration (Benedetti, 2009).  
However, to the authors’ knowledge, no study has assessed the effect of a placebo injection 
on endurance running performance.  Furthermore, carrying out qualitative interviews to 
assess the effects of the perceived r-HuEpo injections on physical self-perceptions is also 
important to further our understanding on how such an intervention may influence 
endurance running performance.  As previously highlighted in section 1.10, Figure 6.1 
illustrates the key factors that influence endurance performance and how an injected 
placebo effect may influence endurance performance.  In addition, the key variables which 
were used to assess placebo influences, during this study (Chapter 6), are also highlighted. 
 
The aim of this study was therefore to determine whether an injectable placebo (0.9% 
saline injected subcutaneously) claiming to be a legal substance (OxyRBX), with similar 
effects to r-HuEpo, would improve endurance running performance in simulated race 
conditions. This study also assessed whether injecting a placebo elicited psychological 
changes associated with a positive performance response.  These effects were assessed 
under real-life competition scenarios as it has been suggested that in such conditions the 
effect of a treatment may be substantially different when compared to a laboratory setting 
(Foster et al., 2004a). 
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Figure 6.1:  Summary of the major cardiovascular variables (black lines) related to V
．
O2max and the maximal velocity that can be maintained in distance races with the 
addition of the Central Governor Model (CGM) (orange lines), the known (red arrows) and potential (red arrows with question mark) pathways that r-HuEpo and an 
r-HuEpo placebo injection (blow arrows with question mark) may influence. Variables measured in Chapter 5 (green border).  HRmax = maximal heart rate; SVmax = 
maximal stroke volume; [Hb] = haemoglobin concentration; %SaO2 = percent oxygen saturation; COmax = maximal cardiac output; (Ca-CvO2)max = maximal arterial-venous 
difference; V
．
O2max = maximal oxygen uptake; % V
．
O2max at LT = percentage of maximal oxygen uptake at lactate threshold. Adapted from (Bassett and Howley, 2000). 
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6.2 Methods 
6.2.1  Participants  
Nineteen endurance-trained male volunteers were initially recruited to take part in the 
study.  Four participants dropped out of the study prior the commencement of ‘OxyRBX’ 
administration.  Three of the four drop-outs mentioned ‘fear’ of the possible complications 
(e.g. blood clotting) associated with OxyRBX use.  One individual did not give a reason 
for dropping-out.  Thus, fifteen participants (age 27.5 ± 6.8 years, height 1.79 ± 0.05 m, 
body mass 73.4 ± 7.6 kg and BMI 22.9 ± 2.0 kg.m-2; mean ± SD) successfully completed 
the experimental protocol.  The fifteen participants were well-trained club level athletes, 
who reported engaging in 213 ± 129 minutes of endurance-based training and 50 ± 58 
minutes of resistance training per week, with personal best times for running 10 km of 39.3 
± 4.4 min (mean ± SD).  All participants were apparently healthy and none were taking any 
medications at the start of the study.  Participants provided written informed consent on the 
basis that they were undertaking a trial to investigate the effects of the legal EPO-like 
substance ‘OxyRBX’ on sporting performance, rather than a trial of the placebo effect 
(Appendix C).    This deception was essential for the study to be successfully undertaken 
and is standard practice in published studies of the placebo effect (Beedie and Foad, 2009).  
Participants were fully debriefed about the true nature of the study, on completion, in a 
final exit interview.   The study was approved by the research ethics committee of the 
College of Medical, Veterinary and Life Sciences at the University of Glasgow and was 
performed according to the World Medical Association (Declaration of Helsinki) code of 
ethics.  
 
6.2.2  Preliminary Study Brief  
Prior the commencement of the performance trials, the effects of r-HuEpo administration 
on exercise performance were described to participants and discussions took place 
concerning its alleged use particularly amongst elite cyclists.  Following this, participants 
were informed about purported benefits of ‘OxyRBX’ on performance which was 
described as being a legal EPO-like substance, which had been shown to induce similar 
benefits to EPO in animal studies and which  extensive testing had shown to be safe to use 
in humans. Potential side effects of OxyRBX (e.g. rash; hives; itching; difficulty breathing; 
tightness in the chest; swelling of the mouth, face, lips, or tongue) were also described, but 
it was emphasised that these were extremely rare (less than one case in a million).  This 
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priming process was carried out in order to reinforce beliefs about the effects of OxyRBX 
on exercise performance and the similarity of these effects to those of r-HuEPO.  The 
effectiveness of this reinforcement procedure was confirmed in two post-study interviews.  
 
6.2.3  Experimental Design 
The experimental design is outlined in Figure 6.2.  Participants initially underwent an 
individual familiarisation 3 km time-trial run.  This was carried out to familiarise 
participants to the track and racing over the 3 km distance.  With participants unaware, 
these individual 3 km completion times were used for handicapping purposes for the future 
3 km competition runs.  Participants then followed a randomised cross-over study design 
where each participant underwent tests before and after a 7 day ‘control’ phase, during 
which no intervention was given, and before and after a 7 day ‘placebo’ phase, in which 
participants received daily subcutaneous saline injections (0.5 ml sterile 0.9% NaCl).  
Participants were informed that these injections contained OxyRBX, which should elicit 
similar effects as r-HuEpo.  Eight participants underwent the control phase before the 
placebo phase, with the other seven undergoing the placebo phase before the control phase.  
There was a 2 week ‘washout period’ between the two study phases and participants were 
told that this was to ensure a suitable OxyRBX ‘washout period’ for the participants who 
started with the OxyRBX administration phase.  Participants were regularly informed not 
to discuss which group they have been assigned and, as far as possible, were monitored to 
ensure that no such discussions took place.  
 
At the start and end of each 7-day phase of the study (i.e. 7 days of control and 7 days of 
placebo) each participant’s body weight was measured and a blood sample was collected 
for a full blood count assessment (as described in section 2.6).  In addition, participants 
completed a CSAI-2 and POMS questionnaire (Appendix D) which was then followed by a 
competitive 3 km race.   
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Figure 6.2:  Study design.  F: Familiarisation; I: Interview; FI: Final interview, in two phases, prior to and post revealing deception.  Vertical 
arrows indicate data collection days (i.e. demographics, blood, questionnaires and 3 km time trials).  Placebo injections were self-administered 
on each day of the placebo phase. 
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6.2.4  3 km Race Competitions 
Each participant in each cohort undertook four performance tests as a competitive 3 km 
race on an indoor 200 m running track located at the Kelvin Hall Arena (Glasgow, U.K).  
The competitive 3 km races were carried out in a mean ambient temperature and humidity 
of 17.9 ± 0.8oC and 39.6 ± 3.4%, respectively.  To ensure that the 3 km races were 
competitive, participant starting times were handicapped based on the times achieved 
during the individual 3 km time trial familiarisation runs (i.e. a participant with an 
achieved 3 km time of 11:00 would start 30 seconds before a participant with a predicted 3 
km time of 10:30).  Lap completion times were taken by experimenters for each participant 
during each competition run using standard stopwatches.   Participants were reminded to 
prepare as they would normally for competition and were instructed to refrain from 
consuming alcohol 48 hours preceding each competition run.   Furthermore, in addition to 
handicapping competitor times to ensure a maximal competitive effort during each 
competition run, heart rate measurements were also recorded and monitored on a real time 
basis (Fitpulse, TT Sport S.R.L, Italy) and competition prizes (maximum value £35) were 
provided depending on overall competition finishing positions (i.e. on completion of all 
four competition runs).  All participants were positively encouraged during each 
competition run and only received information on the number of laps remaining.  
Participants were not given any further information or results until completion of the 
experimental protocol. 
 
6.2.5  Haematological Measures 
Standard haematological analyses were made using a haematology analyser (Sysmex XT-
2000i, Norderstedt, Germany), as described in section 2.6, and measures included [Hb], 
Hct and ret.  Samples were collected and immediately analysed prior and post 
control/placebo phases (i.e. 7 days).  The haematology analyser was calibrated against 
diagnostics reference materials prior the measurement of collected samples as described in 
section 2.6.   
 
6.2.6 Training and Diet 
Participants were instructed to maintain their normal training and diet patterns throughout 
the study and were asked to record all training sessions in a diary provided.  Participants 
were asked to replicate training and food intake for the one week and two days, 
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respectively, leading up to each competition run.  Endurance-based and resistance-based 
training were quantified in terms of duration for each week prior and during, both, control 
and placebo conditions.   
 
6.2.7  Study Interviews 
After every 3 km competition race, participants were briefly interviewed on an individual 
basis for feedback on the particular race they had just completed.   On completion of the 
study, participants also underwent two semi-structured interviews (Appendix E) with one 
interview prior to and one after the deception being revealed.  Personal results relating to 
the study were revealed to participants during the first of the final interviews.   
 
6.2.8  Data Analysis 
Statistical analyses were conducted using Statistica 6.0 (Tulsa, OK).  Data are presented as 
mean ± SEM.  Two-way repeated measures ANOVA was used to locate differences 
between conditions for heart rate, 3 km competition runs, RPE, [Hb], Hct, red blood cell 
count (RBC), mean cell volume (MCV), mean corpuscular volume (MCH), POMS and 
CSAI-2, endurance-based and resistance-based training durations.  Statistical significance 
was accepted at P < 0.05. 
 
6.3 Results 
Figures 6.3a and 6.3b illustrate the group average and individual 3 km race completion 
time differences (i.e. post subtracted from pre) in both control and placebo conditions, 
respectively.  Three km running performance improved by 9.73 ± 1.96 seconds in response 
to placebo and by 1.82 ± 1.94 seconds in response to the control condition (p < 0.05) 
(Figure 6.3a).  Eleven participants improved performance more in response to placebo than 
in response to control; change in performance was similar between conditions for one 
participant; and three participants had greater performance increases in the control 
condition (Figure 6.3b).  No significant differences were found between control and 
placebo conditions for average HR, RPE and haematological variables (Table 6.1).  No 
significant differences were found in POMS (Table 6.2) or CSAI-2 (Table 6.3) subscales. 
 
Time spent on endurance-based training and resistance-based training were not 
significantly different in the lead up to (i.e. 1 week prior) and during both control and 
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placebo conditions (Pre-control endurance-based training: 192 ± 33 mins; Control 
endurance-based training: 223 ± 72 mins; Pre-control resistance training: 44 ± 24 mins; 
Control resistance training: 43 ± 9 mins; Pre-placebo endurance-based training: 230 ± 51 
mins; Placebo endurance-based training: 206 ± 31 mins; Pre-placebo resistance training: 
62 ± 21 mins; Placebo resistance training: 50 ± 22 mins; P > 0.05).   
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Figure 6.3: a) Average 3 km Completion Time Difference and b) Individual 3 km Completion Time Differences (post-pre) (Secs). *P < 0.05. 
Values shown as mean ± SEM. 
 
b) a) 
P = 0.02 
* 
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Table 6.1: The effects of an injected placebo on 3 km race time, HR, RPE and haematological variables  
 
 Control Placebo 
   
 Pre Post Pre Post 
3 km Time (s) 665.9 ± 13.8 664.0 ± 13.6 662.0 ± 12.2 652.4 ± 13.1* 
HR (b.min-1) 174.3 ± 0.7 174.6 ± 0.5 177.1 ± 0.4 177.1 ± 0.5 
RPE 18.5 ± 0.4 19.3 ± 0.2 18.9 ± 0.2 19.5 ± 0.2 
Hb (g.dl-1) 14.3 ± 0.2 14.5 ± 0.2 14.3 ± 0.2 14.4 ± 0.1 
Hct (%) 43.2 ± 0.5 43.9 ± 0.6 43.2 ± 0.7 43.0 ± 0.3 
RBC (10^9.1-1) 4.8 ± 0.1 4.9 ± 0.1 4.8 ± 0.1 4.8 ± 0.0 
MCV (fL) 90.8 ± 0.8 90.3 ± 0.7 90.3 ± 0.9 90.4 ± 0.7 
MCH (pg) 30.0 ± 0.3 29.9 ± 0.3 29.9 ± 0.2 30.0 ± 0.2 
HR: Heart rate; RPE: Rate of perceived exertion; Hb Haemoglobin; Hct: Haematocrit; RBC: Red blood cell count; MCV: Mean cell 
volume; MCH: Mean corpuscular haemoglobin. Each value is the mean ± SEM. * Different from pre-control, post control and pre-
placebo.  * P < 0.05. 
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Table 6.2: The effects of an injected placebo on psychological POMS sub-scales   
POMS  Tension Depression Anger Vigour Fatigue Confusion 
Pre 2.93 ± 0.59 0.20 ± 0.14 0.13 ± 0.09 7.33 ± 0.99 3.40 ± 0.87 0.47 ± 0.27 
Control 
Post 2.53 ± 0.64 1.07 ± 0.93 0.53 ± 0.27 7.93 ± 1.02 3.27 ± 0.79 1.20 ± 0.94 
Pre 3.13 ± 0.48 0.53 ± 0.53 0.33 ± 0.21 8.47 ± 1.12 3.47 ± 0.56 0.60 ± 0.35 
Placebo 
Post 2.53 ± 0.64 0.33 ± 0.21 0.53 ± 0.41 8.47 ± 1.19 2.40 ± 0.48 0.00 ± 0.00 
POMS: Profile of mood states; CSAI-2: Cognitive state anxiety inventory-2.  Each value is mean ± SEM. * P < 0.05. 
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Table 6.3: The effects of an injected placebo on psychological CSAI-2 sub-scales 
CSAI-2  Cognitive Somatic Self- confidence 
Pre 15.73 ± 1.08 14.93 ± 0.85 23.13 ± 0.99 
Control 
Post 14.73 ± 1.17 13.27 ± 0.78 23.07 ± 1.13 
Pre 15.87 ± 1.12 14.00 ± 0.75 22.33 ± 1.19 
Placebo 
Post 15.8 ± 1.07 14.13 ± 0.79 23.93 ± 1.15 
POMS: Profile of mood states; CSAI-2: Cognitive state anxiety inventory-2.  Each value is mean 
± SEM. * P < 0.05. 
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6.4 Discussion  
The aim of this study was to determine whether an injectable placebo, claiming to be a 
legal substance with similar effects to r-HuEpo, would improve endurance running 
performance. Effects on psychological changes which may be conducive to improving 
running performance, in the form of 3 km completion times under simulated race 
conditions, were also assessed. The principal finding was that participants completed the 3 
km distance 1.2% faster in the post-placebo condition when compared to the post-control 
condition – a difference that was statistically significant and of relevance in a sporting 
context.     
  
The 1.2% faster running performance reported post-placebo is an important finding 
particularly, as a <1.0% difference in events ranging from 1000 to 4000 m is likely to mean 
the difference between a gold and silver medal in major sporting events (Foster et al., 
1994).  The findings reported in this study complement studies previously published where 
a placebo has deceptively been administered whilst claiming to be a potential performance 
enhancer (Beedie and Foad, 2009).  A recent study by Stone and colleagues (Stone et al., 
2011) was the first to present the beneficial effects of deceptive feedback on previously 
achieved time trial performance during self-paced cycling in trained individuals.  These 
authors reported that, with deceptive feedback, participants improved (i.e. achieved faster 
times) by 1.7% compared to baseline and by 1.0% compared to the accurate feedback 
condition.  However, the findings were inconclusive as to whether or not this performance 
effect was solely down to deception due to a study design limitation being the lack of a 
correctly informed deception group.  As a result, the authors could not elucidate the 
potential effect of competition in this particular case.   
 
The present study is the first (to the best of the author’s knowledge) to report an improved 
running performance, in simulated race conditions, with an injected placebo claiming to 
have similar performance enhancing effects to r-HuEpo in trained participants.  An 
explanation as to these findings is difficult as all other measured variables such as heart 
rate, haematological indices and psychological subscales did not differ significantly 
between control and placebo conditions (Tables 6.1, 6.2 and 6.3, respectively).  Some 
authors, however, have previously proposed a potential explanation as the presence of a 
dissociative task during performance assessment (Sporer and McKenzie, 2007, Stone et al., 
2011).  Self-paced exercise has been suggested to be regulated within the brain involving 
complex interactions between peripheral sensory feedback and comprehension of exercise 
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duration (Amann and Dempsey, 2008a, Swart et al., 2009a).  More specifically, there has 
been speculation that afferent sensory information related to body tissue homeostasis 
involves the dorsal posterior insula of the brain which is generated into a sensation by the 
right anterior insula of the brain (Hettinga et al., 2011).  A dissociative task can take the 
form of competition (Foster et al., 2004a) which can become the focus of one’s attention, 
in turn, restricting one’s ability to process distressing cues from sensory afferents.  This, 
therefore, distracts the ability to perceive cues related to fatigue (Sporer and McKenzie, 
2007).  However, for this present study, the dissociative task of ‘competition’ is not a 
possible explanation for the improved running performance found post placebo as 
‘competition’ was a feature of every race and was therefore controlled.  Furthermore, 
endurance-based and resistance-based training was similar between control and placebo 
conditions and is therefore unlikely to explain the faster running performance found in 
response to the placebo condition.  
   
Thus, it is unclear why placebo improved performance in the present study.  However, the 
results shown in this study may also be related to task dissociation, but in a different form 
to that previously described.  It is possible that the dissociative task in this case may have 
been internal thought processes in relation to the belief that a performance enhancing drug 
has been administered.  This, as a result, may have limited the participants’ ability to pick 
up distressing cues during the race and this may have potentially diminished the sensation 
of fatigue during the run itself.  The fact that RPE ratings did not differ significantly 
between conditions, despite participants running faster in the placebo condition, is 
consistent with this hypothesis; although this does not provide unequivocal evidence in 
support.   
 
Qualitative assessments of participants immediately post each 3 km competition race 
provides some insight into how participants felt during each race.  When interviewed 
immediately after each 3 km competition race, eleven of the fifteen participants described 
feeling different and/or commented that taking OxyRBX had an effect on performance.  
Effects of recovery were also mentioned.  The magnitude of effects reported did vary 
between participants and notable examples include:  
 
Participant 2: “…better today [in reference to the race immediately post 
the placebo week] than last week, felt like I could put in more effort.  Feel 
fresher, don’t know why as training was identical.  Definitely felt quicker 
this week than last…partly due to the substance.  Felt like I took 
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advantage of the drug week, was easier to talk when training and people 
mentioned that I looked more comfortable than usual.  Felt thirsty more 
than usual though…possibly due to the drug or training harder?” 
 
Participant 6:  “…felt pretty good [in reference to the race immediately 
post the placebo week].  Felt like I started quicker and maintained a better 
pace…more of an adrenaline rush this time [in contrast to the control race 
condition].  I believe I have done better than last week [in reference to 
immediately post control week].  Felt quicker and felt that I was more able 
to stick it out…certainly gave me the confidence to go for it harder”. 
 
Participant 9: “I was nervous before the race [in reference to prior the 
placebo race], but I wasn’t bothered about who was on the drug or not 
through.  I tried to focus whilst going down to the track.  During the run, I 
just ran according to how my body felt.  This week [in reference to 
placebo week] I felt like I could work harder, especially during the last 3 
laps of the race.  Muscles felt good…drug has definitely had an effect, you 
know, you’ve got this drug in your body…so let’s push, push.  I felt like I 
recovered quicker too, same RPE, but recovered faster than last week [in 
reference to immediately post control week]”. 
 
Furthermore, when interviewed on completion of the study, the same eleven out of the 
fifteen participants re-affirmed these feelings.  Three notable examples include: 
 
Participant 2: “…the effect of the substance just made everything 
quicker.  I have to admit when I was on the substance I was on the verge 
of injury…I kept pushing myself, probably too hard…just because I felt I 
could.  I was taking something…that’s why.  Maybe it was all in my head, 
although I am sure I did notice a difference in breathing.  Then again I 
could have put new running shoes on and felt lighter or something …could 
be psychological? It certainly boosts self-confidence”.   
 
Participant 3: “…the finishes of the races stood out for me throughout 
the trial…I really enjoyed every race.  During the drug week training and 
recovery felt better, but unsure whether it could just be psychological?  
My second competition race, post drug, the final laps felt faster…”.  
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Participant 14: “Wow…my fastest run was post drug [after being shown 
results in the first interview].  Yeah, that correlates with how I felt.  I 
certainly felt like the first run [in reference to the control race] was the 
slowest.  I felt tired during that run…physically.  The fastest run [in 
reference to post placebo race] surprises me actually, wow, that’s faster 
than what I expected…although I knew it was my fastest race.  Wow, 
pretty consistent splits as well.  I knew it…I felt that was my best race.  
Certainly faster than what I thought I could do…I am elated.  I have 
exceeded my expectations.  I mean, it was hard, but training was 
normal…if I just trained without some external influence [in reference to 
drug] I doubt I would have achieved that time.  So, it does make you think, 
maybe there is a little element being me, but 90% must be a result of the 
injections to be honest”.   
 
These qualitative assessment examples suggest that participants, overall, believed that 
taking a performance enhancing drug would improve performance and may have 
specifically done so by helping participants disassociate from picking up cues related to 
fatigue. 
 
Studies assessing pacing strategies and exercise performance have proposed that the brain 
may act to regulate exercise output in order to prevent full depletion of aerobic energy 
reserve (Amann and Dempsey, 2008b, Swart et al., 2009a, Swart et al., 2009b).  This 
mechanism of action has been proposed to occur in order to insure that exercise can be 
carried out safely without a catastrophic biological failure (Swart et al., 2009b).  If this 
holds true, one could infer that during self-paced exercise the brain, via specific neural 
control mechanisms (Noakes, 2007), essentially determines a work intensity relative to 
maximal but below absolute capacity (Amann and Dempsey, 2008b, Amann and Dempsey, 
2008a, Swart et al., 2009a, Swart et al., 2009b).  This may be subconsciously done in an 
attempt to avoid the negative complications of severe metabolite build up or biological 
failure which may, in turn, suggest the potential existence of a metabolic and/or central 
reserve (Stone et al., 2011, Noakes et al., 2004, Noakes, 2007, Tucker and Noakes, 2009, 
Tucker, 2009, Swart et al., 2009b).  Discovering new ways and understanding their 
respective underlying mechanisms in order attenuate one’s ability to detect cues related to 
fatigue will further improve endurance performance by accessing and ‘pushing’ these 
central and/or metabolic reserves to their own safe hypothetical limits – if they do indeed 
exist. 
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Figure 6.4: Summary of the major cardiovascular variables related to VO2max and the maximal running. 
This diagram shows the major variables which determine VO2max and the maximum sustained running velocity. The known interactions are shown as black lines.  
The known interactions with the Central Governor Model (CGM) are shown as orange lines.  
The known influences of r-HuEpo injections are shown by red arrows. Potential influences of placebo injections are shown by blue arrows with question mark.  
Red ticks mark variables found to be of significance immediately post placebo administration and red crosses mark variables which were not found to be of significance 
immediately post placebo administration.  HRmax = maximal heart rate; SVmax = maximal stroke volume; [Hb] = haemoglobin concentration; %SaO2 = percent oxygen saturation; 
COmax = maximal cardiac output; (Ca-CvO2)max = maximal arterial-venous difference; V O2max = maximal oxygen uptake; % VO2max at LT = percentage of maximal oxygen 
uptake at lactate threshold.   This figure is adapted from (Bassett and Howley, 2000). 
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6.5 Conclusions 
To summarise, participants completed the 3 km race distance significantly faster following 
the placebo condition compared to the control condition.  The magnitude of the effect of 
placebo on performance (i.e. 1.2%) is highly relevant in terms of sporting competition.  It 
is not clear why placebo improved performance to this extent, as measured heart rate, 
haematological variables and psychological subscales did not differ significantly between 
control and placebo conditions.  It is possible that the belief that a performance enhancing 
drug had been administered may have caused participants to disassociate cues related to 
fatigue during running.  Limiting one’s ability to detect distressing cues during running 
may have assisted participants to diminish or attenuate the perception of fatigue which, in 
turn, has likely encouraged a faster running performance.  Further study is needed to 
confirm whether this mechanism contributed to the observed performance-enhancing 
placebo effect.   
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7. General Discussion 
 
 A summary of the main findings found in each chapter are provided below: 
i) Chapter 3 was the first study (to the best of the author’s knowledge) to assess the 
K4b2 portable metabolic device during submaximal and maximal running 
velocities outdoors.  Initially, the K4b2 metabolic device appeared to be valid for 
the measurement of V
．
O2 during submaximal and maximal running velocities in an 
outdoor environment.  Upon further investigation, however, this apparent 
agreement was a consequence of two different errors which acted in opposite 
directions (i.e. a 5.2 ml.kg-1.min-1 negative offset in V
．
O2 coupled with a 14.2% 
higher gradient in the relationship between the K4b2 outdoors and the Douglas bag 
method for measuring V
．
O2).  Furthermore, a K4b2 outdoors mean bias of 2.3 
ml.kg-1.min-1 with a 95% confidence interval limits of agreement range from -6.1 
and 10.7 ml.kg-1.min-1 (equivalent to a measurement typical error of 6.5%) was 
found which indicates unacceptable degree of error.  The K4b2 device also 
significantly overestimated V
．
O2 indoors when compared to the Douglas bag 
method. As a result of these findings, unfortunately, the K4b2 could not be 
considered for use in further experimental Chapters due to the sensitive 
physiological measurements required.  Thus, the level of measurement accuracy 
required by users must seriously considered prior using the K4b2 portable device.  
ii) Chapter 4 assessed the effect of r-HuEpo administration on haematological, 
psychological and exercise performance measures to provide further insight into 
how this powerful perturbation may impact those systems that, as previously 
described, limit endurance exercise capability.  According to the author’s 
knowledge, this experimental study is the first to assess r-HuEpo mediated 
performance effects in both laboratory and field conditions.  Chapter 4 confirmed 
the erythropoietic effect of r-HuEpo administration with increases in [Hb] and Hct 
associated with improvements in V
．
O2max.  Three km time trial performance also 
improved immediately post r-HuEpo administration by 4.9%.  However, no clear 
associations were found between [Hb], Hct or V
．
O2max and 3 km performance which 
suggested that factors other than changes in [Hb], Hct and V
．
O2max are likely to have 
influenced running performance.  Furthermore, the improvement in 3 km time trial 
performance persisted for 4 weeks post r-HuEpo administration, despite the r-
HuEpo mediated changes in [Hb] and Hct declining by more than 50% over this 
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interval.  Finally, changes in psychological measures (i.e. anxiety and tension) were 
found which warrant further investigation as a potential contributor to enhancing 
performance.   
iii) Chapter 5 qualitatively assessed participants (i.e. via semi-structured interviews) on 
the associated effects of r-HuEpo administration on endurance performance as well 
as on psychosocial factors and consequences associated with the practice.  This 
study also offered unique insights into athlete viewpoints on drugs (as well as 
potential contrasts before and after using a banned substance, i.e. r-HuEpo), 
impacts on sporting performance and on doping in sport.  The study found that all 
participants reported experiencing a performance enhancing effect as a result of r-
HuEpo administration.  The majority of participants (i.e. 83% or 5 out of 6 
participants) referred to an enhancement in recovery periods either in between 
training intervals or between training days.  However, with these ‘positive’ 
enhancement effects were also psychosocial implications such as feelings of guilt, 
shame and/or embarrassment.  From an anti-doping perspective, all participants 
generally maintained an anti-doping sentiment; however some more convincingly 
than others especially when comparing to those deemed to be privileged with living 
at altitude. 
iv) Chapter 6 determined whether an injectable placebo, claiming to be a legal 
substance with similar effects to r-HuEpo, would improve endurance running 
performance in simulated race conditions.  Exercise performance was assessed in 
the field (i.e. 3 km track time trial), but with the element of competition introduced 
(i.e. racing opponents).  Results were compared to those obtained from Chapter 4 
and previous literature assessing the placebo effect on endurance performance.  
Participants completed the 3 km race distance significantly faster following the 
placebo condition compared to the control condition by 1.2%.  This magnitude of 
change is highly relevant in terms of sporting competition.  However, it was not 
clear as to what caused this enhancement in performance as measured heart rate, 
haematological variables and psychological subscales did not differ significantly 
between control and placebo conditions.  It may be possible that the belief that a 
performance enhancing drug had been administered may have caused participants 
to disassociate cues (or limit one’s ability to detect distressing cues) related to 
fatigue during running.  Further study is needed to confirm whether this mechanism 
contributed to the observed performance-enhancing placebo effect.     
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Figure 7.1 illustrates the measured variables in order to assess the effects of r-HuEpo 
administration and r-HuEpo placebo injections on endurance performance and, of these, 
which have been found to significantly change immediately post r-HuEpo administration 
according to the experimental chapters.  
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Figure 7.1: Summary of determined (ticks) and potential effects (question mark) of r-HuEpo (red colour) and injected r-HuEpo placebo (blue 
colour) immediately post administration on endurance performance capability.  
 
HRmax = maximal heart rate; SVmax = maximal stroke volume; [Hb] = haemoglobin concentration; %SaO2 = percent oxygen saturation; COmax = 
maximal cardiac output; (Ca-CvO2)max = maximal arterial-venous difference; V
．
O2max = maximal oxygen uptake; % V
．
O2max at LT = percentage of 
maximal oxygen uptake at lactate threshold. Adapted from (Bassett and Howley, 2000). 
 
 
[Hb] %SaO2 
COmax 
Maximum Velocity 
in Distance Race 
Oxidative 
Enzymes 
Velocity at LT 
V
．
O2max 
Capillary 
Density 
%V
．
O2max at LT 
Running 
Economy 
(Ca-CvO2)max 
SVmax HRmax 
Muscle Fibre 
Recruitment? 
- Mood     
 
- Anxiety  
 
Coronary Flow 
Placebo? 
Placebo? 
r-HuEpo 
r-HuEpo 
r-HuEpo 
r-HuEpo 
r-HuEpo 
r-HuEpo 
Placebo? 
? 
? 
X 
X 
X X 
r-HuEpo 
Chapter 7.  General Discussion                               198 
______________________________________________________________________________ 
198 
 
7.1 The K4b2 Portable Metabolic Device and Associated Limitations  
Unfortunately, due to the high level of accuracy required in subsequent studies (i.e. 
experimental Chapters 5 and 6), it was ultimately concluded that the K4b2 would not 
provide accurate enough measures to justify its further use.  In Chapter 3, the K4b2 
metabolic device initially appeared to be valid for the measurement of V
．
O2 during 
submaximal and maximal running velocities in an outdoor environment.  However, with a 
K4b2 outdoors mean bias of 2.3 ml.kg-1.min-1 with a 95% confidence interval limits of 
agreement range from -6.1 and 10.7 ml.kg-1.min-1 (equivalent to a measurement typical 
error of 6.5%), the device showed an unacceptable degree of error.  This, in addition to 
unusual performances during indoor conditions, warrants caution when collecting and 
interpreting data collected by the device.  Overall, no single factor was responsible for the 
inaccuracies reported and it was most likely the cause of several errors found in various 
sub-component variables (i.e. FEO2 and V
．
E), used to derive V
．
O2, as well as the potential 
negative impact of wearing the K4b2 on running economy. 
Even when taking into account such problems, however, field-based portable metabolic 
devices are still vital in order to be able to assess exercise performance in ‘truer’ 
environments.  This is essential in order to improve ecological validity for 
health/exercise/sports performance related studies.  It is clear that improvements are 
required in order to improve the accuracy of the K4b2 measures in order for it, and other 
similar technologies, to be more readily used with confidence in the result obtained.  
However, in addition to the required technological improvements required, there must also 
be a general consensus with regards to how metabolic validity studies are carried out, both 
under laboratory and field-based conditions.   
Authors have previously highlighted the lack of standardisation in how validity and 
reliability between portable metabolic analysers and criterion methods are assessed and 
reported (Atkinson et al., 2005).  Since Atkinson and colleagues first reported this in 2005, 
little has changed and even less has been done to standardise field-based validity and 
reliability studies.  This is peculiar given the importance ‘ecological validity’ is given in 
science.  Furthermore, different data analysis approaches have also been used in different 
studies to assess validity and/or reliability.  For example, the previous study assessing 
K4b2 validity by Pinnington et al. (Pinnington et al., 2001) merely reported Pearson 
correlation coefficients between the K4b2 device and metabolic cart measurements (FEO2: 
r = 0.971; FECO2: r = 0.925; V
．
E: r = 0.982).  It is now well established that utilising such 
methods alone, is not sufficient for comparisons between methods as they do not assess 
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systematic bias (Bland and Altman, 1986, Bland and Altman, 1996).  In another study, 
McLaughlin et al. (McLaughlin et al., 2001) may have taken this into consideration as 
these authors used Bland-Altman plots to compare the K4b2 and Douglas Bag.  However, 
in this instance, these authors only reported sample mean differences and did not report 
95% limits of agreement which is a better indicator of likely differences in population 
means (Atkinson et al., 2005).    
Chapter 3 offers useful insights on the validity of the K4b2 portable device using a variety 
of unique comparison exercise tests with runners.  The authors believe it to be novel in that 
it provides both K4b2 indoor and K4b2 outdoor comparisons against a criterion Douglas 
bag system.  In turn, Chapter 3 is an important contribution to existing literature examining 
the validity of portable metabolic systems for use in the field, during indoor sporting 
activities and other general activities.  Furthermore, this experimental chapter offered a 
unique solution for assessing portable metabolic devices outdoors without the necessity of 
wind tunnels (which are not easily accessible and are more costly).  Fundamentally, 
however, to confirm or refute the findings, future key investigations must assess the effects 
of facing head winds under controlled laboratory conditions using industrial-sized fans or a 
wind tunnel. 
 
From another perspective, this general discussion section provides an opportunity to 
discuss the wider relevance of portable metabolic systems in our world today.  It is clear 
that there is a growing global prominence of portable metabolic analysers as solutions to 
various problems from global health issues to space flight.  The personalised portable 
metabolic analysis market is ever growing with various industries including the National 
Aeronautics and Space Administration (NASA) (e.g. the development of the portable unit 
for metabolic analysis –‘PUMA’) and commercial fitness and health industries (e.g. 
Breezing –currently the world’s only metabolic assessment tool that links to your mobile 
phone) showing increasing interest.  This is no surprise given that such devices can be 
targeted for a variety of applications including: 
 
- The determination of personalised caloric requirements for daily living 
- The determination and manipulation of energy profiles through the development of 
personalised dietary/nutritional/weight-loss/exercise programs 
- Field testing, training and coaching of athletes for performance assessments and 
training programs 
- The determination of the metabolic cost of activities related to various situations for 
the development of occupational health/fitness strategies 
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- Various nutritional applications from food-metabolism related assessments in 
normal and in clinical situations.  
Furthermore, the BBC’s ‘The Health Show’ (BBC News, 2013)  recently featured the ever 
growing relevance of personalised medicine by showing the latest advances in a variety of 
fields, including biotechnologies, in order to help combat global health challenges.  The 
development of unique portable metabolic devices, such as ‘Breezing’ 
(http://breezing.co/), as a potential solution to global obesity, for example, will likely prove 
increasingly more and more important in order to engage the world population in solving 
such issues.  The global obesity pandemic example is a key global health issue and recent 
reports by World Health Organisation, stating that obesity has doubled since 1980 (World 
Health Organisation, 2013), clearly demonstrates this to be the case.  As portable metabolic 
devices seem to be playing an ever increasing role in global health solutions, the relevance 
of accurate and reliable measures will become increasingly more important as this industry 
continues to grow.  In order for this to occur, interested parties must establish standards to 
allow for more direct comparisons to made between validation/reliability studies, on 
relevant devices, under both laboratory and field conditions.  
To summarise, the degrees of error for the measurement of V
．
O2, as reported in 
experimental Chapter 3, are unacceptable when considering the level of accuracy required 
for physiological measures such as V
．
O2max and running economy, amongst others.  Such 
differences can have significant impacts on data interpretation and conclusions in research 
studies.  Thus, it was concluded that potential users must seriously consider the level of 
measurement accuracy required prior using the K4b2 portable device.  
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7.2 The Effect of Recombinant Erythropoietin on Endurance 
Performance 
The investigation in Chapter 4 demonstrated the positive ergogenic effect r-HuEpo 
administration has on endurance performance, not only, in a laboratory setting but also in 
the field.  The r-HuEpo mediated changes in haematological measures (Table 4.1) and 
psychological measures (Table 4.3), associated with improvements in performance 
measures (Table 4.2), demonstrate the mechanistic complexities behind the impacts of r-
HuEpo administration on those systems that limit endurance performance capability.  To 
the author’s knowledge, this is the first study to assess the effect of r-HuEpo administration 
on psychological, haematological and performance measures and is the first to assess the 
transferability of r-HuEpo mediated endurance performance enhancement from the 
laboratory to the field. 
The administration of r-HuEpo improved endurance exercise capacity (i.e.V
．
O2max) and 
exercise performance (i.e. 3 km time trial performance) (Table 4.2).  Maximal oxygen 
uptake did not change significantly over the course of the protocol, but was numerically 
5.2% higher immediately post r-HuEpo administration when compared to baseline.  This 
percentage change was in the right direction and is comparable to previous literature 
(Table 7.1).  In reference to Table 7.1, the average reported change in V
．
O2max was 7.6% 
(with a range of 6.6 to 9.3% depending on the r-HuEpo administration employed) and this 
was achieved using a minimum of 8 participants.  Thus, if it were possible to achieve a 
similar number of participants for Chapter 4, the average change in V
．
O2max would very 
likely have not suffered from a lack of statistical power.  Interestingly however, no 
significant relationships were found between changes in V
．
O2max and 3 km time trial 
performance (Table 4.3) which is likely to be a spurious finding given previous evidence 
(Hawley and Noakes, 1992, Ramsbottom et al., 1988, Coyle et al., 1988).  
 
Fundamentally, Chapter 4 reported a significant improvement in 3 km time trial 
performance immediately post r-HuEpo administration by 4.9% and this enhancement was 
sustained for 4 weeks post r-HuEpo administration (by 4.0% compared to baseline).  
Interestingly, no significant relationships were also found between changes in 3 km time 
trial performance with changes in other performance related measures including V
．
O2max (r 
= -0.532; P = 0.278), LT (r = -0.380; P = 0.528), OBLA (r = 0.219; P = 0.723), LTP (r = 
0.183; P = 0.769) or running economy (r = -0.055; P = 0.918).  Even when taking into 
account the potential effect of a type 2 statistical error (i.e. small sample size), it is possible 
that the improvements found in 3 km time trial performance were due to both 
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haematological and psychological underpinning mechanisms.  This could also be described 
as r-HuEpo potentially attenuating the onset of fatigue by alleviating those limitations 
associated with such systems.  In addition to what has already been discussed previously,  
other potential effects/mechanisms will now be explored further.  
 
In line with previous studies (Audran et al., 1999, Parisotto et al., 2000b, Birkeland et al., 
2000, Ashenden et al., 2001, Russell et al., 2002a, Ashenden et al., 2006) [Hb], Hct, ret 
and tHb increased immediately post r-HuEpo administration when compared to baseline 
measures.  The collective evidence, as a result, strongly suggests r-HuEpo administration 
to have a significant effect on the cardiovascular system by improving its ability to deliver 
O2 to the exercising muscles.  The increases in [Hb], Hct, ret and, in particular tHb, may 
mean that this improvement is, in part, underpinned by an improved cardiac output and O2 
carrying capacity (Bassett and Howley, 2000).  Although cardiac output was not directly 
measured (Brink-Elfegoun et al., 2007), tHb was determined using the optimised carbon 
monoxide rebreathing method (Schmidt and Prommer, 2005a), which can also be used to 
calculate blood volume – a contributing factor of cardiac output.   
 
Determining tHb provides an accurate and reliable measure of tHb (Durussel, 2011) which 
is not influenced by haemodilution and/or heamoconcentration as a result of fluid 
ingestion, fluid loss or infusion of plasma expanders, as examples (Schmidt and Prommer, 
2005a).  The tHb values increased from baseline to a maximum measure, immediately post 
the 4 week r-HuEpo treatment period, by 11.9% (Table 4.1).  Interestingly, although this 
increase was found, blood volume remained relatively stable (baseline: 7044 ml, 
immediately post r-HuEpo administration: 6639 ml).  This may appear surprising as one 
could likely assume a concomitant increase in blood volume with the reported increase in 
[Hb] which would, therefore, provide some evidence for an improved cardiac output in 
addition to O2 carrying capacity.  However, the reported blood volumes found in Chapter 4 
are in line with previous literature and an explanation is likely to involve the depression of 
plasma volume (Lundby et al., 2007) – a potentially debilitating paradoxical effect of r-
HuEpo administration.   
 
Lundby and colleagues have reported a ~300 ml increase in red blood cell volume with a, 
concomitant, ~400 ml reduction in plasma volume (Lundby et al., 2007).  These authors 
also reported reduced plasma rennin activity and aldosterone concentrations resulting in 
blood volume remaining relatively unchanged, but with a slight transient decrease when 
compared to baseline (Lundby et al., 2007).  Chapter 4 is in agreement where r-HuEpo 
administration induced an increase in [Hb] by increasing red blood cell volume, but by also 
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potentially decreasing plasma volume.  This may mean, therefore, that r-HuEpo 
administration improves endurance performance capability by improving arterial O2 
content (i.e. improving O2 carrying capacity in the body), but cardiac output may remain 
relatively unchanged.   
 
The potentially debilitating ‘paradoxical’ effect of plasma volume depression, associated 
with r-HuEpo administration, is an interesting factor to consider. A paradoxical 
comparison can be made to the ‘athlete paradox’ or ‘sports anaemia’ where exercise 
training has been associated with post-exercise plasma expansion, intensified haemolysis 
during physical efforts, iron deficiency, losses of erythrocytes via digestive and urinary 
tracts and potential disturbances in erythropoiesis (Szygula, 1990).  Similarly, in a 
paradoxical sense, although the depression of plasma volume is likely to contribute to a 
‘performance enhancing’ increase in [Hb], this may also concomitantly causes an increase 
in blood viscosity.  Without careful monitoring and control, increased blood viscosity can 
be life threatening and this is clearly a potentially ‘performance debilitating’ effect.  This is 
particularly the case if Hct levels reach >50% which is more often associated with 
endurance sports due to natural dehydration (Scott, 1990, Jenkins, 2002).   
 
Interestingly, anecdotal verbal feedback indicated in Chapter 4 suggested that some 
participants did indeed feel more thirsty than normal throughout the r-HuEpo 
administration phase.  Although this was naturally counteracted by drinking more water, 
the potential dehydrating effects, particularly after strenuous exercise, may have also 
contributed to increasing [Hb].  Furthermore, with plasma depression comes potential 
consequences including high blood pressure and thrombosis, associated with increased 
blood viscosity and decreased cardiac output (Gauthier, 2001).  Stroke and myocardial 
infarction have also been associated with a rapid rate of rise in haemoglobin (Smith et al., 
2003).  Thankfully, none of these consequences were observed in the study presented in 
Chapter 4.    
 
As previously highlighted, the haematological and performance findings also have 
importance in relation to anti-doping.  As indicated in Chapter 4, the results highlight the 
variability in the duration of r-HuEpo induced haematological changes from baseline 
measures which, in this instance, remained for 28 days after the cessation of r-HuEpo (in 
contrast to, for example, 21 days (Parisotto et al., 2000b, Parisotto et al., 2001)).  It is 
acknowledged that these findings may only likely apply to an r-HuEpo administration 
protocol of 50 UI.kg-1 three times a week over a 4-week period, although alternative 
regimens have produced similar haematological profiles (Ninot et al., 2006).  This provides 
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support to WADA’s ‘Athlete Biological Passport’ as such measures (e.g. haematological 
measures) can be monitored over time on an individual bases, thus indirectly indicating 
any potential doping effect.  This removes any limitations (e.g. drug wash-out times) 
associated with the more traditional approach of ‘drug detection’.  
 
The administration of r-HuEpo clearly improved exercise endurance performance.  A 
likely contribution to this effect is a cardiovascular adaptation from which peripheral 
systems are likely to have benefited.  However, there were also indications of possible 
psychological effects as significant psychological measures were also identified (Table 
6.3).  Both the CSAI-2 ‘cognitive’ subscale and the POMS ‘tension’ subscale decreased 
significantly compared to baseline, immediately post r-HuEpo administration, by 18.3% 
and 61% (P<0.05), respectively.  Although no relationships were found between such 
changes and changes in performance, previous studies have suggested the contrary 
(Martens, 1971, Craft, 2003).  For example, there have been reports of r-HuEpo 
administration eliciting improved mood (Miskowiak et al., 2008b) and physical 
conditioning (Ninot et al., 2006) in healthy individuals.  It must also be acknowledged, 
however, that recent studies, using healthy participants, have also concluded no attenuation 
in central fatigue or in cognitive performance strategy (Rasmussen et al., 2010).  This 
study found this based on, in part, increased RPE with no changes in cognitive function 
following the administration of high-doses of r-HuEpo (Rasmussen et al., 2010).  These 
authors do acknowledge, however, that the employed cognitive tests may have not been 
sensitive enough to detect a change in cognitive function in healthy participants – as 
opposed to reported effects within patients with pre-existing cerebral dysfunction 
administered with r-HuEpo (Moore et al., 2011).   
 
Rasmussen and colleagues (Rasmussen et al., 2010) also attempted to demonstrate central 
fatigue via the assessment of central motor drive during activation of the elbow flexor.  
The administration of high (30,000 IU/day) and low (5,000 IU/day) doses of r-HuEpo, over 
a 3 day and 3 month period, respectively, indicated no discrepancies in central motor drive 
between the two conditions.  The authors argue that the inability to fully activate the elbow 
flexor as a result of high doses of r-HuEpo, which has been reported to cross the blood 
brain barrier (Xenocostas et al., 2005), is indicative of a lack of influence on central 
systems.  This suggests that r-HuEpo enhances endurance capability solely via improving 
O2 carrying capacity.     
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Fundamentally, however, conflicting evidence still remains. Whether the psychological 
changes, reported in Chapter 4, are directly as a result of r-HuEpo administration remains 
to be elucidated.  These findings do warrant further investigation as these potential changes 
may indeed be r-HuEpo induced psychological changes, as determined by POMS and 
CSAI-2 subscales, or may simply be reflections of greater central effects – as recent 
evidence also suggests (Core et al., 2011).  In this example, Core and colleagues (Core et 
al., 2011) investigated r-HuEpo’s neuroprotective effects, for cerebral malaria (involves 
the occlusion of blood vessels located in the brain), which includes the activation of 
endogenous neural stem cells.  The authors reported a rapid increase in neural stem cells, 
which was r-HuEpo dependent, during cerebral malaria pathology.  The connotations of 
such research are tremendous and similar novel applications must be carried out on 
whether such effects play a role on r-HuEpo-mediated performance enhancing effects.  
Furthermore, there also still remains a requirement to attempt to quantitatively explain the 
qualitative measures often associated with the performance enhancing effects of 
performance enhancing beliefs. Such research will also further enhance our understanding 
on how r-HuEpo mediates its effects, but will also provide possible answers to those 
factors that fundamentally limit human physicality.     
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Table 7.1: Results comparison with previous literature assessing r-HuEpo administration for haematological 
measures and V
．
O2max 
Study Participants 
r-HuEpo Dose 
(IU/Kg/Week) 
Treatment 
Period (Weeks) 
Hct 
(%∆) 
[Hb] 
(%∆) 
tHb 
(%∆) 
V
．
O2max 
(%∆) 
Lundby et al. (2008) 8 Healthy 120 4 12.0 - 10.2 6.6 
Thomsen et al. (2007) 16 Healthy 180 13 9.2 9.4 8.3 12.6 
Russel et al. (2002) 9  Recreational 94 8 6.0 - - 7.0 
Audran et al. (1999) 9 Trained 350 - 11.5 9.3 - 9.3 
Parisotto et al. (2000) 8 Trained 150 4 10.1 10.7 12 6.9 
Ashenden et al. (2006) 2 Well-trained 348 5 - 18.1 - - 
Birkeland et al. (2000) 10 Well-trained 207 4 19.0 14.5 - 7.6 
Ross et al. (2012) 7 (6) Trained 150 4 8.7 21.2 12 5.4 
r-HuEpo: Recombinant Human Erythropoietin; Hct: Haematocrit; Hb: Haemoglobin; tHb: Total Haemoglobin Mass;  
V
．
O2max: Maximal Oxygen Uptake.  Ross et al. (2012): haematological variables (n=7), V
．
O2max (n=6).  All %∆ values 
represent baseline to maximum change for each study. 
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7.3 Viewpoints from Well-trained Individuals during and after r-HuEpo 
and Placebo Trial Participation: Performance Effects 
According to the majority of evidence to date, there is no doubt that r-HuEpo assists in 
improving endurance performance capability by impacting the cardiovascular system (e.g. 
by increasing O2 carrying capacity in the human body), but this is not exclusively.  In 
addition to physiological changes, Chapters 4 and 6 also provided evidence of participants 
verbally reporting benefits during and immediately after, both, r-HuEpo and placebo 
administration.  The similarities between comments made by participants, from both r-
HuEpo and placebo trials, provide evidence for this.  Example comparisons include: 
Comparison A: 
Participant 2 (r-HuEpo trial):  “That was the day when I came in, my heart 
rate fell down quickly, massively, within a couple of minutes. I probably 
was thinking that must be the EPO kicking in. I think yeah, anytime I did 
run like that, I must have thought yeah that must be the EPO”. 
 
Participant 4 (r-HuEpo trial): “I found that I became quite tired at the end 
of EPO, I don’t know, maybe ‘cause I was trying to do .....maybe I knew I 
was on EPO, so I thought I could do much more so I went out hard, but at 
the end it was taking more days to recover. I just remember, getting quite 
tired”. 
Participant 2 (Placebo trial): “Definitely felt quicker this week than 
last…partly due to the substance.  Felt like I took advantage of the drug 
week, was easier to talk when training and people mentioned that I looked 
more comfortable than usual…” 
 
Comparison B: 
Participant 6 (r-HuEpo trial): “I think that when you’re training so hard 
and then still be able to recover and then still train really quick that you 
confidence is high so your confidence plus EPO has a big boost. And then 
the fact that you are willing to risk in training, like running faster, ‘cause 
you think during training, I’m on this drug and going to get better, so I’m 
going faster...let’s take more risks, let’s run till you drop... See where this 
will take you, so maybe you feel a bit more I would say ‘immortal’ in 
training. You would feel as if like, I felt, there were sessions where I could 
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feel I could run so fast where I would generate no lactate, but didn’t know 
why, but at the end of the sessions you would feel lactate, but during the 
first few reps your still running really quick. And you got lots of 
confidence, your running going like you can’t feel the burn yet… 
brilliant! And people behind you chasing you. Gives you a massive boost 
psychologically…that’s something that I’ve not got in my locker usually”. 
Participant 3 (r-HuEpo trial):  “… certainly I would say looking at the 
times I was running, I mean that was certainly what I would expect from a 
much longer period of training. So something’s done something for 
sure…and the recovery was something that I noticed, the recovery 
sessions felt so much better…quicker”. 
 
Participant 2 (Placebo trial):  “…the effect of the substance just made 
everything quicker.  I have to admit when I was on the substance I was on 
the verge of injury…I kept pushing myself, probably too hard…just 
because I felt I could.  I was taking something…that’s why.  Maybe it was 
all in my head, although I am sure I did notice a difference in breathing.  
Then again I could have put new running shoes on and felt lighter or 
something …could be psychological? It certainly boosts self-confidence”.   
 
Participant 3 (Placebo trial):  “…the finishes of the races stood out for me 
throughout the trial…I really enjoyed every race.  During the drug week 
training and recovery felt better, but unsure whether it could just be 
psychological?  My second competition race, post drug, the final laps felt 
faster”. 
 
Comparison C: 
Participant 4 (r-HuEpo trial):  “One day, just, I was running with the same 
people I would normally…they started to struggle and then I took off and 
left them, it was ridiculous, I got quite embarrassed, and you know it was 
like where the hell did that come from. I thought that must be the EPO.  
 
Participant 14 (Placebo trial):  “Wow…my fastest run was post drug [after 
being shown results in the first interview].  Yeah, that correlates with how 
I felt.  I certainly felt like the first run [in reference to the control race] 
was the slowest.  I felt tired during that run…physically.  The fastest run 
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[in reference to post placebo race] surprises me actually, wow, that’s 
faster than what I expected… although I knew it was my fastest race.  
Wow, pretty consistent splits as well.  I knew it; I felt that was my best 
race.  Certainly faster than what I thought I could do…I am elated.  I have 
exceeded my expectations.  I mean, it was hard, but training was normal… 
if I just trained without some external influence [in reference to drug] I 
doubt I would have achieved that time.  So, it does make you think, maybe 
there is a little element being me, but 90% must be a result of the 
injections to be honest”.   
 
 
An important element that is often associated with all r-HuEpo regimes, employed in 
studies assessing the effects of this powerful perturbation on exercise capability, is the 
belief, by participants, that a performance outcome should improve.  In other words, the 
belief of change can often result in real or tangible change (Kirsch, 2004) where the CNS, 
either subconsciously or consciously, may regulate a response to stimulate an enhancement 
effect of a specific process or several underlying processes (Benedetti et al., 2005, Wager 
and Nitschke, 2005, Eippert et al., 2009).  Indeed, participant blinded studies are designed 
to control for this.  However, there remains a possibility that the simple action of injecting 
a substance believed to be r-HuEpo may alone contribute to a performance enhancing 
effect.  This can also be inferred as being psychological and/or central effects. 
Furthermore, previous studies have reported the route of delivery, in which interventions 
are carried out, as being influential on measured outcomes with, for example, injected 
placebos inducing a larger effect than placebos administered orally (Zhang et al., 2008).  
As result, the study in Chapter 6 aimed to make study findings in Chapter 4 more robust by 
assessing a ‘control’ comparative group who believed the saline received was r-HuEpo.  In 
addition, Chapter 6 also aimed at assessing participant’s belief system, which was further 
facilitated with the process of having to self-inject, on endurance performance capability 
due to reasons as previously described.  Experimental Chapters 4 and 6 outcomes are also 
summarised in Figure 7.2.  It is acknowledged that a potential third group could have 
consisted of participants who were aware they were receiving a placebo.  However, the 
difficulties associated with recruiting further trained/training participants into an r-HuEpo 
administration trial did prove challenging.  
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The major finding, in the study described in Chapter 6, was a 1.2% improvement in 3 km 
performance in the placebo condition (652.4 ± 13.1; p<0.05) when compared to control 
(664.0 ± 13.6; p<0.05).  Consequently, however, potential explanations could not be 
identified in measured variables (i.e. HR of each competing individual during each 3 km 
race, RPE ratings immediately upon completing 3 km distance, haematological variables, 
and psychological measures) aimed at providing some mechanistic reasoning as to the 
reported improvement in performance.  It is speculated, however, that the performance 
improvement may be associated with the disassociation of cues related to fatigue, during 
running, as a result of believing that a potent performance enhancing drug was 
administered.  Comments obtained during the study discussed in Chapter 6 provide some 
support for this, as previously highlighted.  
It is clear that the reported performance improvement of 1.2% is a significant finding, as 
for example,  Foster and colleagues (Foster et al., 1994) have indicated a ~1.0% difference 
in events ranging from 1000 to 4000 m as being a difference between a gold and silver 
medal.  Furthermore, when assessing the positional time differences in the Beijing 
Olympics 2008 and London Olympics 2012 for the men’s 10,000 m race, the time 
difference between 1st and 7th position was 0.43% and 0.24%, respectively, and Figure 7.3 
r-HuEpo Placebo                            
(i.e. believe r-HuEpo) 
Cardiovascular 
improvement 
indications 
Potential 
psychological 
indications 
Performance 
improvement 
   
Figure 7.2: Simplified summary of selected outcomes associated with r-HuEpo 
administration and believing r-HuEpo was being administered 
? 
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provides an interesting perspective on this.  It is theoretically possible, therefore, that the 
individual who finished 7th (and actually several positions beyond) in these races, could 
have potentially finished 1st – assuming all other factors remained constant.  .   
It is acknowledged that care must be taken when extrapolating performance results from 
well-trained individuals to world-class individuals.  Myburgh (Myburgh, 2003), for 
example, raised questions as to the applicability of exercise science research findings as 
often these are carried out on sub-elite individuals.  Sub-elite individuals are a different 
calibre of athlete in comparison to the world-class individual as the adaptations to 
consistent training and experiences is achieved over many years in the latter 
(Verkhoshansky, 1998).  In agreement, Laursen and Jenkins (Laursen and Jenkins, 2002) 
also support this notion; commenting that results of training studies on participants who are 
previously untrained, or who are recreationally trained, are not applicable to elite athletes.  
Assuming that results obtained from well-trained individuals are applicable to the world-
class individuals may, indeed, prove problematic.  However, an important additional 
feature of the study discussed in Chapter 6 is the inclusion of handicapped group 
competition races in the field-based 3 km exercise performance assessment protocol.  In 
addition to small monetary prizes and having heart rate measured real-time, this 
competitive handicapping element assisted in ensuring that all competing individuals were 
carrying out their best efforts and being truly competitive.   
  
Chapter 7.  General Discussion                               212 
______________________________________________________________________________ 
212 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
a) b) 
Figure 7.3: Finishing line photo shot at a) Beijing Olympics 2008 and b) London Olympics 2012 
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Competitiveness should therefore, theoretically, be the same regardless of the calibre of 
athlete.  Thus, competitiveness may instead be an association between personality types 
and how these varying types interact with the placebo effect and racing in a competitive 
environment.  It is therefore possible that a specific personality type may have 
supplemented the enhancement in endurance performance under such conditions.  From 
another perspective, only 44% of athletes indicated good understanding of the placebo 
effect (and how it can be used) in a study including 96 national-level Australian athletes 
(Brooling et al., 2008).  This further suggests that over 50% of athletes may be suggestible 
in this instance.  Interestingly, there have also been anecdotal reports of under-performing 
world-class sportsmen being encouraged, by team managers, to take illegal substances (e.g. 
growth hormone) in attempt to turn their performance around.  Instead the athlete is 
actually administered with a placebo, believing an illegal substance has been used.  Not 
only discovering the mechanistic but also discussing the ethical complexities behind such a 
situation, if an athlete were to report such activities to the authorities, is a very interesting 
topic, but is one that is also outwith the remits of this thesis.    
Realistically, being able carry out a similar study using world-class individuals will likely 
be impossible, for obvious reasons.  Therefore research in the area of performance 
enhancement will likely, more often than not, be constrained by this limitation.  
Fundamentally however, Chapter 6 offers unique insights into how the Central Governor 
may work in order to attenuate fatigue and improve performance.  In reference to previous 
literature (Benedetti et al., 2005, Wager and Nitschke, 2005, Eippert et al., 2009), it 
appears that this improvement in performance was achieved subconsciously.  Interestingly, 
previous studies have proposed that the brain (i.e. in a possible subconscious nature) may 
act to regulate exercise output in order to prevent full depletion of aerobic energy reserve 
(Amann and Dempsey 2008).  This mechanism of action has been proposed to occur in 
order to insure that exercise can be carried out safely without a catastrophic biological 
failure (Swart et al., 2009b).  If this holds true, one could infer that during self-paced 
exercise the brain, via specific neural control mechanisms, essentially determines a work 
intensity relative to maximal but below absolute capacity (Amann and Dempsey 2008).     
This may have been subconsciously done (as demonstrated in Chapter 6) in an attempt to 
avoid the negative complications of severe metabolite build up or biological failure which 
may, in turn, suggest the potential existence of a metabolic and/or central reserve. 
Furthermore, although competitors, on average, ran faster post-placebo they did not 
perceive that they were working harder to achieve this (as indicated by no significant 
changes in RPE measures).  This also suggests that the competitors may not have been 
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aware that a greater work output was being produced and so this is likely to be of be of a 
sub-conscious mechanistic nature which may have enabled individuals to access and use 
slightly more of their a metabolic and/or central reserve.  Thus, Chapter 6 provides unique 
insights into the effects of an injected placebo, perceived to be a known powerful 
performance enhancing agent, on endurance performance.   
Discovering new ways to assess current models on exercise fatigue is important to further 
our understanding in this field.  Furthermore, attempting to understanding underlying 
mechanism that enabled the performance improvement, possibly explained by being able 
to access and ‘push’ central and/or metabolic reserves to their own safe hypothetical limits, 
(if they do indeed exist), remains of importance.  Thus, a very fundamental necessity 
remains- the necessity to discover the mechanisms behind such a subconscious effect.  
Such findings certainly support the potential role of the Central Governor (as opposed 
those physiological measures that were assessed), but mechanistic explanations are 
required in order to explain such findings.   
Fundamentally, however, the administration of r-HuEpo did elicit a greater improvement 
in endurance performance capability, in the field, when compared to the placebo (4.9% vs. 
1.2%, respectively) with a net improvement of 3.7%.  This supports the notion that 
physiological impacts outweigh psychological (or central governor) ones.  However, the 
potential impact of the placebo effect, particularly on psychology, should never be 
underestimated 
 
7.4 Viewpoints from Well-trained Individuals during and after r-HuEpo 
and Placebo Trial Participation: Psychosocial Considerations 
As previously highlighted, utilising powerful perturbations such as illegal performance 
enhancing drugs, in a legal setting, provides a unique opportunity to assess the associated 
psychosocial issues and experiences.  The uniqueness is further exemplified by the 
minimising, or even possible removal, of the social desirability effect of dishonesty due to 
the nature of which experimental Chapters 4 and 6 were carried out - a factor often 
overlooked by doping research (Petroczi et al., 2011, Petróczi, 2012).  Ethical reasons, 
indeed, prohibited the use of competitive athletes and so participants abstained from 
sporting competition for the duration of both the r-HuEpo and placebo trials.  In the case of 
Chapter 4, participants refrained from competition for a further 28 days after receiving the 
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final r-HuEpo injection.  However, all other activities, including training environment for 
example, continued as normal.  This, in turn, provided unique insights into the 
psychosocial consequences of using such substances/techniques, which can often improve 
performance over relatively short period of time, on psychological well-being and social 
interaction effects.   
 
As the below quotes from Chapter 4 indicate, however, psychosocial impacts are likely to 
include a sense of embarrassment, shame and/or guilt (Bloodworth and McNamee, 2010): 
 
Participant 3: “I didn’t tell anybody at my club that I was doing this, one 
thing that I hadn’t considered, we all gauge our fitness on other people… 
didn’t realise that it could have a negative effect on other people when 
they see how quickly I am improving. They are doing the same training 
and same sessions, but they aren’t getting the same results. On a couple 
of occasions people did say like they just weren’t improving the way they 
should be…that kind of thing. Obviously it was noticed, it was noticed by 
coaches in club… ‘you’ve gained shape quite quickly’, but I didn’t say 
anything, although, it is kind of funny from my point of view…it must be 
quite dispiriting for others. I just attributed to the miles of running... 
yeah… never even considered it until I was in the situation. Maybe not 
ashamed, but I felt bad for those kinds of people...” 
 
Participant 4:  “One day, just, I was running with the same people I would 
normally, they would finish the run and I would be the back of the group, 
but half way through the run they were running fast, and they were 
running fast they were saying ‘you know we are running pretty fast’ and I 
was with them. They started to struggle and then I took off and left them… 
it was ridiculous, I got quite embarrassed, and you know it was like where 
the hell did that come from. I thought that must be the EPO. You could 
see people in the group when they came in at the end, they are like ‘how 
you doing?’  I was like, ‘I’m off’. I was embarrassed. I felt like that 
was....but then again, since then, I have had experiences where I have run 
as well, so I don’t know if that was a special day, or were they 
struggling? But that was one occasion where I took off”. 
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The fact that participants told nobody, outwith the testing environment, of their 
participation in a perfectly legal trial (except those who regularly trained with a trusted 
coach who they then only informed), is a further indication of the, potentially, very dark 
underworld of doping.        
 
The consequences may also help to persuade those who are tempted by doping to avoid 
such a path as, alongside potential sporting success, there will likely be serious moral 
anxiety, stress, guilt and shame.  Such consequences, for some, will likely be a strain on 
mental well-being and maybe even affect quality of life in general.  For example, Lucidi 
and colleagues (Lucidi et al., 2008) assessed the longitudinal effects of social-cognitive 
mechanisms on the self-reported use of doping substances and supplements amongst 
Italian high school students.  These authors reported stronger intentions and moral 
disengagement as contributors to increased use of doping substances (Lucidi et al., 2008).  
If increased moral disengagement, in particular, is associated with increased doping 
substance use, the reverse effect is also possible where further doping substance use may 
lead to further moral disengagement.  This is likely to have psychosocial complications – 
most likely negative ones.  There were hints of this and potential doping ‘addictiveness’ (in 
Chapter 5) which, like taking any ‘feel good’ drug, can contribute to psychosocial harm.  
For example, participant comments made via interviews carried out in Chapter 4 included:  
 
Participant 3: “…it was quite exciting the whole way through to see what 
kind of changes would take place, and then afterwards, I don’t know, I 
suffered a mental withdrawal....I need more!” 
 
Participant 6: “…I’m no [i.e. not] so confident as what I was.  I’m almost 
running the same times through the constant training, but I’m no running 
the same as on EPO.  I’m finding it harder to achieve things now”. 
 
Another point for consideration is that with potential addiction (due to r-HuEpo mediated 
performance enhancing effects) may also come resentment against those deemed 
privileged with geographically advantages of altitude, as in the case of participant 6 in 
Chapter 6: 
 
Participant 6: “I think we are disadvantaged in this country simply 
because the place is the way it is” [referring to altitude of Great Britain in 
comparison to East Africa].  
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It is important to reiterate that this particular individual did not condone the use of 
substances such as r-HuEpo as long as they were still categorised as being illegal.  
However, with the ever increasing pressures involved in elite sport and the ever growing 
rewards, it is unclear as to whether such individuals will remain ‘clean’ or whether the 
temptation, at some point, will cause a change in attitude.  
 
As a result of such ‘psycho-social’ issues, anti-doping research (e.g. the WADA Social 
Science Research Grant Program) has started to, only more recently, focus on what the 
agency have termed ‘tertiary prevention’ schemes. The ‘tertiary prevention’ schemes have 
a particular focus on decreasing doping relapse in athletes who have been sanctioned and 
this is likely an indication of possible problems associated with ‘doping addiction’.  This is 
a vital consideration; however, it is also vital that such research focuses on identifying 
factors (e.g. personality traits), situations (e.g. geographical disadvantages) and/or 
circumstances (e.g. competitors known to be cheating and who are not caught) that could 
turn those ‘clean’ athletes, who feel ‘disadvantaged’, into becoming ‘cheats’ themselves.    
 
Regarding the research presented in Chapters 4 and 6, however, none of the participants 
recruited indicated serious signs or desires to pursue continuing the use of r-HuEpo 
illegally, even though positive performance enhancing effects were experienced.  It might 
possibly be the case that participants, who took part in Chapter 4, will have likely realised 
the level of care required when using such a substance.  This, in turn, may have hopefully 
encouraged any potential ‘doper’ not to pursue the path as ‘black market’ drug taking will 
certainly not come with the level of care and attention that was provided in this study.  
 
 
7.5 Future directions  
Chapter 3 assessed the K4b2 portable metabolic device during submaximal and maximal 
running velocities outdoors.  According to the author’s knowledge this is the first study to 
do so.  Assessing portable metabolic analysers, in conditions that they were designed and 
often used, both in the field and laboratory, is clearly of great importance to insure data 
integrity.  Future work should encompass the testing of reliability between differing K4b2 
devices (with the same specifications) in order to investigate general K4b2 device 
comparability.  The K4b2 should also be tested further, in the field, under varying 
environmental conditions (e.g. high ambient temperatures, humidity and varying levels of 
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pollution) as well as during different work modes (e.g. skill based games, skiing, cycling).  
Such studies are essential in order to truly assess the K4b2 and, indeed, other similar 
devices.  
Chapters 4 and 6 reported improvements in endurance performance after both r-HuEpo and 
placebo interventions, respectively.  Future work should attempt to assess, more directly, 
the effects of such interventions on the varying endurance performance limiting factors, as 
previously described, similar to what has previously been attempted (Rasmussen et al., 
2010).  The incorporation of new technologies, as they become available, is a vital process 
as past technologies may not be sensitive enough to detect potential changes.  This is 
particularly relevant to studies assessing CNS activity as very recently highlighted by 
Tanaka and Watanabe (Tanaka and Watanabe, 2012) where, for example, the authors 
suggest advances in neuroimaging are required to further evaluate the inhibitory and 
facilitative systems as part of the CNS.  More specifically, as in the case with the 
Rasmussen et al. study (Rasmussen et al., 2010) which assessed the effects of r-HuEpo on 
cerebral metabolism and exercise capacity, developing methodologies that can detect 
potential changes in CNS activity more directly in the areas involved in exercise (e.g. 
quadriceps activation during cycling/running, as opposed to assessments of non-exercising 
areas such as the elbow flexor) will help to more concretely assess CNS activity and 
fatigue during endurance exercise activities in both drug and placebo trials.  For example, 
for running based activities, future studies could assess effects of such interventions on 
lower leg muscle EMG pre-activation activity and stiffness (e.g. via foot contact duration) 
where improved leg stiffness has been associated with improved running performance 
capability (Jones, 2002, Hobara et al., 2010).   
The r-HuEpo mediated performance enhancing ‘paradoxical’ effect of depressing plasma 
volume to assist in increasing [Hb] should also be explored further.  For example, further 
studies could assess the concomitant effects of administrating r-HuEpo whilst also 
carefully expanding plasma volume (e.g. infusion of saline) on physiological variables 
including, in particular, cardiac output (due to a potentially improved afterload) on 
endurance performance capability.    
Finally, assessing training activities in more detail in terms of ‘quality’ of session could 
also provide further insights into potentially behavioural changes associated with taking an 
actual and/or believed performance enhancing drug.  
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From a wider perspective in regards to this area of research, it seems reasonable to suggest 
that proposed theories and models (e.g. cardiovascular versus central governor) actually 
work together in order determine performance outcome or ‘hold back’ together in order to 
cause/induce fatigue.  However, further evidence is necessary to refine how much 
mechanisms contribute to the overall outcome effect. This is particularly the case for the 
central governor model as mechanistic evidence is often lacking.  Therefore, researchers 
should aim to assess novel ways to study the central governor model and its relative 
importance to a measured outcome.  Specific research approaches of particularly potential 
should involve blood manipulations (e.g. increasing red blood cell count), but then 
removing this effect (i.e. by removing the ‘added’ red blood cell volume) and testing 
performance outcome.  Another approach could be the use of carbon-monoxide where the 
effect of enhancing oxygen carrying capacity (by r-HuEpo administration or blood 
transfusion) could be calculated to cancel out the enhanced oxygen carrying capacity 
effect.  Performance outcome can then be assessed to test this effect of such an 
intervention.  The findings of such studies would be of great interest to the field, however, 
researchers must try to ensure that potential mechanism can be identified and explained if 
findings of significance are reported.  In agreement with Tanaka and Watanabe (Tanaka 
and Watanabe, 2012), measurement tools must be carefully selected and also improved in 
order to detect potentially very sensitive changes. 
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7.6 General Conclusions 
Preventing and/or attenuating fatigue experienced during endurance exercise in order to 
improve human performance, for any calibre of individual, is a considerable topic of 
investigation and is continually debated to this day.  Understanding the mechanism behind 
prolonged exercise induced fatigue is even more complex and this is demonstrated on a 
number of levels throughout the previous chapters.  
Chapter 3 revealed, initially, that the K4b2 metabolic device appeared to be valid for the 
measurement of V
．
O2 during submaximal and maximal running velocities in in the field 
(i.e. outdoors).  However, upon further investigation, this initial apparent agreement was a 
consequence of two different errors which acted in opposite directions (i.e. a 5.2 ml.kg-
1.min-1 negative offset in V
．
O2 coupled with a 14.2% higher gradient in the relationship 
between the K4b2 outdoors and the Douglas bag method for measuring V
．
O2).  The K4b2 
device also significantly overestimated V
．
O2 indoors when compared to the Douglas bag 
method.  As a result of these findings, unfortunately, the K4b2 could not be considered for 
use in further experimental chapters due to the sensitive physiological measurements 
required.  Outwith the purposes of this thesis, potential users of the K4b2 device must 
seriously consider the level of measurement accuracy required prior use. 
Chapter 4 provided confirmation on the erythropoietic effect of r-HuEpo administration 
where increases in [Hb] and Hct were associated with improvements in V
．
O2max.  Three km 
time trial performance also improved, immediately post r-HuEpo administration, by 4.9%.  
Interestingly, no clear associations were found between [Hb], Hct or V
．
O2max and 3 km time 
trial performance.  This suggests that factors, other than changes in [Hb], Hct and V
．
O2max, 
are likely to have influenced 3 km time trial running performance.  Furthermore, the 
improvement in 3 km time trial performance remained for 4 weeks post r-HuEpo 
administration.  This was despite [Hb] and Hct declining by more than 50% over the 4 
week post r-HuEpo administration phase.  Finally, changes in psychological measures (i.e. 
anxiety and tension) were found which warrant further investigation as a potential 
contributor to enhancing performance.   
Chapter 5 offered unique insights into athlete viewpoints on drugs, contrasts before and 
after using r-HuEpo, impacts on sporting performance and on doping in sport.  The study 
found that all participants reported experiencing a performance enhancing effect as a result 
of r-HuEpo administration.  The majority of participants commented on an enhancement in 
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recovery periods either in between training intervals or between training days.  However, 
alongside these ‘positive’ enhancement effects, psychosocial implications such as feelings 
of guilt, shame and/or embarrassment were also present.  From an anti-doping perspective, 
all participants generally maintained an anti-doping sentiment; however some more 
convincingly than others, especially when participants considered ‘geographical privileges’ 
(i.e. living and training with the use of altitude). 
Chapter 6  found that participants completed the 3 km race distance significantly faster 
following the injected placebo condition (perceived to be a form of r-HuEpo) compared to 
the control condition (saline injection) by 1.2%.  This magnitude of change has been found 
to be highly relevant in terms of the potential sporting success in competition.  However, it 
was not clear as to what caused this enhancement in performance as measured heart rate, 
haematological variables and psychological subscales did not differ significantly between 
control and placebo conditions.  Furthermore, no relationships were found between 
changes in any of these factors with 3 km time trial performance.  It may be possible that 
the belief that a performance enhancing drug had been administered may have caused 
participants to disassociate cues (or limit one’s ability to detect distressing cues) related to 
fatigue during running. Further study is needed to confirm whether this mechanism 
contributed to the observed performance-enhancing placebo effect.     
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Appendices 
Appendix A: Participant Information Sheet 
 University of Glasgow 
Faculty of Biomedical & Life Sciences 
  
INFORMATION SHEET 
 
Study Title: To assess the accuracy of a pioneering portable metabolic 
measurement system (K4b2) only previously done during sub-maximal exercise. 
 
You are being invited to take part in a research study. Before you decide whether to   
with friends, relatives and your GP if you wish. Ask us if there is anything that is 
not clear or if you would like more information. Take time to decide whether or not 
you wish to take part. 
 
Thank you for reading this. 
 
What is the purpose of the study?  Modern technological developments in human 
gas analysis have helped improve laboratory practices enabling researchers to carry 
out the analysis of human gas, in a portable manner, out on the field. The 
development in measures of performance not only allows for the interpretations of 
cardiovascular health, but can potentially have even greater impacts on valid 
performance testing when attempting to measure endurance capacity, running 
economy and energy expenditure, as examples. The key aspect in this study 
involves the concept of performance testing as this is key in training programmes 
and athlete development and despite performance analysis via means of gas 
analysis being widely accepted as being a useful indicator of performance in a wide 
range of activities, methodological limitations (e.g. the constraints of the laboratory 
setting) still exist that hinder the obtaining of data that reflects ‘true’ exercise 
performance.  
 
Why have I been chosen? You have been selected as a possible participant in this 
investigation because you regularly take part in endurance activity and you are in 
good health. Twenty volunteers are being sought. 
 
Do I have to take part? It is up to you to decide whether or not to take part. If you 
decide to take part you will be given this information sheet to keep and be asked to 
sign a consent form and fill in a lifestyle questionnaire. If you decide to take part 
you are still free to withdraw at any time and without giving reason. 
 
What will happen to me if I take part? You will be asked to visit the laboratory 
on two occasions and a running track once, where a series of assessments will be 
carried out. All experimental trials should last no longer than 2 hours. On your 
initial visit to the laboratory you will be medically examined by a qualified doctor. 
The first test will take place in the laboratory on a motorised treadmill at a fixed 1% 
gradient. During this test you will be instructed to run continuously at 10, 12, 14, 
16 and 18 km⋅h-1 (or until volitional exhaustion) for 3 minutes at each speed. This 
will be done using a ‘Gold standard’ method. The second test is exactly the same, 
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except it will be conducted using the K4b2 unit. The final third test will be 
conducted outdoors on a 400m running track; an investigator will cycle next to you 
to monitor and control the running speed.  
 
Heart rate and expired gas will be recorded throughout all tests via a heart rate 
monitor and a flexible rubber mouthpiece, respectively. Your height and weight 
will also be measured on each visit to the lab. Finally, you will not be able to 
perform any exercise 24 hours prior to testing or consume any alcohol 48 hours 
prior to each lab visit. You will be excluded from participating in this study if you 
take drugs (recreational or performance enhancing drugs). 
 
What are the side effects of taking part? There are none. 
 
What are the possible disadvantages and risks of taking part? Exercise has a 
negligible risk in healthy adults, although maximal exercise has a small risk of 
myocardial infarction (“heart attack”). The primary symptom of myocardial 
infarction is chest pain on exertion. If you experience any unusual sensations in 
your chest during the experiment, you should cease exercising immediately.  
 
You will breathe through a rubber mouthpiece during the tests, in order for us to 
collect the air you breathe out. You will also wear a noseclip during the first testing 
session. You may experience difficulty swallowing while breathing through a 
mouthpiece and wearing a noseclip, due to some pressure in the ears. In addition 
some participant s experience increased salvation when breathing through a 
mouthpiece. 
 
What are the possible benefits of taking part?  We hope to find out whether or 
not this pioneering device can be used out on the field with full confidence that it 
serves its purpose. The information collected will help us to decide whether the 
device is reliable and accurate or if changes are required. This testing will also 
allow us to provide you with feedback with regards to your physiology which 
would include a V
．
O2max value.  
 
What if something goes wrong?  If you are harmed by taking part in this research 
project, there are no special compensation arrangements. If you are harmed due to 
someone’s negligence, then you may have grounds for a legal action but you may 
have to pay for it. The principal investigators, although not medically qualified, are 
fully trained in Advanced Life Support. In the event of an untoward incident, the 
principal investigator(s) will provide basic life support including chest 
compressions and ventilation until emergency medical staff are on hand. You may 
want to consult your GP if you are experiencing any side effects from taking part in 
the study and should also inform the principal investigator. 
 
Will my taking part in this study be kept confidential? All information about 
you that is collected during the course of the research will be kept strictly 
confidential. 
 
What will happen to the results of the research study? Results will be published 
in a peer-reviewed scientific journal once the study is completed. You will 
automatically be sent a copy of the full publication. You will not be identified in 
any publication. 
If you wish to find out more about this investigation, you can contact: 
Dr Yannis P. Pitsiladis                                 
Institute of Biomedical & Life Sciences                                        
West Medical Building                              
University of Glasgow                                
Glasgow, G12 8QQ                                                              
E-mail: Y.Pitsiladis@bio.gla.ac.uk 
Ramzy Ross                                                  
Institute of Biomedical & Life Sciences                  
West Medical Building                                    
University of Glasgow                                       
Glasgow, G12 8QQ                                        
E-mail:ramzyross5@gmail.com 
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CONSENT 
 
Title of Investigation:  Evaluation of the Cosmed K4b2 Portable Metabolic System 
during Running Outdoors 
 
I ………………………………….. 
 
Give my consent to the research procedures which are outlined above, the aim, 
procedures and possible consequences of which have been outlined to me. 
 
 
 
Signature ………….................................. 
 
 
Date ………….................................. 
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Appendix B: Participant Information Sheet 
University of Glasgow 
Institute of Biomedical and Life Sciences 
University of Glasgow 
 
INFORMATION SHEET  
 
Study title: A Gene-Microarray Based Approach to the Detection of Recombinant 
Human Erythropoietin Doping in Endurance Athletes 
  
You are being invited to take part in a research study. Before you decide whether to 
participate, it is important for you to understand why the research is being done and 
what it will involve. Please take time to read the following information carefully 
and discuss it with friends, relatives and your GP if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. This project is being financed and 
supported by the World Anti-Doping Agency. 
 
Thank you for reading this. 
 
What is the purpose of the study? The project is aimed at validating a number of 
blood tests that can be used to detect erythropoietin (Epo) abuse. Presently, Epo 
abuse is detected indirectly in blood or directly in urine samples. The objective of 
this study is to build on the work already performed in the area of blood testing to 
detect Epo abuse and potentially provide alternative and robust gene based testing 
methods in the battle against drugs in sport, and in particular, Epo abuse. This will 
benefit athletes who believe in drug free sport.  
 
Why have I been chosen? You have been selected as a possible participant in this 
investigation either because of your status as an athlete, who is indigenous to sea-
level (Caucasian) or to moderate altitude (east African) to provide a comparison for 
findings on gene expression profiles following altitude training or Epo 
administration. 40 volunteers are being sought. 
 
Do I have to take part? It is up to you to decide whether or not to take part. If you 
decide to take part you will be given this information sheet to keep and be asked to 
sign a consent form. If you decide to take part you are still free to withdraw at any 
time and without giving a reason. 
 
What will happen to me if I take part? Initially, you will be asked to undergo a 
medical examination to establish your suitability as a participant in the study.  
  
If selected, you will receive 50 U.kg-1 body mass subcutaneous injections of r-
HuEpo every two days over a 4-week period. You will also receive daily iron 
tablets providing ~105 mg of iron. Saline injections will substitute r-HuEpo 
injections when a pre-determined blood concentration is reached in response to r-
HuEpo. You will then resume the standard r-HuEpo regimen. We would like to 
take a small amount of blood from an intravenous line in the back of your hand pre, 
during (days 1, 3, 10, 15, 17, 22, 26, 28) and for 4 weeks after r-HuEpo 
administration (days 5, 7, 12, 14, 19, 21, 26, 28).  
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On your first visit to the lab you will be asked to complete two confidential 
questionnaires; the first will allow us to obtain information related to your general 
health; and the second will allow us to quantify your past exercise/activity 
involvement.  
 
Your height, weight and percentage body fat will also be measured on each visit to 
the lab. Your percentage body fat will be estimated by a bioelectrical impedance 
technique, which involves placing slightly adhesive small patches (“electrodes”) on 
your right hand and foot and introducing a very small and imperceptible electrical 
current between these. 
 
In order to estimate your nutritional intake and energy expenditure, we may ask you 
to record your normal food and drink intake for 24 hour prior to each test and to 
keep a diary of your physical activity. 
 
Finally, you will not be able to consume any alcohol 48 hours prior to each lab 
visit. You will be excluded from participating in this study if you take drugs 
(recreational or performance enhancing drugs). 
 
What are the possible side effects, disadvantages and risks of taking part? 
There are only minimal risks associated with the blood sampling procedure. Slight 
bruising may occur around the site of collection, but this can be minimised by 
applying pressure at the site for a minimum of 3 minutes. Blood will be collected 
by either, a qualified phlebotomist and/or a medically qualified individual. 
 
There have been no reports of significant side effects as a result of Epo injections in 
normal healthy individuals. In athletes, there has been one report of elevated 
systolic blood pressure (from 177 to 191 mmHg) during moderate-intensity 
exercise (compared with mild- or low-intensity exercise) following treatment with 
Epo at doses of ~30 units per kilogram body weight over 6-7 weeks. Other side 
effects reported include flu like symptoms (mild and of short duration), suppression 
of natural Epo production, a burning sensation associated with subcutaneous 
injection of Epo, joint pains, rashes, and one case of a hypotensive episode 
associated with Epo injection. There is also an increased risk of seizures and 
thrombo-embolic events. The management of side effects including allergy and 
arthalgia, and those listed above, will include cessation of treatment and withdrawal 
from further participation in the study. Doses of Epo have been used up to 1200 
units per kilogram body weight per week, far beyond those in the present study.  
 
Mild gastrointestinal discomfort (i.e. loose bowel, constipation) may results from 
oral iron supplementation, which is relieved upon cessation of the supplementation. 
 
What are the possible benefits of taking part? It is envisaged that this research 
will result in the formulation of new genetic method(s) with improved 
discriminatory power relative to current haemoglobin and haematocrit detection 
protocols and in doing so significantly reduce (hopefully eliminate) the possibility 
of false positives due to athletes living and/or training at altitude and false 
negatives due to inadequate detection.  
 
What if something goes wrong? If you are harmed by taking part in this research 
project, there are no special compensation arrangements. If you are harmed due to 
someone's negligence, then you may have grounds for a legal action but you may 
have to pay for it. The principal investigators, although not medically qualified, are 
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fully trained in Advanced Life Support. In the event of an untoward incident, the 
principal investigator(s) will provide basic life support including chest 
compressions and ventilation until emergency medical staff is on hand. You may 
want to consult your GP if you are experiencing any side effects from taking part in 
the study and should also inform the Principal Investigator.  
 
Will my taking part in this study be kept confidential? All information about 
you that is collected during the course of the research will be kept strictly 
confidential 
 
What will happen to the results of the research study? Results will be published 
in a peer-reviewed scientific journal once the study is completed. You will 
automatically be sent a copy of the full publication. You will not be identified in 
any publication. 
  
If you wish to find out more about this investigation, you can contact: 
 
Dr Yannis Pitsiladis 
Reader, Faculty of Biomedical and Life Sciences 
West Medical Building 
University of Glasgow 
Glasgow, G12 8QQ  
Phone: 0141 330 3858 
e-mail: Y.Pitsiladis@bio.gla.ac.uk 
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INFORMED CONSENT (Participant ’s copy/Investigator’s copy) 
 
PRE-STUDY VISIT 
 
I, __________________________________________________ hereby (give 
permission to have my child) consent to take part as a volunteer in the research project 
entitled “A Gene-Microarray Based Approach To the Detection of Recombinant 
Human Erythropoietin Doping in Endurance Athletes”. 
 
• I acknowledge that I have read the Information Sheet in relation to the above-
mentioned project. I have had the project, so far as it affects me, fully explained to my 
satisfaction by the research worker(s). My consent is given freely. 
 
• I understand that the purpose of this project is to determine blood and genetic 
indicators of Epo doping in athletes.  
 
• I understand that this study will aid in the further development of tests for detecting 
abuse of Epo doping in athletes. 
 
• I have had all medical risks explained to me. 
 
• I have been informed that I (my child) will not be identified and my (child’s) personal 
results will not be divulged while information is gained during the study for the 
purpose of publication and/or presentation. 
 
• I understand that I am (my child is) free to withdraw from the project at any time. 
 
• I have retained a copy of this consent form and the information sheet. 
 
 
Signature of Participant : ________________________ Date: ________________ 
 
Signature of Witness/Parent/ 
Guardian of Minor: _________________________ Date: ________________ 
 
I, the undersigned, was present when the study was explained to the participant /s in 
detail and to the best of my knowledge and belief it was understood. 
 
Signature of Researcher: _____________________ Date: ___________ 
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Appendix C: Participant Information Sheet 
                 
 
VOLUNTEER INFORMATION SHEET  
 
A study to assess the effects of OxyRBX on sporting performance in well 
trained individuals 
  
You are being invited to take part in a research study. Before you decide whether to 
participate, it is important for you to understand why the research is being done and 
what it will involve. Please take time to read the following information carefully. 
Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part.  
 
Thank you for reading this.  
What is the purpose of the study? Erythropoietin (EPO) plays an important role 
in the creation of red blood cells. An increase in red blood cells results in increases 
in several blood factors including haematocrit which essentially allows you to 
increase your ability to carry and transport oxygen around your body. This can 
often enhance sporting performance. However, the use of EPO for performance 
enhancement is illegal as indicated by the ‘World Anti-Doping Agency’ (WADA) 
code. A new legal substance, called OxyRBX, has been developed which has 
similar effects to EPO on the blood profile.  We are testing the effects of OxyRBX 
on sporting performance. 
 
Why have I been chosen? You have been selected as a possible participant in this 
investigation because of your status as a well-trained individual who has lived at 
sea-level for the majority of your life. A total of 16 volunteers are being sought. 
 
Do I have to take part? It is up to you to decide whether or not to take part. If you 
decide to take part you will be given this information sheet to keep and be asked to 
sign a consent form. If you decide to take part you are still free to withdraw at any 
time and without giving a reason. A decision to withdraw at any time, or a decision 
not to take part, will not affect the standard of care you receive. 
 
What will happen to me if I take part? Initially, you will be asked to undergo a 
screening procedure to establish your suitability as a participant  in the study. This 
will involve: 
• a discussion regarding your health, family history, and physical activity 
levels 
• a blood pressure measurement  
• your height and weight being measured 
• an opportunity for you to ask any relevant questions 
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You will undergo either a ‘control phase’ (7 days) or ‘OxyRBX’ intervention 
phase’ (7 days) followed by the other separated by a 14 day ‘wash out’ period. 
Please see Figure 1 below: 
 
 
 
 
 
 
 
 
 
You will be asked to attend the laboratory on 9 occasions as follows: 
 
• A screening visit during which you will be provided with written and oral 
information about the study and given the opportunity to ask questions. You will 
also be asked to complete questionnaires related to health and sports participation; 
have your blood pressure measured; and provide written informed consent.   
• A blood sample, blood pressure measurement, questionnaires and 3 km time trial 
performance test will be carried out on Day 1 and Day 7 of both control and 
OxyRBX phases. 
• During the OxyRBX phase, on each day (days 1-7) an injection containing 
OxyRBX (0.5 ml, about a tenth of a teaspoon) will be provided to you to self-inject 
into your tummy.  
• During the control phase no intervention will be carried out between days 1-7. 
• Finally, on the final day of the trial, you will be interviewed and asked questions 
concerning the trial. This will be an opportunity to discuss your results which will 
include blood results, 3 km time trial performance results, and questionnaire results. 
 
Psychological questionnaires 
The questionnaires used in this study contain a number of questions. You will be asked 
to choose from 0 (not at all) to 4/5 (extremely/very much) for each question. Each 
questionnaire takes approximately 5 minutes to complete.  
 
Blood sampling  
A small needle will be inserted into your arm and a small blood sample (10ml, 
approximately 2 teaspoons full) will be taken. 
 
3 km time trial 
You will carry out a 3 km running time trial on days 1, 7, 21 and 28 and this will be 
carried out on a 200 m indoor running track at the Kelvin Hall Arena, Glasgow. These 
time trials will be carried out as a competition, so you will meet other participants.    
 
Training, diet and general monitoring 
You will receive a diary to log your diet and training activities both during the total 28 
day trial period and also 1 week prior starting each phase (i.e. control/ OxyRBX 
phases).  Please do inform us if you suffer from any illness, or have any significant 
change in lifestyle (e.g. you start taking a certain medication). 
 
CONTROL / OxyRBX
7 Days 7 Days14 Days
Wash out
Figure 1: Schematic plan of the study design. Arrows indicate days when data collection (height, weight, blood, 
questionnaires and 3km time trials) will be carried out. OxyRBX injections will be self-administered on each day of the 
OxyRBX phase. 
Day 1 Day 7 Day 21 Day 28
CONTROL / OxyRBX
 257 
   
 
Finally, you will not be able to consume any alcohol 48 hours prior to each lab 
visit. You will be excluded from participating in this study if you take drugs 
(recreational or performance enhancing drugs). This protocol includes 15 visits 
per participant. 
 
 
What are the possible side effects, disadvantages and risks of taking part?  
 There are only minimal risks associated with the blood sampling procedure. Slight 
bruising may occur around the site of collection, but this can be minimised by 
applying pressure at the site for a minimum of 3 minutes. Blood will be collected 
by a qualified phlebotomist and/or a medically qualified individual. 
 
 There have been no reports of significant side effects as a result of OxyRBX 
injections in normal healthy individuals. However rare (less than one in ten 
thousand) side effects might include: allergic reactions (rash; hives; itching; 
difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or 
tongue). In these circumstances stopping OxyRBX use results in complete 
resolution of symptoms within 24 hours.  
 
 Doses of OxyRBX up to 10 times higher than the dose used in the present study 
have been safely used in previous studies.  
 
 Exercise testing will be at a maximal level and so there is a possibility, very 
occasionally, that certain changes may occur during or shortly after the exercise 
performance test. This might include abnormal blood pressure, fainting or a change 
in the normal rhythm of the heartbeat.  
 
 There is a small possibility that taking part in this study will reveal a health 
problem that you already have, such as high blood pressure. If such a problem is 
revealed, we will seek your permission to inform your GP to ensure that you 
receive the appropriate treatment.  
 
What are the possible benefits of taking part?  
There may be no direct benefits to you, but as a result of taking part in this study you 
will receive health and fitness information about yourself including blood 
measurements, blood pressure, and exercise performance tests as well as information 
on your psychological performance. Further, this research will provide further insight 
into what effect OxyRBX has on sporting performance. 
 
What if something goes wrong?  
If you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone's negligence, then you 
may have grounds for a legal action but you may have to pay for it. The principal 
investigators, although not medically qualified are fully trained in Advanced Life 
Support. In the event of an untoward incident, the principal investigator(s) will provide 
basic life support including chest compressions and ventilation until emergency 
medical staff is on hand. You may want to consult your GP if you are experiencing any 
side effects from taking part in the study and you should also inform the Principal 
Investigator.  
 
Will my taking part in this study be kept confidential?  
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All information about you that is collected during the course of the research will be 
kept strictly confidential. Any information about you which leaves the University of 
Glasgow will have your name and address removed so that you cannot be recognised. 
 
What will happen to the results of the research study?  
Results will be published in a peer-reviewed scientific journal once the study is 
completed. You will automatically be sent a copy of the full publication. You will not 
be identified in any publication. 
 
Who has reviewed this research study? 
This study has been reviewed and approved by the College of Medical, Veterinary and 
Life Sciences (Institute of Cardiovascular & Medical Sciences) Ethics committee at the 
University of Glasgow. 
   
  
If you wish to find out more about this investigation, you can contact: 
 
Ramzy Ross on 0141 330 3475 (Office) or 07799197099 (Mobile) (email: 
r.ross.1@research.gla.ac.uk) 
 
Dr. Jason Gill (email: Jason.Gill@glasgow.ac.uk) 
 
You will be given a copy of this information sheet and signed consent form to keep for 
you records. 
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INFORMED CONSENT (Participant ’s copy) 
 
 
I, __________________________________________________ hereby consent to take 
part as a volunteer in the research project entitled, ‘A study to assess the effects of 
OxyRBX on sporting performance in well trained individuals’. 
 
 
• I acknowledge that I have read the Information Sheet in relation to the above-
mentioned project. I have had the project, so far as it affects me, fully explained to 
my satisfaction by the research worker(s). My consent is given freely. 
 
• I understand that the purpose of this project is to assess the effects the effects of 
OxyRBX on sporting performance in well trained individuals. 
 
• I have had all medical risks explained to me. 
 
• I have been informed that I will not be identified and my personal results will not 
be divulged while information is gained during the study for the purpose of 
publication and/or presentation. 
 
• I understand that I am free to withdraw from the project at any time. 
 
• I have retained a copy of this consent form and the information sheet. 
 
 
I, the undersigned, was present when the study was explained to the participant /s in 
detail and to the best of my knowledge and belief it was understood. 
 
Signature of Participant : ________________________ Date: ________________ 
 
 
Signature of Researcher: _____________________ Date: ________________ 
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INFORMED CONSENT (Investigator’s copy) 
 
 
I, __________________________________________________ hereby consent to take 
part as a volunteer in the research project entitled, ‘A study to assess the effects of 
OxyRBX on sporting performance in well trained individuals’. 
 
 
• I acknowledge that I have read the Information Sheet in relation to the above-
mentioned project. I have had the project, so far as it affects me, fully explained to 
my satisfaction by the research worker(s). My consent is given freely. 
 
• I understand that the purpose of this project is to assess the effects the effects of 
OxyRBX on sporting performance in well trained individuals. 
 
• I have had all medical risks explained to me. 
 
• I have been informed that I will not be identified and my personal results will not 
be divulged while information is gained during the study for the purpose of 
publication and/or presentation. 
 
• I understand that I am free to withdraw from the project at any time. 
 
• I have retained a copy of this consent form and the information sheet. 
 
I, the undersigned, was present when the study was explained to the participant /s in 
detail and to the best of my knowledge and belief it was understood. 
 
 
Signature of Participant : ________________________ Date: ________________ 
 
 
Signature of Researcher: _____________________ Date: ________________ 
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Appendix D: Questionnaires 
 CSAI-2 (Prior Performance Trial)  
Name:  ______________________________ Date:  ____________________ 
Directions:  A number of statements that athletes have used to describe their feelings 
before competition are given below.  Read each statement and then circle the appropriate 
number to the right of the statement to indicate how you feel right now - at this moment.  
There are no right or wrong answers.  Do not spend too much time on any one statement, 
but choose the answer which describes your feelings right now. 
 
Not       Moderately       Very  
At All     Somewhat            So    Much  So 
1. I am concerned about this   
competition   1  2  3           4  
2. I feel nervous   1  2  3           4 
3. I feel at ease   1  2  3           4  
4. I have self-doubts  1  2  3           4 
5. I feel jittery   1  2  3           4  
6. I feel comfortable  1  2  3           4  
7. I am concerned that I may not   
do as well in this competition 
as I could   1  2  3            4 
8. My body feels tense  1  2  3            4 
9. I feel self-confident  1  2  3            4 
10. I am concerned about losing 1  2  3            4 
11. I feel tense in my stomach 1  2  3            4 
12. I feel secure   1  2  3            4 
13. I am concerned about 
choking under pressure  1  2  3            4 
14. My body feels relaxed  1  2  3            4 
15. I’m confident I can meet 
the challenge   1  2  3            4 
16. I’m concerned about 
performing poorly  1  2  3            4 
17. My heart is racing  1  2  3            4 
18. I’m confident about 
performing well  1  2  3            4 
19. I’m concerned about 
reaching my goal  1  2  3            4 
20. I feel my stomach sinking 1  2  3   
21. I feel mentally relaxed  1  2  3            4 
22. I’m concerned that others 
will be disappointed with 
my performance  1  2  3            4 
23. My hands are clammy  1  2  3            4 
24. I’m confident because I 
mentally picture myself 
reaching my goal  1  2  3            4 
25. I’m concerned I won’t be 
able to concentrate  1  2  3            4 
26. My body feels tight  1  2  3            4 
27. I’m confident of coming 
though under pressure  1  2  3            4 
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POMS SCALE 
Name: _____________________        Age__________years 
  
 
Below is a list of words that describe feelings people have.  Please read each one 
carefully.  Then tick the answer that best describes HOW YOU FEEL RIGHT 
NOW.  Make sure you answer every question. 
 
 
 
 
Not at all A little Moderately Quite a bit Extremely 
1. Panicky 0 1 2 3 4 
2. Lively 0 1 2 3 4 
3. Confused 0 1 2 3 4 
4. Worn out 0 1 2 3 4 
5. Depressed 0 1 2 3 4 
6. Downhearted 0 1 2 3 4 
7. Annoyed 0 1 2 3 4 
8. Exhausted 0 1 2 3 4 
9. Mixed- up 0 1 2 3 4 
10.Sleepy 0 1 2 3 4 
11.Bitter 0 1 2 3 4 
12.Unhappy 0 1 2 3 4 
13.Anxious 0 1 2 3 4 
14.Worried 0 1 2 3 4 
15.Energetic 0 1 2 3 4 
16.Miserable 0 1 2 3 4 
17.Muddled 0 1 2 3 4 
18.Nervous 0 1 2 3 4 
19.Angry 0 1 2 3 4 
20.Active 0 1 2 3 4 
21.Tired 0 1 2 3 4 
22.Bad 
tempered 
0 1 2 3 4 
23.Alert 0 1 2 3 4 
24.Uncertain 0 1 2 3 4 
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Appendix E: Interview Schedule 
 
 
INTERVIEW SCHEDULE FOR R-HuEpo (Chapter 4) and PLACEBO 
(Chapter 6) 
 
(Prior Deception Revealed for Placebo study- Chapter 6) 
 
Part 1 – Ice Breakers 
 
1. You have undertaken the research project.  Was it a worthwhile and interesting 
experience?   
 
2. How did you feel about it before hand? Did you understand the risks of 
participating?  How did you evaluate these? 
 
3. Did you anticipate any effects taking r-HuEpo / OxyRBX? 
 
4. Are you glad you took part in the trial or was it burdensome? 
 
 
Part 2 – Experience of effects during the trial  
 
1. Did you have any anxieties about taking such a substance? 
 
2. Whether you did or did not, did you ‘kind of’ relish the thought of taking such a 
substance legitimately? 
 
3. Did you imagine it would alter your performance at all/significantly? 
 
4. Can you describe how you felt, if differently at all, during the experiment? 
 
5. How did training/performing/running feel during the experiment? 
 
6. Was your recovery any different?  Did you change any aspects of your training 
regime in a way that might have affected things? 
 
7. Did you note any side effects whether positive or negative? 
 
 
Part 3 – Post Data 
 
Introduce data here 
(All data revealed apart from blood results) 
 
 
1. Do you understand the data that I have shared with you?  Do you want to ask any 
questions about them? 
2. Is it what you expected or are you surprised in any way? 
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3. How do you feel about it? (Important Question – Help prompt if struggling: happy, 
elated, guilty, ashamed, anxious about returning to competition, unable to look 
fellow club athletes in the eye? And so on…) 
 
4. (If performance has improved) To what extend do you feel this is a response to 
your own hard work; that the substance just allowed you to work harder? 
 
5. Do you think athletes should be able to use such a substance as a component of 
their training? 
 
 
Part 4 – Post Data (Deception Revealed for placebo study Chapter 6 and blood results 
now shown) 
 
1. Now that you have had time to read the debriefing document and reflect, how do 
you feel now having learnt that a placebo was being administered? 
 
2. Did you ever have any suspicion that this may the case throughout the study? If so, 
when? 
 
Introduce data here 
(All data revealed again, including blood results now) 
 
3. Do you understand the data that I have shared with you?  Do you want to ask any 
questions about them? 
 
4. Is it what you expected or are you surprised in any way? 
 
5. How do you feel about it?  
 
6. Do you think athletes should be able to use such techniques (e.g. Pre-conditioning) 
as a component of their training? 
 
7. Now that the deception has been revealed.  Was taking part in this study a 
worthwhile or interesting experience?   
 
8.  Is there anything else you would like to say or ask me? 
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Appendix F: Health Screening and Physical Activity Questionnaire 
 
UNIVERSITY OF GLASGOW 
INSTITUTE OF BIOMEDICAL AND LIFE SCIENCES 
 
PARTICIPANT ’S QUESTIONNAIRE AND ASSENT FORM FOR 
HIGH-INTENSITY EXERCISE TESTING 
 
If you feel unwell on the day of a proposed test, or have been feeling poorly 
over the preceding day or two, DO NOT TAKE PART in a high-intensity 
exercise test. 
The considerations which follow apply to people who are feeling well at the time. 
 
 
Name: 
 
Sex (M/F) _______ Age _______ (yrs) Height _______ (m)          
Weight ________ (kg) 
 
Exercise Lifestyle 
 
a) What kind(s) of exercise do you regularly do (20 + min/session)?  (Please 
circle) 
 
Number of times per average week 
  
Walking    1 2 3 4 5 
Running    1 2 3 4 5 
Cycling    1 2 3 4 5 
Swimming    1 2 3 4 5 
Skiing                1 2 3          4          5 
Rowing    1 2 3 4 5 
Gymnastics    1 2 3 4 5 
Martial arts    1 2 3 4 5 
Tune Up    1 2 3 4 5 
Pop mobility               1 2 3 4 5 
Sweat Session               1 2 3 4 5 
Field athletics               1 2 3 4 5 
Weight training                                   1          2          3          4          5 
Racquet sports              1 2 3 4 5 
Rugby/soccer/hockey              1 2 3 4 5 
 
Other(s) *     1 2 3 4 5 
 
* (Please specify)   ________________________________________ 
 
 
b) How long have you been exercising at least twice/week for at least 20 
min/session? 
__________________________________________________________________ 
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Smoking 
(Please tick one) 
Never smoked  __________ 
Not for > 6 months __________ 
Smoke <10 per day __________ 
Smoke > 10 per day __________ 
 
Illnesses 
Have you ever had …?  (Please circle Yes or No) 
 
Asthma    YES  NO 
Diabetes    YES  NO 
Epilepsy    YES  NO 
Heart Disease   YES  NO 
High Blood Pressure  YES  NO 
 
 
Any other illness that could affect your safety in performing maximal exercise 
 
YES  NO 
 
(If YES, please specify)  ___________________________________________ 
 
Symptoms 
Have you ever had any of the following symptoms to a significant degree? 
i.e., have you had to consult a physician relating to any of the following? 
(Please circle Yes or No) 
 
 
 
Breathlessness    YES  NO 
Chest Pain    YES  NO 
Dizzy fits / Fainting  YES  NO 
Heart Murmurs    YES  NO 
Palpitations    YES  NO 
 
Muscle or joint injury 
 
Do you have / or have had any muscle or joint injury which could affect your 
safety in performing maximal exercise or strength testing or strength training? 
 
YES  NO 
Medication 
Are you currently taking any medication? YES  NO 
(Please circle Yes or No) 
 
(If Yes, please specify)  ______________________________________ 
 
Signature ____________________________________________ 
 
Date  ____________________________________________ 
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Signed _____________________   Date   ____________________ (Proposer of 
research) 
  
 
 
Where the proposal is from a student, the Supervisor is asked to certify the 
accuracy of the above account. 
 
 
Signed ____________________________Date   ______________(Supervisor of 
student) 
  
 
 
 
Email the completed form to: S.Morrison@bio.gla.ac.uk 
 
And send the signed hard copy to: 
 
Stuart Morrison 
Faculty Research Office 
Faculty of Biomedical & Life Sciences 
West Medical Building 
University of Glasgow 
Gilmorehill 
Glasgow 
G12 8QQ 
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Appendix G: Demographic Data Collection Sheet 
 
Subject Surname __________________________ First Name 
__________________ 
 
Subject Number _______________   Date  ___/ ___/ ___ 
 
DEMOGRAPHICS 
 
Height: ________cm  Weight: __________kg 
 
BLOOD COLLECTION 
 
Was a blood sample taken?     Yes   No  
 
Sampling Time  ____:____ am/pm 
 
Have you had a training session in the last 24 hours?  Yes   No  
If YES, when was the most recent session?   Today 
 Yesterday 
If YES, how long did you train? _______________ (hs)   
If YES, what time did you finish training? __ __:__ __ am/pm 
 
Comments on sample collection  
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
____________________ 
BLOOD PRESSURE 
 
Have you consumed tobacco, caffeine or alcohol in the last hour? Yes  
 No  
 
Measurement 1 of the right arm: _______________________ 
Measurement 2 of the right arm: _______________________ 
Measurement 3 of the right arm: _______________________ 
 
   Mean of the right arm: _______________________ 
Comments on blood pressure measurements 
_______________________________________________________________________
_______________________________________________________________________ 
 
 
Signature of Investigator ___________________  Date: ___/___/___ 
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Appendix H: Clinician Medical Examination Form 
 
 
EPO STUDY SUBJECT MEDICAL ASSESSMENT  
 
NAME: 
 
D.O.B./AGE: 
 
HOSPITAL NO.: 
 
SYSTEMIC ASSESSMENT: 
 
CVS:  CHEST PAIN / PALPITATIONS / ORTHOPNOEA  
 
RESP: SOB / COUGH / SPUTUM / HAEMOPTYSIS 
 
GU: DYSURIA / HAEMATURIA / FREQ. 
 
GI: NAUSEA / VOMITING / DIARRHOEA / MALAENA / HAEMATEMESIS 
  
NEURO: HEADACHE / WEAKNESS / ALTERED SENS. / VISUAL DIST. 
 
OTHER: 
 
 
PAST MEDICAL HISTORY 
 
IHD     MI    CVA     EPILEPSY     ASTHMA     DIABETES      
 
THYROID     JAUNDICE     PREV. TB     DU     RHEUM ARTH  
  
CON. HEART DISEASE     CLOTTING DISORDER  
 
OTHER: 
 
 
ALLERGIES: 
 
 
CURRENT MEDICATION (INCL. NON-PRESCRIPTION): 
 
 
 
SOCIAL HISTORY: 
SMOKING: YES / NO / EX   (_____/DAY)             ALCOHOL: 
_____UNITS/WEEK 
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FAMILY HISTORY: 
 
 
 
EXAMINATION: 
 
GENERAL APPEARANCE: 
 
 
CVS:                                                                             RESP: 
Peripheries                                                                  Cyanosis 
JVP                                                                              Trachea 
Heart sounds                                                                Percussion 
Oedema                                                                       Breath sounds 
 
 
ABDO:                                                                         NEURO: 
                                                                                   GCS        /15 
                                                                                   Pupils 
                                                                                   Eye movements 
Masses                                                                         Limbs                                           
Bowel sounds                                                               Plantars 
 
 
 
INITIAL OBSERVATIONS: 
 
BP         /          H              Sats                    RR                     Temp 
 
 
INITIAL BLOOD RESULTS: 
Hb                                Na                         Bil 
MCV                              K                           AST 
WCC                             Cl                          ALT      
Neut                             Bic                         AlkP 
Plts                               Ur                         GGT 
                                            Cr                          TotPr 
                                           eGFR                      Alb 
 
 
 
 
Signatures:         -----------------------------------  -------------------------- 
                            (Consultant)                   (Volunteer) 
 
 
 
Date (D/M/Y):   -----------------------------------  -------------------------- 
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Appendix I: Maximal Incremental Exercise Checklist  
VO2MAX DATA COLLECTION SHEET:
Subject:
Date:
Speed (km.hr-1)  Time (mins)  Time (if change) (mins) RPE HR
Blood Sample 
Present (Y/N) 
6 0-3
3 3-6
8 6-9
3 9-12
10 12-15
3 15-18
12 18-21
3 21-24
13.5 24-27
3 27-30
15 30-33
3 33-36
16.5 36-39
3 39-42
18 42-45
3 45-48
19.5 48-51
3 51-54
21 54-57
3 57-60
22.5 60-63
3 63-66
24 66-69
Recovery Samples  Time Post ex.(if change) (mins)
Blood Sample 
Present (Y/N) 
Post ex. min 1 x x
Post ex. min 2 x x
Post ex. min 5 x x
Post ex. min 10 x x
Notes / Comments:  
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Appendix J: 3 km Time Trial Data Collection Sheet  
TIME TRIAL 
STUDY VISIT…. 
 
 
Subject Surname __________________________ First Name __________________ 
 
Subject Number _______________   Date  --/ --/ --  Time  --/-- 
 
 
 
Have you had a training session in the last 7 days?   Yes   No  
If YES, how many training sessions have you had? _______________ 
If YES, describe in terms of intensity (strenuous/moderate/easy) and duration (min) each training 
sessions: 
______________________________________________________________________________ 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________
______________________________________________________________________________ 
______________________________________________________________________________
______________________________________________________________________________ 
Is this a typical training week?      Yes   No  
If NO, please describe a typical training week. 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________
______________________________________________________________________________ 
______________________________________________________________________________ 
 
Have you consumed caffeine or alcohol in the last 24 hours? Yes   No  
If YES, what? 
If YES, when? _______________ 
If YES, how much? _______________ 
 
 
Overall, have you been prepared for this time trial as similar as before a competition? 
Yes   No  
If NO, what has been unusual? ___________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________  
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Name
Time start
Distance [m] Comments:
Time lap 1 200
Time lap 2 400
Time lap 3 600
Time lap 4 800
Time lap 5 1000
Time lap 6 1200
Time lap 7 1400
Time lap 8 1600
Time lap 9 1800
Time lap 10 2000
Time lap 11 2200
Time lap 12 2400
Time lap 13 2600
Time lap 14 2800
Time lap 15 3000
min sec csec
Final time RPE score
Time TrialExperimenter:
Temperature [°C]
Humidity [%]
 
Subject Surname __________________________ First Name __________________ 
 
Subject Number _______________   Date  --/ --/ --  Time  --/-- 
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Appendix K: Chapter 4 – Participant Schedule Sample  
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